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GenerAl introduCtion And outline of tHe tHeSiS
Hemostasis
Hemostasis is a complex balance between procoagulant and anticoagulant factors to prevent 
individuals from bleeding. Multiple factors are involved in the hemostatic system, which 
consists of three different parts: primary hemostasis by which the clot is formed,mainly by 
platelets,  secondary hemostasis which strengthens the clot by fibrin formation, and the 
fibrinolytic system  by which the clot is dissolved after wound healing. An important player in 
primary hemostasis is Von Willebrand Factor (VWF). This multimeric glycoprotein mediates 
platelet adhesion and aggregation which leads to the formation of a platelet plug (1).
Von Willebrand factor
Von Willebrand Factor (VWF) is mainly produced by endothelial cells and megakaryocytes 
(1, 2), and is synthesized as a precursor propeptide and forms dimers via disulfide bonds in 
the endoplasmic reticulum. These VWF dimers are transported to the Golgi apparatus where 
VWF multimers are formed. The VWF multimers differ in size and some can consists of up 
to 500 monomers. In the trans-Golgi network the propeptide is cleaved from the subunits 
and mature VWF proteins remains. VWF is secreted into the circulation constitutively or 
tubulized and packaged into Weibel Palade Bodies (WPBs) within the endothelial cells (2-4). 
A small portion is stored in the alpha-granules of platelets (5). Upon stimulation endothelial 
cells release ultra-large high molecular weight (ULHMW) VWF multimers, which are the 
most procoagulant forms and can lead to thrombus formation. ULHMW VWF multimers 
are cleaved by the metalloprotease ADAMTS13 (A Disintegrin And Metalloprotease with 
ThromboSpondin motif repeats 13) into smaller, less procoagulant forms (6, 7). 
The VWF gene is located on the short arm of chromosome 12 and encompasses 52 exons. 
VWF plasma levels in normal individuals differ between around 0.60 and 1.40 IU/mL (8). 
Different factors, genetic and non-genetic, influence the plasma levels including age, 
inflammation, and ABO blood group(9). Individuals with blood group O have 20-25% lower 
VWF plasma levels than individuals with blood group non-O (10, 11). This is due to the 
fact that individuals with blood group O have a different glycosylation profile of VWF which 
influences its clearance (11, 12). In addition, several single nucleotide polymorphisms (SNPs) 
in and outside the VWF gene are known to influence VWF plasma levels (13, 14) (Figure 1).
VWF functions also as a carrier protein for coagulation factor VIII (FVIII), thereby preventing 
FVIII from proteolytic degradation (15, 16). FVIII is an important factor for secondary 
hemostasis and changes in VWF levels in circulation will also results in variability of FVIII 
levels. 
The VWF protein consists of four types of homologous domains. Each of the domains has a 
specific function and binding properties. ADAMTS13 cleaves VWF in the A2 domain (figure 2) 
between Tyrosine 1605 and Methionine 1606 (6, 7). This scissile bond becomes exposed 
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when VWF undergoes a conformational change at moments of high shear stress or when 
it is bind to subendothelial structures. Other domains of VWF are involved in binding with 
GPIb on platelets, collagen, heparin, ristocetin, GPIIb/IIIa, or FVIII (2, 17). 
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figure 1. Determinants of VWF plasma levels
 
figure 2. Domain organization of VWF, ADAMTS13 cleaves VWF at the A2 domain. Adopted from J.T.B. 
Crawley et al. Blood 2011. 
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AdAMtS13
The ADAMTS13 gene is located on chromosome 9q34 and compises 29 exons (18). 
ADAMTS13 is part of the ADAMTS family which shares the homology of domain structures, 
a signal peptide and a propeptide (7, 19, 20). ADAMTS13 consists of a catalytic domain, a 
disintegrin domain, TSP1-motif, a cysteine-rich domain, a spacer domain, seven other TSP-1 
domains (2-8) and two CUB-domains. 
ADAMTS13 is synthesized in hepatic stellate cells in the liver and also vascular endothelial 
cells are found to synthesize and secrete ADAMTS13 (21, 22). ADAMTS13 is also released 
from platelets upon activation (23). 
After initiation of the hemostasis, platelets will adhere to ULHMW VWF which is anchored 
to the activated endothelial cell or the exposed subendothelium. A conformational change 
of VWF is induced when shear stress forces are present and when VWF is bound to the 
glycoprotein Ib receptor on platelets via the A1 domain, thereby exposing the A2 domain 
for ADAMTS13 binding. ADAMTS13 cleaves VWF at the Tyr1605-Met1606 peptide bond, 
predominantly at or close to the anchoring sites of the ULHMW VWF multimers. After 
cleavage the remaining strings of VWF are less biologically active and less susceptible for 
cleavage (24). So far this is the only function known for ADAMTS13
The importance of ADAMTS13 is exemplified in patients with Thrombotic Thrombocytopenic 
Purpura (TTP). In these patients there is a complete deficiency or strongly reduced ADAMTS13 
level which results in the inability to cleave ULHMW VWF into smaller , less procoagulant 
forms. Subsequently this can result into microthrombi formation and microangiopathy. TTP 
is characterized by a classical pentad of signs and symptoms including hemolytic anemia, 
neurological symptoms, renal dysfunction, fever, and profound thrombocytopenia (25). 
Most individuals presenting with TTP are acquired, however TTP may also be congenital, 
caused by mutations in the ADAMTS13 gene. In acquired TTP the cause is the formation of 
auto-antibodies against ADAMTS13 (26-28). 
ADAMTS13 deficiency has also been described in other diseases, including liver cirrhosis 
and systemic lupus erythematosus (SLE) (29-31). Patients with pre-eclampsia and the anti-
phospholipid syndrome also have reduced levels of ADAMTS13 and are prone for thrombotic 
complications (32-34). 
It has been suggested that ADAMTS13 is involved in inflammation. Recent studies have 
shown an association between ADAMTS13 levels and severe sepsis, septic shock, severe 
Plasmodium Falciparum malaria and Dengue virus infection (35-38). Therefore, ADAMTS13 
may be a link between inflammation and thrombosis. 
Cardiovascular disease, atherosclerosis and atherothrombosis
Cardiovascular disease, including myocardial infarction and stroke, are a major cause of 
morbidity and mortality in the world. In the Netherlands, approximately 40,000 individuals 
die each year due to cardiovascular disease (39). The pathogenesis of cardiovascular disease 
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is complex. Many risk factors, environmental and genetic, are known to influence the risk 
of cardiovascular disease, including smoking, hypertension, diabetes, family history  and 
hypercholesterolemia. One of the most important risk factor for cardiovascular disease is 
atherosclerosis. Atherosclerosis is a chronic disease characterized by lipid accumulation and 
inflammation (40). Atherosclerosis starts already in the childhood with a focal thickening 
of the intima called fatty streaks, and lipid accumulation (41). The lesions may progress by 
migration of smooth muscle cells from the media to the intima of the vessel wall where the 
cells proliferate and synthesize several matrix components. Smooth muscle cells within the 
deep layer of the fatty streaks are susceptible to apoptosis and form a necrotic core (42). The 
layer of this core is covered with a fibrous cap which stabilizes the plaque. Multiple factors 
contribute to the development of atherosclerosis, including inflammation and endothelial 
dysfunction. Endothelial dysfunction occurs early in the process of atherosclerosis and 
has been shown to contribute to the formation, progression, and complications of an 
atherosclerotic plaque (43). Additionally, many inflammatory cells play a role in the 
formation of an atherosclerotic plaque (44). 
Different components of an atherosclerotic plaque can be distinguished and may be used 
as a marker of atherosclerosis. One of the components are calcifications which can be 
present in advanced atherosclerotic lesions which consist of a necrotic lipid rich core (45). 
However, calcifications may also be present at earlier stages of atherosclerosis (46). Previous 
studies have shown an association between calcified lesions and the total plaque area or 
the presence of cardiovascular disease (47-50). In addition, intraplaque hemorrhages are 
commonly observed in atherosclerotic plaques and it has been shown to be associated with 
plaque progression and risk of ischemic stroke (51, 52). 
Rupture of an unstable atherosclerotic plaque triggers coagulation and may lead to 
platelet aggregation (53) and finally to thrombus formation and clinical symptoms such as 
myocardial infarction and stroke. Plaque rupture may also be silent leading to progression of 
atherosclerosis, stenosis and arterial remodeling (54, 55). Studies have shown that different 
plaque characteristics, including thin-cap fibroatheromas and a minimal luminal area, 
predict plaque rupture and major adverse cardiovascular events (56, 57). 
Although many risk factors for cardiovascular disease are known, there are still many patients 
suffering from cardiovascular disease in whom no risk factor can be found. Therefore, there 
is still a need to identify new risk factors. 
Additionally, there is a lack of good therapeutic options in especially ischemic stroke 
patients. Currently antithrombotic agents, such as platelet inhibitors, thrombolysis, 
and thrombectomy are used as treatment options (58, 59). However, thrombolysis and 
thrombectomy have only shown to improve outcome when given within 4-6 hours after 
onset of symptoms. Therefore, there is also a need to identify new therapeutic goals.
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Von Willebrand factor, AdAMtS13 and arterial thrombosis
Variations in coagulation factor levels have shown to be associated with a higher risk of 
arterial thrombosis (60, 61). Previous studies have shown an association between high VWF 
levels and the risk of cardiovascular disease, including myocardial infarction and stroke, 
suggesting that VWF is a risk factor for cardiovascular disease (62-65). 
Because high levels of VWF are associated with arterial thrombosis risk, it has been 
hypothesized that ADAMTS13, its main cleavage enzyme, may also modify the risk of 
thrombosis. Theoretically low levels of ADAMTS13 may reduce cleavage of VWF, resulting 
in more active VWF, increased platelet aggregation and therefore to a higher thrombosis 
risk. So far the association between ADAMTS13 and cardiovascular disease has not yet been 
established because of controversial results of a limited number of studies (66-68). However, 
so far this has only been investigated in case-control studies, which are inconclusive. 
Therefore large prospective studies on the association of ADAMTS13 levels and arterial 
thrombosis, including ischemic stroke and myocardial infarction are urgently needed. 
The exact pathogenic role of VWF and ADAMTS13 in arterial thrombosis is yet unknown. Due 
to the fact that endothelial dysfunction is related with atherosclerosis and VWF is released 
from WPBs in case of endothelial dysfunction, there might be an association between VWF 
and the extent of atherosclerosis. Two previous studies have focused on the association 
between VWF levels and atherosclerosis, measured by the intima-media thickness (IMT) 
and ankle brachial index, and both found a significant association, suggesting that there is an 
association between VWF and atherosclerosis (69, 70). Previous animal studies have shown 
less formation of atherosclerosis in VWF deficient mice and pigs (71-73). These studies 
suggested that VWF is causally involved in the formation of atherosclerosis. Controversially, 
studies in humans with Von Willebrand disease (VWD) type 3, characterized by a total 
deficiency of VWF, have shown a similar extent of  atherosclerotic lesions compared with 
healthy individuals (74-76). This suggests that in humans there is no causal role for VWF in 
the development of atherosclerosis. However, VWF increase due to endothelial dysfunction 
accompanying atherosclerosis may lead to increased thrombus formation and an increased 
risk of cardiovascular events. However, further studies are needed to establish this 
association using more accurate, objective measurements of atherosclerosis. 
Aim and outline of this thesis
The aim of this thesis is to obtain more insight in the role of VWF and ADAMTS13 in the 
pathogenesis of cardiovascular disease, including ischemic stroke and myocardial infarction.
In the first part of this thesis we will study the association between VWF and atherosclerosis 
and cardiovascular disease. The second part of the thesis will focus on the association 
between ADAMTS13 and cardiovascular disease.
First, we will review the current literature on the association between VWF, ADAMTS13 and 
cardiovascular disease by performing a systematic review and meta-analysis (chapter 2).
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In the first  part of this thesis the association between atherosclerosis and VWF levels is 
studied. First, we will study the association in the Erasmus Stroke Study, which includes 
consecutive patients suffering from ischemic stroke and Transient Ischemic Attack (TIA) 
referred to the Erasmus University Medical Center (chapter 3). In these patients we will 
measure the calcification volume as a marker of atherosclerosis. Additionally, we investigate 
the association between VWF levels and outcome of stroke  in these patients. In chapter 
4 we investigate the association between coronary atherosclerosis and VWF levels. The 
association between atherosclerosis and VWF will be studied in patients with either an acute 
coronary syndrome or a stable angina pectoris. Atherosclerosis will be measured by plaque 
burden using intravascular ultrasound (IVUS) at the moment of coronary catheterization. 
We will also investigate the association between VWF levels and outcome after 1 year. 
Lastly, different markers of atherosclerosis will be measured in the ParisK study. This study 
investigate the association between carotid atherosclerosis and VWF levels and ADAMTS13 
activity to obtain more insight in this association. The Parisk study is a multicenter 
prospective study in which all ischemic stroke and TIA patients with a mild to moderate (30-
69%) carotid artery stenosis were included. These patients have a high risk of recurrence 
and do not have beneficial effect of carotid endarterectomy, with respect to patients with a 
carotid artery stenosis of 70% and more. Atherosclerosis is measured by different markers 
including calcification volume, the presence of ulcerations, and intraplaque hemorrhage. 
We studied whether these markers were associated with VWF levels and ADAMTS13 activity 
(chapter 5). 
Next, we investigate in a large population based cohort study, the Rotterdam Study, 
the association between ADAMTS13 activity and both stroke (chapter 6) and coronary 
heart disease (chapter 7). With these studies the association between  ADAMTS13 and 
cardiovascular disease will be assessed. The hypothesis is that low ADAMTS13 is associated 
with an increased risk of stroke and myocardial infarction and may be used to predict the 
risk of these diseases in healthy elderly individuals. In the Rotterdam Study, we will also 
investigate the association between VWF levels,  ADAMTS13 activity and the risk of all-cause 
and cardiovascular mortality (chapter 8). 
Subsequently, we investigate determinants of the secretion mechanism of VWF to determine 
factors which can influence VWF levels.  We will study the effect of important mediators, 
including lifestyle factors, environmental factors and common genetic variations in STXBP5, 
STX and VWF on the release of VWF by endothelial cell activation, known to be associated 
with the increase of VWF levels during heavy exercise in healthy individuals (chapter 9). 
In the last chapter (chapter 10), we will summarize and discuss the most important findings 
of this thesis. Also, the possible clinical implications and future perspectives are discussed. 
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AbStrACt
Von Willebrand Factor (VWF) plays an important role in hemostasis by mediating platelet 
adhesion and aggregation. Ultralarge VWF multimers are cleaved by ADAMTS13 in smaller, 
less procoagulant forms. An association between high VWF levels and cardiovascular disease 
has frequently been reported, and more recently also an association has been observed 
between low ADAMTS13 levels and arterial thrombosis. We reviewed the current literature 
and performed meta-analyses on the relationship between both VWF and ADAMTS13 
with arterial thrombosis. Most studies showed an association between high VWF levels 
and arterial thrombosis. It remains unclear whether ADAMTS13 is a causal independent 
risk factor because the association between low ADAMTS13 and arterial thrombosis is 
so far only shown in case-control studies. Prospective studies are awaited. A causal role 
for ADAMTS13 is supported by mice studies of cerebral infarction where the infusion of 
recombinant human ADAMTS13 reduced the infarct size.
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1. introduCtion
Arterial thrombosis, specifically coronary heart disease and ischemic stroke, is associated 
with a high mortality and morbidity in the Western World. Multiple risk factors for arterial 
thrombosis are known, including the classical risk factors hypertension, diabetes and 
obesity. Many studies have shown that the variation in coagulation factors may also confer 
a higher risk of arterial thrombosis (1-4). Previous studies have suggested a role for Von 
Willebrand Factor (VWF) in the pathogenesis of arterial thrombosis. VWF, a large multimeric 
glycoprotein, has an important function in primary hemostasis. It facilitates platelet adhesion 
and aggregation by interacting with the GPIb receptor on platelets and it is a carrier protein 
of factor VIII, thereby protecting factor VIII from proteolytic degradation (5). ADAMTS13, A 
Disintegrin and Metalloprotease with TrompoSpondin motif repeats 13, cleaves ultralarge 
very active VWF multimers into smaller, less procoagulant forms (6, 7). Hypothetically, lower 
levels of ADAMTS13 are associated with increased VWF activity and can thereby contribute 
to arterial thrombosis. Many studies have focused on the role of VWF in the pathogenesis of 
arterial thrombosis, both on the occurrence of the first event and on recurrence. A limited 
number have been published on the role of ADAMTS13 in arterial thrombosis yet. In this 
review we summarize the current literature on VWF and ADAMTS13 in arterial thrombosis. 
We additionally present meta-analyses of the published studies on this research topic.
2
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2. MetHodS
2.1 Search strategy and selection criteria
Medline and Embase were used to search literature till October 1st 2013. The following 
search was used:
(‘von Willebrand Factor’/de OR ‘Von Willebrand Factor cleaving proteinase’/de OR 
(‘Willebrand Factor’ OR ADAMTS13 OR ‘ADAMTS 13’):ab,ti) AND (‘Brain ischemia’/exp 
OR (stroke* OR CVA OR ((brain OR cerebr* OR neural) NEAR/4 (ischem* OR ischaem* OR 
accident* OR circulat* OR flow*))):ab,ti OR ‘Ischemic heart disease’/exp OR (((myocardial 
OR heart OR cardia* OR cardio*) NEAR/4 (ischem* OR ischaem* OR infarct*)) OR (coronary 
NEAR/4 (syndrome* OR disease* OR obstruct* OR occlusi* OR stenos* OR thromb* OR 
atherosclero*)) OR angina):ab,ti). 
The search strategy was restricted to published data and the English language. In total, 
2656 citations were found of which titles and abstracts were screened. Potentially suitable 
studies were read in full text. Studies were selected when the following criteria were met: 
1) prospective cohort studies or case-control studies; 2) association between VWF or 
ADAMTS13 and myocardial infarction, coronary heart disease, (unstable) angina pectoris or 
ischemic stroke. 
2.2 Statistical analysis
Odds ratios were presented in the forest plots using random effects models. The overall 
effects were determined using the Z-test. P-values <0.05 were considered statistically 
significant and 95% confidence intervals were given. Statistical heterogeneity between 
studies was determined by a Tau2 test, a Chi2 test and I2 statistics. Log odds ratios and 
standard errors were calculated of all studies based on the odds ratio of the highest VWF/ 
lowest ADAMTS13 group compared with the lowest VWF / highest ADAMTS13 group. Some 
studies had slightly differences in odds ratios after calculating using the log odds ratio and SE. 
Only studies which gave an odds ratio were included in the meta-analyses. All analyses were 
performed using Review Manager version 5.2 (The Nordic Cochrane Center, Copenhagen, 
Denmark). 
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3. Von Willebrand factor (VWf)
Von Willebrand Factor (VWF) is a multimeric glycoprotein that plays a crucial role in primary 
hemostasis. At moments of vascular injury or high shear conditions, VWF acts as a bridging 
molecule for platelets, resulting in platelet adhesion and aggregation, the initial steps 
in thrombus formation (5). VWF also acts as a carrier protein for coagulation factor VIII, 
thereby preventing factor VIII from proteolytic degradation (8, 9). The importance of VWF 
is highlighted in von Willebrand’s disease, which is the most common inherited bleeding 
disorder, characterized by a deficiency of VWF or qualitative abnormal VWF, resulting in 
various, mainly mucocutaneous, bleeding symptoms (10). 
The VWF gene is located on chromosome 12 and is composed of 178 kilobases (kb) and 52 
exons (11-14). The VWF plasma concentration varies widely and is determined by multiple 
factors, including age, pregnancy and stress. Sixty percent of the VWF level variability is 
accounted by genetic variation, of which ABO blood group has the largest effect and explains 
around 25%. Individuals with blood group O have an increased clearance of VWF, resulting in 
lower VWF levels than individuals with non-O blood groups (15), because the sugar groups 
that VWF shares with the red blood cells in blood group A and B individuals, protects VWF 
from clearance (16). 
VWF is synthesized mainly in endothelial cells and also to some extent in alpha-granules of 
megakaryocytes and stored in Weibel-Palade bodies in the endothelial cells. VWF undergoes 
a process of dimerization and multimerization (5, 17) and the biological activity of VWF 
depends largely on its multimer size; the larger the multimer size, the more active the VWF 
molecule. VWF multimers, released from the Weibel-Palade bodies by agonists such as 
thrombin, epinephrine and collagen, are larger than those are normally present in plasma. 
Circulating VWF is almost completely of endothelial origin and in case of endothelial damage, 
plasma levels of VWF increase. Therefore VWF is considered as a marker of endothelial 
damage or dysfunction (18). VWF mulitmers are cleaved in circulation by ADAMTS13 (A 
Disintegrin and Metalloprotease with ThromboSpondin Motif repeats 13), in the A2 domain 
between residues Y1605 and M1606, which converts ultralarge VWF multimers to smaller, 
less procoagulant forms (6, 7).
3.1 VWf and arterial thrombosis 
3.1.1 VWF and coronary heart disease
As VWF plays an important role in thrombus formation, several studies have been performed 
to assess the relationship between VWF and myocardial infarction and coronary heart disease. 
Two meta-analyses have been published previously on the association between VWF and 
coronary heart disease, including more than 15 prospective cohort studies consisting of 899 
and 6556 cases, respectively (19, 20). Both analyses showed a significant association (OR 
1.5 95% CI 1.1 – 2.0 and OR 1.16 95% CI 1.10 – 1.22) (19, 20). In Table 1 we summarized all 
prospective cohort studies, of which most were included in these meta-analyses. A number 
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of these studies found a positive association between VWF and coronary heart disease 
(1, 19-30), including the large prospective ARIC study that included 1802 coronary heart 
disease cases aged 45 – 64 years (30). This was also observed in many case-control studies, 
listed in table 2 (3, 31-49), suggesting a pathogenic role for VWF in coronary heart disease. 
However, there are doubts whether VWF is causal or mainly a marker of endothelial damage. 
Some other prospective cohort and case-control studies did not find this association (Table 
1, 2) (4, 50-69). This might be due to differences in adjustment for a variety of possible 
confounders. In some studies the observed associations between VWF and coronary heart 
disease disappeared after adjustment for C-reactive protein (CRP) or factor VIII (1, 21, 23, 29, 
30, 56, 57, 69). This may suggest that the association between VWF and arterial thrombosis 
may be driven by other conditions known to increase VWF levels, such as inflammation. 
Because VWF levels are increased during the acute phase of an event due to endothelial 
dysfunction or acute phase response (70, 71), the moment of blood sampling will influence 
the results and this needs to be controlled. Especially in the case-control studies, the time 
between the event and the blood sampling should be at least several months. One study 
measured VWF levels both in the acute phase and after reconvalescence and only observed 
a significant difference in VWF levels between MI patients and controls in the acute phase 
of the event (42). Furthermore, most studies have measured VWF:antigen (VWF:Ag) levels 
as representative of the VWF plasma levels. However, it might be possible that not the 
concentration of VWF is associated with coronary heart disease, but rather the functional 
activity of VWF, however this has hardly been studied so far. 
Although studies on the association between VWF and coronary heart disease have been 
different in design and population and therefore difficult to compare, most studies found 
a positive association. Therefore, the data allow the conclusion that high VWF levels are 
associated with an increased risk of coronary heart disease. 
Several studies have studied the association between VWF levels and cardiovascular 
outcome, which in most studies was defined as cardiovascular mortality. High VWF levels 
were associated with cardiovascular outcome (4, 23, 24, 34, 47, 50, 72-75), although 
others could not confirm these findings (59, 60, 63, 76). Whincup et al. have shown in a 
meta-analysis that in patients with a pre-existent vascular disease that high VWF levels are 
associated with recurrent coronary heart disease and cardiovascular mortality (OR 1.6 95% 
CI 1.0 - 2.5) (19). 
3.1.2 VWF and ischemic stroke
Coronary heart disease and ischemic stroke have several risk factors in common and because 
VWF is associated with CHD, it has been hypothesized that VWF may also be associated with 
the risk of ischemic stroke. In table 3, we summarized the prospective cohort studies and 
in table 4 the case-control studies. An association between high VWF levels and ischemic 
stroke has been found in most studies (2, 25, 30, 33, 77-92). However, two recent studies did 
not observe an association between VWF levels and subclinical cerebral infarction on MRI 
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(93, 94). The fact that not all studies observed an association between VWF and ischemic 
stroke (4, 48, 51, 53, 60, 95-97) might be explained by a lack of power of some studies due to 
small numbers of patients. We performed a meta-analysis of all prospective cohort studies, 
consisting of 1567 cases, on the association between VWF and ischemic stroke and found an 
odds ratio of 1.17 [95% CI 1.08 – 1.26] (Figure 1). This clearly indicates a positive association 
between high VWF levels and ischemic stroke. In addition, if we included the case-control 
studies, of in total 2532 patients, in the meta-analysis we found an OR of 1.55 (95% CI 1.31 
– 1.83) (data not shown).
The origin of ischemic stroke is very diverse and can be classified into different subtypes 
based on the etiology using the widely used TOAST or ASCO classification (98, 99). Large 
artery atherosclerosis subtype of ischemic stroke is classified as ≥ 70% atherosclerosis in the 
carotid arteries and has been associated with higher levels of VWF in several studies (83, 84, 
88, 100, 101). However, ischemic stroke due to cardio-embolism and lacunar stroke, which 
are not associated with atherosclerosis, were also associated with VWF levels (84, 86, 100).
Most studies even found an association between high VWF levels and ischemic stroke 
mortality (72, 78, 80, 89, 92, 102). In the study by Lip et al., VWF levels were found to be 
significantly higher in ischemic stroke patients who died, when compared with patients who 
were still alive at 12 months follow-up (81). 
In conclusion, the studies performed so far, indicate that VWF levels are associated with 
ischemic stroke and with subtypes of ischemic stroke, mainly with large artery atherosclerosis. 
In addition, VWF levels are also associated with outcome of ischemic stroke. 
3.2 VWf deficiency and atherosclerosis in animals and humans
An important role of VWF in the development of atherosclerosis has been shown in 
animal studies using VWF-deficient pigs and mice. VWF knock-out animals showed less 
atherosclerosis compared with wild type animals (103-106). These studies suggest a causal 
role for VWF in the formation of atherosclerosis. However, other animal studies showed 
contradictory results, which has been attributed to the influence of a polymorphism in 
Apolipoprotein B100, which has a major role in determining the severity of diet-induced 
hypercholesterolemia and thereby results in a higher degree of atherosclerosis (106, 
107). Despite the causal role for VWF suggested in animal models, human studies on the 
pathogenesis of VWF in atherosclerosis are limited. Several studies in individuals with severe 
von Willebrand disease (VWD), characterized by a deficiency of VWF in the circulation, did 
not observe reduced atherosclerosis (108-110). In patients with VWD type 3, characterized 
by a total deficiency of VWF, the extent of atherosclerosis was similar to that in controls 
(111). This suggests that VWF does not have an important causal role in the formation 
of atherosclerosis in humans. Recently, a lower prevalence of myocardial infarction and 
ischemic stroke was observed in a large group of moderate and severe adult VWD patients 
(N=635) compared with control populations (112), which stresses the importance of VWF in 
atherothrombosis, which may be caused by less thrombus formation. 
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4. AdAMtS13
Von Willebrand factor (VWF) cleavage protease was discovered simultaneously by Furlan et 
al and Tsai in 1996 (113, 114). A few years later, the gene was cloned and the protease was 
discovered as part of the family of A Disintegrin and Metalloprotease with TromboSpondin 
motif and was designated as ADAMTS13 (7, 115, 116). The ADAMTS13 gene is located on 
chromosome 9q34 and is composed of 37 kb, spans 29 exons and encodes a protein with 
1427 amino acids (117). So far, the only known physiological function of ADAMTS13 is the 
cleavage of ultralarge VWF multimers into smaller, less procoagulant multimers (6). The 
cleavage occurs at a single site of the VWF molecule, the Tyr1605-Met1606 bond within 
the A2 domain (118). ADAMTS13 is mainly produced by the liver (119), although it can also 
be synthesized by vascular endothelial cells (120). The clinical importance of ADAMTS13 
is exemplified by the potentially fatal thrombotic disorder Thrombotic Thrombocytopenic 
Purpura (TTP). TTP is characterized by a severe deficiency of ADAMTS13, which leads to 
the characteristic hallmarks of the disease, including micro-angiopathic hemolytic anemia, 
profound thrombocytopenia, renal dysfunction and neurologic deficits by micro-vascular 
thrombotic complications (121). In addition, TTP patients regularly develop ischemic stroke 
and acute myocardial infarction. More recent studies have indicated that ADAMTS13 may 
also be involved in the pathogenesis of inflammation and determine outcome of other 
disease states such as severe sepsis (122-126). 
4.1 AdAMtS13 assays
Several assays to measure ADAMTS13 activity or antigen levels in plasma have been 
developed. The first activity assays were based on the loss of collagen binding when VWF 
is cleaved by ADAMTS13 (127). A disadvantage of this test is the high analytical coefficient 
of variation. Furthermore, the original test was very elaborate, time-consuming and 
measures ADAMTS13 under non-physiological conditions. Several ADAMTS13 assays have 
been developed since then. Antigen assays (ELISAs) have become available using different 
antibodies (128-130). In 2005, a test based on the FRETS (Fluorescence Resonance Energy 
Transfer Substrate) principle was developed, which uses a VWF peptide containing the 
ADAMTS13 cleavage site (131). An advantage of this test is the short duration of less than 4 
hours. The disadvantage may be that it uses a peptide as ADAMTS13 substrate and not the 
native VWF protein. However, the activity tests have been extensively compared and give 
similar test results in healthy controls and TTP patients (132, 133). The FRETs assay is the 
most widely used nowadays.
4.2 AdAMtS13 in congenital and acquired ttP
Congenital ADAMTS13 deficiency was first demonstrated in 1998 during episodes of TTP, 
mostly preceded by infectious periods or other stressful situations (134). In several of 
these individuals, mutations in the ADAMTS13 gene have been described in the last years 
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(117, 135-137). Treatment consists of regular infusions of fresh frozen plasma to maintain 
ADAMTS13 levels to prevent TTP exacerbations. In the future it may be treated by infusion 
of recombinant ADAMTS13, as it has been shown to be effective in mice models to treat TTP 
and (sporadically) in humans (138, 139). 
Acquired TTP was first reported in 1952 by Moschcowitz (140). Acquired ADAMTS13 
deficiency is due to the formation of auto-antibodies against ADAMTS13 (141). Acquired TTP 
is characterized by a classical pentad of thrombocytopenia, micro-angiopathic hemolytic 
anemia, fever, neurological symptoms and renal insufficiency (121). This is caused by the 
presence of ultra large (UL)VWF multimers, due to the absence of ADAMTS13-induced 
VWF cleavage, that are highly active and spontaneously form platelet aggregates and 
microthrombi. 
4.3 AdAMtS13 and arterial thrombosis
4.3.1. ADAMTS13 and coronary heart disease
Because strongly reduced levels or absence of ADAMTS13 is associated with the occurrence 
of microangiopathies in TTP and because high VWF levels are associated with arterial 
thrombosis, it has been hypothesized that a reduction of ADAMTS13 levels increases the risk 
of arterial thrombosis. So far only eight case-control studies have been performed of which 
four showed a significant association between low levels of ADAMTS13 and risk of myocardial 
infarction (MI) or coronary heart disease (Table 5) (33, 41, 46, 142). Remarkably, one study in 
elderly men found exactly the opposite, as high levels of ADAMTS13 were associated with a 
significant increased risk of MI (31). Others did not find a significant difference in ADAMTS13 
levels between MI patients and controls (32, 42, 143). We performed a meta-analysis of 
all studies which included cases with a first MI or coronary heart disease (N = 1578) and 
provided an odds ratio (31-33, 41, 46). We did not find a significant association between 
ADAMTS13 levels and myocardial infarction or coronary heart disease (OR 1.45, 95% CI 0.71-
2.98) (figure 2). We found a high odds ratio but a wide confidence interval, suggesting a lack 
of power to find statistical significance. This suggests that there is no association between 
ADAMTS13 and coronary heart disease. Three other studies have shown that ADAMTS13 
was associated with the recurrence of cardiovascular events in patients with a prevalent 
coronary heart disease (40, 45, 61). The role of ADAMTS13 in coronary heart disease was 
found to be independent of VWF. Individuals with high VWF levels and low ADAMTS13 levels 
confer the highest risk of arterial thrombosis (33), which suggests that ADAMTS13 and VWF 
are independent risk factors. 
In conclusion, several studies suggested an association between low ADAMTS13 levels and 
AMI or CHD that is independent of VWF levels, although the studies performed did not 
include sufficient numbers of patients. Another problem is that all published studies have a 
case-control design, therefore prospective studies are needed to definitely assess the role 
for ADAMTS13 levels in AMI or coronary heart disease. 
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 Cases Controls Odds Ratio Odds Ratio
Study or Subgroup Total Total IV, Random, 95% IV, Random, 95% CI
Smits 1997 45 1174 1.15 [0.85, 1.55]
Folsom 1999 191 14522 1.71 [1.09, 2.68]
Knuiman 2001 159 1234 1.15 [0.96, 1.37]
Johansson 2002 87  216  1.01 [0.61, 1.68]
Smith 2005 133 2090 0.97 [0.61, 1.55]
Tzoulaki 2007 168 177 1.33 [1.02, 1.73]
Carcaillon 2009 111 1055 1.06 [0.49, 2.28]
Gottesman 2009   196 214 1.90 [1.00, 3.61]
Wieberdink 2010 290 5960 1.10 [0.96, 1.26]
Wannamethee 2012 187 3171 1.18 [1.02, 1.36]
Total 95% CI) 1567 29813 1.17 [1.08, 1.26]
Heterogeneity: Tau2 = 0.00; Chi2 = 7.65, df = 9 (P = 0.57); I2 = 0% 
Test for overall effect: Z = 4.03 (P < 0.0001)
 
Figure 1. Forest plot of the association between VWF and iscemic stroke
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Figure 2. Forest plot of the association between ADAMTS13 and coronary heart disease
 Cases Controls Odds Ratio Odds Ratio
Study or Subgroup Total Total IV, Random, 95% IV, Random, 95% CI
Chion 2007 551 635 0.64 [0.45, 0.91]
Crewley 2007 488 484 1.89 [1.14, 3.12]
Bongers 2009 218 332 5.20 [2.67, 10.13]
Peyvandi 2010 138 199 0.63 [0.35, 1.12]
Andersson 2011 205 638 1.80 [1.10, 2.94]
Total 95% CI) 1578 2288 1.45 [0.71, 2.98]
Heterogeneity; Tau2 = 0.60; Chi2 = 41.31, df = 4 (P < 0.00001); I2 = 90% 
Test for overall effect: Z = 1.01 (P = 0.31)
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Figure 3. Forest plot of the association between ADAMTS13 and ischemic stroke
 Cases Controls Odds Ratio Odds Ratio
Study or Subgroup Total Total IV, Random, 95% CI IV, Random, 95% CI
Bongers 2006 124 125 1.70 [0.74, 3.90]
Bongers 2009 109 332 1.76 [0.90, 3.43]
Andersson 2011 175 638 3.10 [1.60, 6.00]
Lambers 2013 20 8 12 5 7.30 [2.74, 19.45]
Total (95% CI) 616 1220 2.72 [1.52, 4.86]
Heterogeneity: Tau2 = 0.20; Chi2 = 6.86, df = 3 (P < 0.08); I2 = 56% 
Test for overall effect: Z = 3.36 (P = 0.0008)
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4.3.2. ADAMTS13 and Ischemic Stroke 
Only a few studies have been performed on the association between ADAMTS13 levels 
and ischemic stroke (Table 6) (33, 46, 85, 144). Of those studies, two found a significant 
increased risk of ischemic stroke in individuals with low ADAMTS13 levels (33, 144) and 
the other two studies had similar risk estimates, but did not reach statistical significance 
(46, 85), probably because of a lack of power due to small number of patients (46, 85). We 
performed a meta-analysis of these studies, consisting of 616 cases, and showed a clear 
association between ADAMTS13 and ischemic stroke (OR 2.72, 95% CI 1.52 – 4.86) (Figure 
3), indicating that low ADAMTS13 levels are associated with an increased risk of ischemic 
stroke. An association between stroke subtype and ADAMTS13 levels could not be observed 
in a pediatric cohort study (144), but also in this study only a small number of patients 
were included. Taken together, all studies on the association between ADAMTS13 and 
ischemic stroke have limited numbers of patients and a case-control design and therefore 
it is difficult to draw conclusions from these studies, although our meta-analysis showed a 
significant association. Prospective cohort studies are needed to definitely confirm the role 
of ADAMTS13 in the pathogenesis of ischemic stroke. 
4.3.3. ADAMTS13 and Atrial Fibrillation (AF)
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with an 
increased risk of stroke (145). There have been a limited number of studies performed 
investigating the role of ADAMTS13 in atrial fibrillation and the risk of cardiovascular events 
such as ischemic stroke. A study by Uemura et. al showed significant lower ADAMTS13 levels 
in AF patients compared with controls (146), which could not be confirmed by another 
study (147). Furthermore, low ADAMTS13 levels were found to be a predictor of major 
cardiovascular events in patients with AF, although these levels were not associated with 
all-cause mortality (76).
4.5 AdAMtS13 and atherosclerosis in mouse models
Studies in ADAMTS13 deficient mice showed more extensive atherosclerosis and plaque 
formation in the major vessels compared with wild type mice (148, 149). Others have 
shown that inducing cerebral or myocardial ischemia in ADAMTS13 deficient mice results 
in larger infarctions compared with wild type mice (150-155). Infusion of recombinant 
human ADAMTS13 (rhADAMTS13) after induced focal cerebral or myocardial ischemia, 
reduced the infarct size and improved the functional outcome without producing more 
bleeding symptoms (150, 152, 155). Additionally, ADAMTS13 deficient mice have more 
leukocytes and macrophages infiltration compared with wild type mice suggesting a role for 
ADAMTS13 in inflammation (148, 149, 151-154, 156). Although human studies showed that 
VWF and ADAMTS13 are independent risk factors, ADAMTS13 deficient and ADAMTS13/
VWF deficient mice showed similar reduction of infarct size and inflammatory parameters, 
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suggesting that the role of ADAMTS13 on ischemia and inflammation is mediated via VWF 
(150, 153, 154, 156). Infusion of recombinant ADAMTS13 after occlusion may result in 
smaller VWF multimers and less platelet aggregation and thrombosis. In conclusion, previous 
mice studies showed a causal role for ADAMTS13 in myocardial and cerebral ischemia and 
atherosclerosis and infusion of rhADAMTS13 reduces infarct size.
 
5. Possible mechanism for the role of VWf and AdAMtS13 in arterial thrombosis
The mechanism by which VWF and ADAMTS13 lead to myocardial infarction and ischemic 
stroke is not yet known. It has been hypothesized that there might be a role for both these 
factors in atherosclerosis, as previous mouse models have shown more atherosclerosis 
in ADAMTS13 and less atherosclerosis in VWF deficient mice (148, 149). We and others 
have shown that the degree of measured atherosclerosis in humans is strongly associated 
with VWF levels. Our recent study has shown a positive association between well-defined 
atherosclerosis, measured by the calcification volume in the carotid arteries and aortic arch, 
and VWF in ischemic stroke patients possibly related to endothelial damage (101). However, 
another study found no association between VWF levels and the intima media thickness 
(IMT), in healthy individuals (30). As VWF seems to play a role in both ischemic stroke and 
myocardial infarction and was found to be associated with large artery atherosclerosis, it 
may be suggested that VWF is a marker of atherosclerosis and/or inflammation and not a 
risk factor in itself. A causal role of VWF in cardiovascular disease is challenged by the fact 
that, despite the strong effect of ABO blood group on VWF levels, the role of ABO blood 
group in arterial thrombosis is weak and not consistent (157, 158). On the other hand, we 
and others have seen that genetic variations in the VWF and ADAMTS13 gene and other 
related genes, that are associated with VWF and ADAMTS13 levels, are sometimes related 
with arterial thrombosis (159), but not always, as we have recently reviewed (54, 159-161). 
This suggests that there is no causal role for VWF in the development of atherosclerosis, but 
once atherosclerosis has developed this is associated with increased VWF levels and these 
levels may contribute to thrombus formation and arterial thrombosis. 
6. Conclusion
In the last few years many studies have investigated the association between both VWF levels 
and ADAMTS13 levels and the risk of arterial thrombosis. Most previous prospective cohort 
studies and meta-analyses of more than 6500 cases have shown that high VWF levels are 
associated with an increased risk of myocardial infarction. We also confirmed this in a meta-
analysis for ischemic stroke. An association between ADAMTS13 and arterial thrombosis 
has been shown in a few small cross-sectional and case-control studies, therefore it remains 
unclear whether ADAMTS13 is an independent risk factor. Our current meta-analysis of 
the association between ADAMTS13 and ischemic stroke showed a highly significant OR 
of 2.72 (95% CI 1.52 – 4.86) for low levels of ADAMTS13. This result is in accordance with 
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mice studies that show that ADAMTS13 deficient mice have a higher risk of myocardial or 
cerebral ischemia and have shown a promising role for rhADAMTS13 as therapeutic option 
(148-155). 
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table 4. Case-control studies on the association between Von Willebrand Factor and ischemic stroke
Participants n total (% cases) blood sampling after event Mean follow-up 
time
VWf level (iu/ml) in cases VWf level (iu/ml) in controls P-value disease endpoint or (95% Ci)
First ever ischemic stroke (88) 405 (49) Within 7 days and 3-6 
months 
Baseline: 1.84  
Chronic: 1.78 
Baseline: 1.64  
Chronic: 1.64, 
P=0.17 
P=0.21
2.8 [1.5 – 5.2] 
First ever ischemic stroke (85) 249 (50) 7-14 days 1.47 ± 0.66 1.23 ± 0.5 P=0.002 3.2 [1.4 - 7.5]
First ever ischemic stroke or TIA (82) 197 (48) 7-14 days VWF:Ag: 1.32 (0.98 - 1.85)  
VWF:Act: 1.2 (0.9 - 1.8) 
VWF:Ag: 1.22 (0.84 - 1.56)  
VWF:Act: 1.3 (0.9 - 1.7)
P=0.04 
NS
n.a.
First ever ischemic stroke or TIA (77) 549 (50) 7-14 days and 3 months 1.47 ± 0.68  
1.25 ± 0.56 
1.25 ± 0.5 P=0.03 
P<0.001
1.9 [1.0 - 3.3] 
1.9 [1.1 – 3.1]
First ever ischemic stroke (33) 813 (22) 23-146 months 1.0 1.1 n.a. 6.7 [3.2 - 13.8]
Ischemic stroke (79) 40 (48) 72 hours 1.85 ± 0.67 1.34 ± 0.50 P<0.05 n.a.
Ischemic stroke (80) 392 (53) Within 10 days and 3-4 
months
6 months or till 
death
Acute: 1.86 (1.75 - 1.97)  
Chronic: 1.51 (1.42 - 1.60) 
Acute: 1.26 (1.19 - 1.33)  
Chronic: 1.26 (1.19 - 1.33) 
P=0.0001 
P=0.0001
n.a.
Ischemic stroke (78) 196 (83) n.a. 1.44 ± 0.21 1.14 ± 0.16 P=0.0002 n.a.
Ischemic stroke (91) 114 (65) 3-10 days and 1-3 months Acute: 2.31 ± 0.90  
Chronic: 1.98 ± 1.03 
Acute: 1.41 ± 0.41  
Chronic: 1.41 ± 0.41 
P<0.001 
P<0.01
n.a.
Ischemic stroke (83) 138 (60) Within 48 hours and after 
1 months
Acute: 1.78 (1.26 - 2.05) 
Chronic: 1.80 (1.55 - 2.15) 
Acute: 1.33 (1.02 - 1.66)  
Chronic: 1.33 (1.02 - 1.66)
P<0.001 
P<0.001
n.a.
Ischemic stroke (81) 121 (71) At admission, 48hr,  
1 week, 2 weeks,  
3 and 6 months
12 months 1.51 ± 0.39 1.00 ± 0.28 P<0.0001 n.a.
Ischemic stroke (90) 296 (28) Acute n.a. n.a. n.a. 20.14 [6.61 - 85.39]
Ischemic stroke (86) 243 (49) n.a. 1.00 (0.66 - 1.00) 0.40 (0.30 - 0.80) P=0.0001 n.a.
Ischemic stroke (84) 1200 (50) Within 10 days and  
3 months
n.a. n.a. P<0.0001 Acute: 1.87 [1.54 - 2.27]  
Chronic: 1.36 [1.15 - 1.62] 
TIA or cerebral infarct or cerebral 
embolism (87)
CVA: 68 (50) 
TIA: 22 (50) 
CE: 18 (50)
n.a. CVA: 2.08 ± 0.59 
TIA: 1.78 ± 0.95  
CE: 1.03 ± 0.40
CVA: 0.998 ± 0.26  
TIA: 0.99 ± 0.28 CE: 0.98 
± 0.26 
P<0.001 
P<0.02 
NS
n.a.
TIA or minor ischemic stroke (97) 331 (29) At least 4 weeks 1.37 ± 0.65 1.15 ± 0.57 P=0.004 1.42 [0.57 - 3.52]
Non-valvular AF (48) 994 (3.9) At inclusion n.a. n.a. n.a. RR 2.3 [1.0-5.6]
Non-valvular AF with ischemic stroke 
(102)
91 (67) Within 48 hours and  
on day 7, 21 and 90
8.8 months 0.97 ± 0.16 0.92 ± 0.14 P=0.202 n.a.
Non-valvular AF (89) 373 (13.7) 72 hours 3 years n.a. n.a. n.a. 3.69 [1.96 - 4.5]
Intermittent claudication (60) 282 (28) n.a. 6-7 years 1.26 (0.99 - 1.84) 1.31 (1.06 - 1.65) NS RR: 0.97  
[0.78 - 1.21] 
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VWF:Act: 1.3 (0.9 - 1.7)
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Ischemic stroke (79) 40 (48) 72 hours 1.85 ± 0.67 1.34 ± 0.50 P<0.05 n.a.
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death
Acute: 1.86 (1.75 - 1.97)  
Chronic: 1.51 (1.42 - 1.60) 
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n.a.
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Acute: 1.41 ± 0.41  
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P<0.001 
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n.a.
Ischemic stroke (83) 138 (60) Within 48 hours and after 
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Ischemic stroke (81) 121 (71) At admission, 48hr,  
1 week, 2 weeks,  
3 and 6 months
12 months 1.51 ± 0.39 1.00 ± 0.28 P<0.0001 n.a.
Ischemic stroke (90) 296 (28) Acute n.a. n.a. n.a. 20.14 [6.61 - 85.39]
Ischemic stroke (86) 243 (49) n.a. 1.00 (0.66 - 1.00) 0.40 (0.30 - 0.80) P=0.0001 n.a.
Ischemic stroke (84) 1200 (50) Within 10 days and  
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n.a. n.a. P<0.0001 Acute: 1.87 [1.54 - 2.27]  
Chronic: 1.36 [1.15 - 1.62] 
TIA or cerebral infarct or cerebral 
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CVA: 68 (50) 
TIA: 22 (50) 
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n.a. CVA: 2.08 ± 0.59 
TIA: 1.78 ± 0.95  
CE: 1.03 ± 0.40
CVA: 0.998 ± 0.26  
TIA: 0.99 ± 0.28 CE: 0.98 
± 0.26 
P<0.001 
P<0.02 
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n.a.
TIA or minor ischemic stroke (97) 331 (29) At least 4 weeks 1.37 ± 0.65 1.15 ± 0.57 P=0.004 1.42 [0.57 - 3.52]
Non-valvular AF (48) 994 (3.9) At inclusion n.a. n.a. n.a. RR 2.3 [1.0-5.6]
Non-valvular AF with ischemic stroke 
(102)
91 (67) Within 48 hours and  
on day 7, 21 and 90
8.8 months 0.97 ± 0.16 0.92 ± 0.14 P=0.202 n.a.
Non-valvular AF (89) 373 (13.7) 72 hours 3 years n.a. n.a. n.a. 3.69 [1.96 - 4.5]
Intermittent claudication (60) 282 (28) n.a. 6-7 years 1.26 (0.99 - 1.84) 1.31 (1.06 - 1.65) NS RR: 0.97  
[0.78 - 1.21] 
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AbStrACt
background
Large population studies have revealed that increased von Willebrand Factor (VWF) levels 
are associated with an increased risk of ischemic stroke. In previous studies VWF was 
associated with atherosclerosis in healthy individuals. However, it is yet unknown what the 
association is between atherosclerosis and VWF levels in patients with ischemic stroke. 
The aim of our study was to determine the association of atherosclerosis, measured with 
recent developed techniques, and VWF levels in a large, well characterized, cohort of 
ischemic stroke patients and to determine the prognostic value.
Methods 
We included 925 consecutive patients with transient ischemic attack (TIA) or ischemic 
stroke. Calcification volumes (mm3) were scored in the aortic arch and both carotid arteries 
using multidetector computed tomography (CT) angiography. VWF antigen (VWF:Ag) levels 
were measured using ELISA. 
results
Mean VWF:Ag levels were significantly higher in the presence of calcification in either 
the aortic arch (1.47 vs. 1.37 IU/ml [P=0.039]) or the carotid arteries (1.49 vs. 1.34 IU/ml 
[P=0.001]). Patients with a large artery atherosclerosis ischemic stroke had significantly 
higher VWF:Ag levels then the other TOAST subtypes (P<0.0001). High VWF:Ag levels were 
associated with an unfavorable outcome (modified Rankin Scale >2 vs. ≤2; 1.64 vs. 1.41 IU/
ml, [P<0.0001]). 
Conclusion
Our study showed a strong association between the extent of atherosclerosis in both the 
aortic arch and the carotid arteries and VWF levels in patients with TIA or ischemic stroke. 
Higher VWF levels are found in large artery atherosclerosis and are associated with a poor 
outcome.
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introduCtion
Von Willebrand Factor (VWF) plays a crucial role in platelet adhesion and aggregation, the 
initial steps in thrombus formation. VWF is a multimeric plasma protein that is produced 
by endothelial cells and megakaryocytes (1). Since VWF plasma levels increase as the result 
of endothelial damage, VWF levels can be used as a marker of endothelial dysfunction (2). 
Previous studies have shown a positive association between levels of VWF and risk of 
coronary heart disease and stroke (3-6). In ischemic stroke, a particular association of 
VWF levels with etiologic subtypes, such as large artery atherosclerosis and cardioembolic 
stroke, was found(7). Despite the fact that prospective studies have identified VWF levels 
as a predictor of ischemic stroke (8-10), the mechanism by which increased VWF levels are 
related to stroke is still unclear. 
We have previously shown that genetic variation strongly determines VWF levels, however 
these genetic variations are not or minimally associated with ischemic stroke risk (11, 12). 
Therefore it has been suggested that the VWF levels may predominantly be determined by 
endothelial dysfunction and atherosclerosis (13). 
Endothelial dysfunction is the first phase in the development of atherosclerotic plaques. 
Because endothelial activation is related to atherosclerosis and an association of VWF with 
ischemic stroke has been found, atherosclerosis may be a determinant of VWF levels (14). 
Previous studies have shown a significant association between atherosclerosis, measured by 
the ankle-brachial index and intima-media thickness, and increased VWF levels in healthy 
individuals (15, 16). 
In recent years, new techniques have been developed to study the extent of atherosclerosis 
more precisely. Calcification volume is an important indicator of atherosclerosis severity and 
may have a strong association with VWF levels (17-19). 
We hypothesized that a higher degree of calcification volume, measured both in the aortic 
arch and carotid arteries, is associated with higher levels of VWF in patients with ischemic 
stroke, which may provide more insight in the relationship between VWF levels and ischemic 
stroke risk and the prognostic value of VWF.
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MAteriAlS And MetHodS
Study population
We studied 925 consecutive patients with TIA or ischemic stroke from the Erasmus Stroke 
Study, an ongoing registry of patients with cerebrovascular diseases treated at our hospital, 
from December 2005 until December 2010 of whom plasma, DNA and a CT angiography was 
available (20). TIA was defined as a focal neurological deficit of presumed vascular origin 
lasting less than 24 hours, with imaging studies showing no abnormalities. Ischemic stroke 
was defined as a focal neurological deficit of presumed vascular origin lasting ≥24 hours, with 
brain imaging studies showing no abnormalities or typical signs of infarction. Patients were 
classified according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria(21) 
and additionally to a phenotypic classification which is a variant of the A-S-C-O score (22). 
This score is characterized by 9 categories: definite lacunar stroke, definite atherothrombotic 
stroke, probable atherothrombotic stroke, definite cardiac cause, possible cardiac cause, 
definite hematologic cause, possible hematologic cause, other cause of stroke and unknown 
cause of stroke. Definitions are described in the supplemental information. Patients who have 
multiple causes of stroke did not fit into one of the categories and are therefore excluded 
from the analysis (N=125). Hypertension and hypercholesterolemia were defined as the use 
of antihypertensive or cholesterol lowering drugs, respectively, before the inclusion event. 
Diabetes mellitus was defined as the use of oral and/or parenteral antidiabetic drugs before 
the event. Smoking status (smoking versus non-smoking) was assessed at the time of the 
event. Patients were considered to have a history of ischemic heart disease when they had 
a documented myocardial infarction, angina pectoris or cardiac revascularization therapy. 
Peripheral arterial disease was defined as a history of intermittent claudication or peripheral 
vascular surgery or amputation due to lower limb ischemia. A history of cardiovascular 
disease indicates a history of ischemic heart disease and/or peripheral arterial disease and/
or atrial fibrillation and/or TIA or ischemic stroke. The National Institutes of Health Stroke 
Scale (NIHSS)(23) was assessed at admission from the stroke unit or outpatient clinic. The 
functional outcome was assessed using the modified Rankin scale (mRS)(24) at discharge 
and was dichotomized as favorable (≤2) or unfavorable (>2) outcome. 
All participants provided written informed consent. The study was approved by the Medical 
Ethics Committee of the Erasmus University Medical Center. 
MDCTA angiography
A multidetector CT angiography (MDCTA) was performed routinely according to a standard 
protocol. MDCTA was performed at a median of 5 days (interquartile range 2-14 days) after 
onset of symptoms. Image acquisition was performed using a 16, 64 or 128 slice multi-
detector CT system (Sensation 16, Sensation 64, Definition, Definition AS+ or Definition flash, 
Siemens Medical Solutions, Erlangen, Germany) using a standardized optimized contrast-
enhanced protocol (120 kVp, 180-200 mAs, collimation 16 x 0.75 mm; 32 x 2 x 0.6 mm; 64 x 
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2 x 0.6 mm, pitch < 1). The scan range extended from the ascending aorta to the intracranial 
circulation. All patients received 80 ml of contrast agent (320 mg/mL iodixanol, Visipaque, 
Amersham Health, Little Chalfont, UK), followed by 45 ml saline bolus chaser, both at an 
injection rate of 4 or 5 ml/s. Real-time bolus tracking at the level of the ascending aorta was 
used to synchronize passage of contrast agent and data acquisition. Image reconstructions 
were made with field of view of 120 mm, matrix size 512 × 512, slice thickness 0.75 or 1.0 
mm, increment 0.4 - 0.6 mm and with an intermediate reconstruction algorithm. All MDCTA 
studies were evaluated by trained readers blinded for clinical data. Dedicated commercially 
available software (Syngo CalciumScoring, Siemens) was used to quantify calcifications at 
the aortic arch and the carotid arteries; expressed as calcification volume in mm3. The aortic 
arch was defined as the origin of the aortic arch to the first 1 cm of the common carotid 
arteries, the vertebral arteries and the subclavian arteries beyond the origin of the vertebral 
arteries. Both carotid arteries were scored within 3 cm proximal and distal of the bifurcation 
and calcification volume of both carotid arteries was added. A threshold of 600 Hounsfield 
units (HU) was used to differentiate calcifications from contrast material in the lumen. A 
detailed description of the measurement is provided elsewhere(17, 25). 
Reasons for not performing MDCTA were poor renal function, significant comorbidity with 
resultant very short life expectancy and very severe stroke with likely fatal outcome. Patients 
with a time interval between event and MDCTA of more than 180 days were excluded 
(n=20). Because of poor image quality of both the aortic arch and the carotid arteries caused 
by artifacts, 17 scans were not gradable. In 7 patients the aortic arch and in 10 patients the 
carotid arteries could not be analyzed due to dissection of the carotid artery, presence of 
artifacts or stents.
Blood samples, VWF measurement and blood group assessment
Blood sampling was performed at a median of six days (interquartile range 3-14 days) after 
onset of symptoms. There was no significant correlation between VWF levels and time from 
event till blood sampling (ß -0,0001 IU/ml per day; P=0.33). 
Citrated blood was centrifuged at 1700g for 15 minutes at room temperature, and stored 
at -80°C within 2 hours from collection. DNA was isolated from blood using MagNA Pure 
(Roche Diagnostics) and stored at -80°C. VWF antigen (VWF:Ag) levels were determined 
with an in-house ELISA, using rabbit anti-human VWF antibodies (DakoCytomation, 
Glostrop, Denmark) for catching and tagging. Reference standard plasma, calibrated against 
the international standard (Cryocheck Reference, Kordia, Leiden, the Netherlands), was 
used as a calibrator. The intra-assay coefficient of variation was 3.2%. Blood groups were 
assessed with a standard test of blood group antibodies in 572 patients. In the remaining 
353 patients, we genotyped rs687289, which can be used to discriminate blood group O 
from non-O status, using custom TaqMan Genotyping Assays (Applied Biosystems, Foster 
City, CA, USA)(26). Genotyping was successful in 99% of all patients.
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Statistical analysis
Levels of VWF:Ag and the calcification volumes in the aortic arch and carotid arteries were 
normalized by logarithmic transformation. The data are presented as geometric means and 
95% confidence interval (CI). Correlation between two groups was assessed with Spearman 
rank correlation. The aortic arch and carotid calcification volume were divided into four 
subgroups. The first group consists of all patients with a calcification volume of 0 mm3, the 
remaining patients were divided into tertiles. VWF:Ag levels were divided into two categories: 
low level below the median (≤1.43 IU/ml) and high level above the median (>1.43 IU/ml). 
Groups were compared using independent T-tests or ANOVA with Bonferroni correction. 
Linear regression analysis was used to analyze the relationship between calcification volume 
with VWF:Ag levels. All analyses were adjusted for potential confounders: age, sex, ABO 
blood group, smoking, hypertension, hypercholesterolemia, diabetes mellitus and a history 
of cardiovascular disease. Only confounders that were significantly associated with VWF:Ag 
levels were used in the multivariate analyses. All analyses were performed using SPSS 
version 20.0 (IBM, Somers, NY, USA). A P value <0.05 was considered to indicate statistical 
significance. 
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reSultS
Baseline characteristics of the 925 patients in this study are shown in Table 1. Mean age was 
62 ± 13.6 years and 47% were females. As expected in our cohort of patients with TIA or 
ischemic stroke, they frequently suffered from hypertension, hypercholesterolemia and the 
majority of patients smoked. The geometric mean of the VWF:Ag levels in our patients was 
1.43 IU/ml (95% CI 0.63-3.24). Patients with ischemic stroke had significantly higher levels 
of VWF than patients with TIA (1.50 vs. 1.35 IU/ml; P<0.0001). Patients with blood group O 
had significantly lower levels of VWF:Ag compared with patients with non-O blood groups 
(1.24 vs 1.62 IU/ml, p<0.0001). 113 patients had a time interval between event and MDCTA 
of more than one month. The results of the study did not change, when excluding those 
patients.
table 1. Baseline characteristics of the study population 
Patients in whom both calcification volume 
were determined (n = 908)
total cohort
n = 925
no calcification
n = 256
Any calcification
n = 652
P-value
Age, years 62.0 (13.6) 49.0 (11.5) 67.1 (10.7) <0.0001
Female sex 443 (46.8) 137 (53.5) 290 (44.5) 0.014
Smoking 283 (30.6) 82 (32.0) 195 (29.9) 0.677
Body mass index (kg/m²) 27.3 (13.5) 27.9 (5.8) 27.1 (15.6) 0.543
Hypertension 488 (52.8) 76 (29.7) 400 (61.3) <0.0001
Hypercholesterolemia 311 (33.6) 43 (16.8) 258 (39.6) <0.0001
Diabetes Mellitus 128 (13.8) 21 (8.2) 104 (16.0) 0.002
History of CVD 367 (39.7) 54 (21.1) 303 (46.5) <0.0001
Bloodgroup
   O 416 (45) 115 (44.9) 294 (45.1) 0.888
   Non-O 504 (54.5) 141 (55.1) 353 (54.1) 0.888
Diagnosis
   TIA 428 (46.3) 130 (50.8) 289 (44.3) 0.079
   Stroke 497 (53.7) 126 (49.2) 363 (55.7) 0.079
TOAST classification
   Large artery atherosclerosis 154 (16.6) 16 (6.3) 133 (20.4) <0.0001
   Cardioembolism 113 (12.2) 29 (11.3) 79 (12.1) 0.741
   Small vessel occlusion 183 (19.8) 51 (19.9) 129 (19.8) 0.963
   Other determined etiology 50 (5.4) 25 (9.8) 25 (3.8) <0.0001
   Undetermined etiology 425 (45.9) 135 (52.7) 286 (43.9) 0.016
Data are presented as N(%), unless for age and body mass index, where mean (SD) are shownCVD indicates 
cardiovascular disease
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Calcification volume of the aortic arch and VWF:Ag levels
The geometric mean calcification volume of the aortic arch of the total group was 17.59 
mm3 (95% CI 0-3374.8 mm3). Patients with calcifications in the aortic arch (n=593) had 
significantly higher VWF:Ag levels compared with patients without calcifications in the aortic 
arch (n=325; 1.47 vs. 1.37 IU/ml, P=0.039). VWF:Ag levels increased linearly with increasing 
groups of the aortic calcification volume (P for trend 0.003; Figure 1a). After multivariate 
adjustment, age and blood group were significantly associated with levels of VWF:Ag 
(P<0.0001; P<0.0001; respectively). Patients with blood group O, with mean VWF:Ag levels 
of 1.24 IU/ml, had similar aortic calcification volume compared with patients with blood 
group non-O, who had a mean VWF:Ag level of 1.62 IU/ml (17.2 vs. 18.0 mm3, P=0.80). The 
association between the calcification volume and VWF:Ag levels was seen both in blood 
group O and non-O and this was not statistically significant different (P for indication = 0.49). 
Figure 1
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figure 1. Levels of mean VWF:Ag per group of calcification volume 
Mean and standard error (SE) VWF:Ag levels (in IU/ml) in the aortic arch calcification volume groups 
(* P=0.006 compared with the first group; †P<0.0001 compared with the first group)  
Mean and standard error (SE) VWF:Ag levels (in IU/ml) in the carotid calcification volume groups 
(* P=0.001 compared with the first group; † P<0.0001 compared with the first group)
Calcification volume of the carotid arteries and VWF:Ag levels
The geometric mean of the carotid calcification volume of the total group was 5.7 mm3 
(95% CI 0.0-396.9 mm3). Patients with calcifications (n=529) had significantly higher levels 
of VWF:Ag compared with those without calcifications (n=386; 1.49 vs 1.34 IU/ml, P=0.001). 
VWF:Ag levels increased linearly in increasing groups of the calcification volume (P for 
trend <0.0001; Figure 1b). Age and blood group were significantly associated with levels of 
VWF:Ag after multivariate analysis (P<0.0001; P<0.0001, respectively). Patients with blood 
group O, with a mean VWF:Ag levels of 1.24 IU/ml, had a similar carotid calcification volume 
compared with patients with blood group non-O, with a mean VWF:Ag level of 1.61 IU/ml 
(6.4 vs. 5.3 mm3, P=0.25). 
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figure 2. Relationship between aortic arch and carotid calcification volume and mean VWF:Ag levels
Calcification volume of the aortic arch and of the carotid arteries were highly correlated 
(R=0.69; P<0.0001). Patients with calcifications in both arteries were older (67 vs. 49 years, 
P<0.0001) and had more cardiovascular risk factors than those without calcifications (Table 
1). This was similar in the separate arteries. Assessing the mean VWF:Ag level in patients 
using both calcification volume, showed the highest levels in patients with both the highest 
calcification volume (Figure 2). The association between the calcification volume and 
VWF:Ag levels was seen both in patients with blood group O and non-O and this was not 
statistically significant different (P for interaction = 0.11).
Etiologic subtypes of TIA or stroke and levels of VWF:Ag 
Levels of VWF:Ag differed significantly between etiologic subtypes of TIA and ischemic stroke 
(P=0.006; Figure 3). Levels of VWF:Ag were significantly increased in patients with a large 
artery atherosclerosis of TIA or ischemic stroke, compared with the other subtypes (1.59 vs. 
1.40 IU/ml, P<0.0001). Patients with a small vessel occlusion etiology had significantly lower 
levels of VWF:Ag compared with the other patients (1.34 vs. 1.45 IU/ml, P=0.009).
Patients with a definite atherothrombotic stroke using the A-S-C-O score variant had 
significantly higher VWF:Ag levels (1.58 IU/ml) compared with patients with a probable 
atherothrombotic stroke (1.40 IU/ml; P=0.001), other cause of stroke (1.24 IU/ml; P=0.009) 
and unknown cause of stroke (1.32 IU/ml; P<0.0001). Patients with a definite lacunar 
stroke had significantly higher VWF:Ag levels (1.66 IU/ml) compared with probable 
atherothrombotic (P=0.04), other cause of stroke (P=0.013) and with unknown cause of 
stroke (P=0.009). 
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VWF levels were significantly correlated with the NIHSS score at admission (R=0.183, 
P<0.0001) and with functional outcome of the patients, as determined by the modified 
Rankin Scale (mRS) at discharge (R=0.222, P<0.0001). Patients with an unfavorable outcome 
(mRS >2) had significantly higher VWF:Ag levels compared with patients with a favorable 
outcome (mRS ≤2) (1.64 IU/ml vs. 1.41 IU/ml, P<0.0001). However, these patients did not 
have a significant higher calcification volume in both the aortic arch (23.1 vs. 17.0 mm3, 
P=0.17) and carotid arteries (6.6 vs. 5.6 mm3, P=0.45), compared with patients with a 
favorable outcome. Patients with a high VWF:Ag level (>1.43 IU/ml) had a higher risk of an 
unfavorable outcome compared with patients with a low VWF:Ag level (≤ 1.43 IU/ml; OR 
1.45, P<0.0001) and this difference remained after additionally adjustment for aortic arch 
and carotid calcification volume. However, there was no significant difference in outcome 
between patients with blood group O and non-O (OR 0.95, P=0.40). 
Figure 3
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figure 3. Levels of mean VWF:Ag per etiologic subtypes of TIA and ischemic stroke
Mean and standard error (SE) VWF:Ag levels (IU/ml) in the etiologic subtypes of TIA and ischemic 
stroke according to the TOAST criteria. 
* indicates P<0.0001; † P<0.05
LAA indicates large artery atherosclerosis; CE, cardioembolism; SVO, small vessel occlusion; Other, 
stroke of other determined etiology; Undetermined, cerebral ischemia of undetermined etiology
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table 2. Association between calcification volume and VWF:Ag levels
Calcification volume (mm3) Mean VWf:Ag (iu/ml)
Model 1
Mean VWf:Ag (iu/ml)
Model 2
Aortic arch
0 1.26 ± 0.03 1.36 ± 0.03
0.01-41 1.42 ± 0.04 1.41 ± 0.04
41.01-257.4 1.54 ± 0.04 1.48 ± 0.04
>257.4 1.67 ± 0.04 1.54 ± 0.05
P for trend <0.0001 0.03
Carotid artery
0 1.27 ± 0.03 1.34 ± 0.03
0.01-10.1 1.47 ± 0.04 1.43 ± 0.04
10.11-63.9 1.49 ± 0.05 1.46 ± 0.04
>63.9 1.73 ± 0.05 1.61 ± 0.05
P for trend <0.0001 <0.0001
Mean VWF:Ag levels (mean ± SE) per calcification volume subgroup
Model 1: univariate
Model 2: adjusted for age, sex, blood group and cardiovascular risk factors
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diSCuSSion
The main result of our study is a strong positive association between the extent of 
atherosclerosis, determined by the calcification volume in both the aortic arch and the 
carotid arteries, and VWF:Ag levels in patients with ischemic stroke. In addition, we observed 
that levels of VWF were significantly higher in patients with a large artery atherosclerosis 
type of ischemic stroke compared to other stroke subtypes. 
To the best of our knowledge, our study is the first to investigate the extent of atherosclerosis, 
using newly developed quantitative measurements, and VWF levels in patients with TIA 
or ischemic stroke. We found similar positive associations in both aortic arch calcification 
volume and carotid calcification volume with VWF:Ag levels. Furthermore, patients with the 
highest score for both the aortic arch calcification volume and carotid calcification volume 
had the highest VWF:Ag levels. VWF:Ag levels were strongly associated with large artery 
atherosclerosis. 
It is still debated whether VWF itself plays a pathogenetic role in atherogenesis. Despite 
the fact that several animal models indicated that VWF may lead to a reduction of 
atherosclerosis(27, 28), multiple human studies failed to confirm this observation. In these 
studies a similar extent of atherosclerosis in individuals with severe von Willebrand disease 
(VWD), characterized by reduced levels of VWF, was shown compared with controls (29-33). 
It is well known that genetic variations, both within the VWF gene and outside the VWF 
gene, strongly determine VWF levels (11, 12, 34-36). One of the main genetic determinants 
of VWF levels is the ABO blood group, resulting in 25-30% lower levels in individuals with 
blood group O compared to non-O(37). Also in our study, ischemic stroke patients with 
blood group O had 30% lower VWF:Ag levels compared to patients with blood group non-O, 
but did not have lower calcification volumes. This finding suggests that VWF levels do not 
have a major pathogenetic role in atherosclerosis. In addition, it is still debatable whether 
blood group is a risk factor for ischemic stroke (38, 39). An earlier study of our group already 
showed that, despite the fact that several genetic variations were strongly associated with 
VWF levels, the genetic variations did not influence the risk of ischemic stroke(11). This 
suggests that VWF levels are merely a marker of atherosclerosis and thereby determine 
the previously found association between increased VWF:Ag levels and risk of stroke, as 
atherosclerosis is a well-known important risk factor for TIA and ischemic stroke. 
Patients with a small vessel occlusion ischemic stroke had lower levels of VWF:Ag than the 
other stroke patients. This was comparable with another study, which showed that patients 
with a small vessel disease type of stroke, had lower VWF levels compared with the large 
vessel disease and cardio embolism group(7). These lower VWF levels may be explained by 
the fact that in these patients atherosclerosis does not play a major role in the etiology of 
stroke. However, the small arterioles of the brain are presumed to be affected by various 
vascular risk factors(40). This may also lead to endothelial activation, but only to certain 
subtypes of lacunar infarcts (41). However, lacunar stroke described in the A-S-C-O score 
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variant was associated with high VWF:Ag levels. This might be explained by the difference in 
the number of patients (N=22 A-S-C-O score, N=183 TOAST classification) and a difference in 
definition. In this study, VWF:Ag levels were associated with stroke severity, determined by 
the NIHSS at admission and with poor outcome, determined by the mRS at discharge. This 
is in agreement with one previous study in patients with acute ischemic and hemorrhagic 
stroke in which high VWF levels were associated with a poor modified Rankin score (42). 
Recently we showed in the prospective population-based Rotterdam study that increased 
VWF levels are a predictor of stroke (9). In this study we have shown that increased VWF 
levels and not blood group are a predictor of stroke outcome suggesting that VWF levels 
could serve as a risk marker of stroke outcome. Additionally, because levels of VWF are 
increased due to presence of atherosclerosis, VWF could also serve as a useful marker of 
atherosclerosis and thereby as a risk marker of stroke. 
Some methodological issues have to be addressed. Strengths of our study are the large 
number of ischemic stroke patients of all ages, with availability of well-documented clinical 
information, extensive scoring (>96%) of MDCT angiography of the aortic arch and the 
carotid arteries, and the availability of plasma of nearly all consecutive patients. 
Furthermore, we determined calcifications of the aortic arch and carotid arteries using 
dedicated commercially available software in which calcifications of the aortic arch and 
carotid arteries can be reproducible quantified in a specified range. So far only limited data 
was available regarding calcifications in the carotid arteries as a marker of atherosclerosis. 
In this study, we found a significantly higher prevalence of cardiovascular risk factors in 
patients with calcifications in the aortic arch and carotid arteries than in patients without 
calcifications. This is in agreement with another study, which showed an independent 
relationship between several cardiovascular risk factors and carotid calcifications and similar 
risk factor profiles were found in different vessel beds including the coronary arteries, aortic 
arch and carotid arteries (17). Calcifications in the aortic arch and carotid arteries were 
associated with the presence of stroke and luminal stenosis in previous studies (18, 19, 43, 
44). This all shows that calcifications in the aortic arch and carotid arteries can be used as a 
marker of atherosclerosis.
A potential drawback of our study is that calcifications below the threshold of 600 HU or 
outside the scan range were not detected. Another possible limitation concerns the fact 
that calcifications are one of the components of an atherosclerotic plaque and a soft 
atherosclerotic plaque that contains no calcification is therefore not detected (43). However, 
it has been shown that the majority (82%) of atherosclerotic plaques contains some 
calcifications (25) and therefore this would only minimally affect our results. In addition, 
time between stroke and blood sampling was variable. However, there was no significant 
correlation between VWF levels and time from event till blood sampling. This suggests that 
the time of blood drawn did not influence the levels of VWF. Furthermore, patients with 
significant comorbidity, very severe stroke or those who died within 24 hours were not 
included in this study, resulting in a relatively less severely affected cohort. 
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ConCluSion
In conclusion, our study in patients with TIA or ischemic stroke indicates that the extent 
of atherosclerosis, determined by calcifications in the aortic arch and carotid arteries, is 
strongly associated with VWF levels. In addition, highest VWF levels are found in large 
vessel disease, whereas the levels are lower in small vessel disease. Furthermore, our study 
suggests that VWF may have prognostic value in patients with ischemic stroke.
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SuPPleMentAl inforMAtion
Lacunar stroke is defined as a small deep infarct on scan <15 mm in the territory cor-
responding to symptoms in a patient with a clinical syndrome compatible with small deep 
infarct. Definite atherothrombotic stroke is defined by (1) an ipsilateral internal carotid 
stenosis ≥50% or (2) an ipsilateral stenosis ≥50% in another intra/extracranial artery (also 
in vertebrobasilar system if applicable), or (3) mobile thrombus in the aortic arch. Probable 
atherothrombotic stroke is defined as patients with ipsilateral internal carotid or other intra/
extracranial artery <50% stenosis, contralateral stenosis; patients with ≥2 of the following risk 
factors for atherothrombotic disease: hypertension (as defined above), diabetes mellitus, 
smoking at time of event, high cholesterol. Definite cardiac cause is defined as patients 
with atrial fibrillation, atrial flutter, sick sinus syndrome, prosthetic valve, mitral stenosis, 
recent myocardial infarction (<6 weeks), left ventricular thrombus, atrial myxoma, infective 
endocarditis, non-ischemic dilating cardiomyopathy, non-bacterial thrombotic endocarditis. 
Possible cardiac cause is defined by patients with calcific aorta stenosis, mitral valve prolaps, 
mitral annulus calcification, patent foramen ovale, atrial septal aneurysm, ventricular 
aneurysm, ventricular septal defect, other structural cardiac abnormalities not mentioned 
above. Definite hematologic cause is defined as patients with disseminated intravascular 
coagulation, myeloproliferative disorders, essential thrombocythemia, polycythemia vera 
and antiphospholipid syndrome (the full syndrome). Possible hematologic cause is defined 
as patients with protein C deficiency, protein S deficiency, antithrombin deficiency, factor 
V Leiden, isolated lupus anticoagulans, single increased antiphospholipid antibodies (not 
confirmed with second increased measurement), and other hematologic causes. In other 
causes of stroke carotid or vertebral dissection, vasculitis, AVMs, Moyamoya, Fabry, other 
vascular causes, hemodynamic stroke, migrainous stroke, neoplasm and miscellaneous 
causes are included. Unknown cause stroke is defined as patients whom, based on all 
available data, cannot be categorized into either of the above categories.
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AbStrACt
backgrounds
High VWF plasma levels are associated with an increased risk of coronary artery disease. It 
has been suggested that the increase of VWF levels is partly due to endothelial dysfunction 
and atherosclerosis. Our aim was to investigate the association between coronary plaque 
burden, the presence of high-risk coronary lesions as measured by intravascular ultrasound 
virtual histology (IVUS-VH) and VWF levels. In addition, we studied the association between 
VWF levels and 1-year cardiovascular outcome.
Methods
Between 2008 and 2011, IVUS-VH imaging of a non-culprit coronary artery was performed in 
581 patients undergoing coronary angiography for acute coronary syndrome (ACS) (n= 318) 
or stable angina pectoris (SAP) (n= 263). Arterial blood was sampled prior to the coronary 
angiography. VWF antigen (VWF:Ag) levels were measured using ELISA (n= 577).
results
Patients with ACS had significantly higher VWF:Ag levels than SAP patients (median 1.73 IU/
ml [IQR 1.27-2.31] vs. 1.26 IU/ml [0.93-1.63], p<0.001). High coronary plaque burden was 
associated with higher VWF:Ag levels (ẞ= 0.12, p=0.027) in SAP patients, but not in ACS 
patients. In ACS patients, VWF:Ag levels were associated with 1-year MACE (HR 4.14 per SD 
increase of lnVWF:Ag, 95% CI 1.47-11.6), whereas in SAP patients VWF:Ag levels predicted 
1-year all-cause death and hospitalisation for ACS (HR 7.07 95% CI 1.40-35.6).  
Conclusions
Coronary plaque burden was associated with VWF:Ag levels in SAP patients undergoing 
coronary angiography. In ACS and SAP patients, high VWF levels are predictive of adverse 
cardiovascular outcome and death during 1-year follow-up. 
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introduCtion
Von Willebrand Factor (VWF) is a multimeric protein that plays a crucial role in primary 
hemostasis by mediating platelet adhesion and aggregation (1). VWF is produced by 
endothelial cells and megakaryocytes and stored in Weibel-Palade bodies in the endothelium 
and alpha-granules of platelets. VWF plasma levels are increased at moments of endothelial 
damage and are a marker of endothelial dysfunction (2). 
It is well known that high VWF levels are associated with an increased risk of coronary 
heart disease and ischemic stroke in the general population (3-8). However, the underlying 
mechanisms of this association are still unclear. As high VWF levels are seen in situations with 
endothelial dysfunction, which is an important early process in atherosclerosis development, 
it has previously been suggested that VWF has a pathogenic role in atherosclerosis. This 
hypothesis is supported by results from animal studies (9-11). However, studies in patients 
with type 3 von Willebrand disease, characterized by a total deficiency of VWF in the 
circulation, revealed no reduction in atherosclerotic lesions (12-14). The role of VWF in the 
development of atherosclerosis in humans is therefore still unresolved. In a recent study, 
we observed a strong association between the extent of atherosclerosis, measured by the 
calcification volume in the aortic arch and carotid arteries, and VWF levels in ischemic stroke 
patients (15). Because VWF also plays a pivotal role in platelet aggregation and thrombus 
formation, these high VWF levels may further increase the risk of coronary events in patients 
with high risk atherosclerotic lesions. 
Intravascular ultrasound (IVUS) can accurately quantify coronary atherosclerosis (16, 17). A 
previous study in 697 patients with an acute coronary syndrome at inclusion showed that 
half of the incident recurrent cardiovascular events occurred in patients with non-culprit 
lesions present at baseline, assessed by IVUS imaging (18). High-risk coronary lesions that 
are predictive for events include lesions with a plaque burden of at least 70%, a minimal 
luminal area of 4.0 mm2 or less, or the presence of IVUS virtual histology (VH)-derived thin-
cap fibroatheroma lesions (VH-TCFA) (18). 
In order to gain further insight into the relationship between VWF levels and cardiovascular 
outcome, the aim of the present study was to investigate the associations of coronary plaque 
burden, and the presence of high-risk coronary lesions as assessed by virtual histology 
intravascular ultrasound (VH-IVUS) with VWF levels, as well as to investigate the association 
of VWF with 1-year cardiovascular outcome in patients with coronary artery disease (CAD). 
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MetHodS
Study population
The design of The European Collaborative Project on Inflammation and Vascular Wall 
Remodeling in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-IVUS) study has 
been described in detail elsewhere (19). In brief, 581 patients who underwent diagnostic 
coronary angiography or percutaneous coronary intervention (PCI) for an acute coronary 
syndrome (ACS) or stable angina pectoris (SAP) have been included between 2008 and 2011 
in the Erasmus MC, Rotterdam, the Netherlands. 
The ATHEROREMO-IVUS study was approved by the medical ethics committee of the 
Erasmus MC. The study was performed in accordance with the criteria described in the 
declaration of Helsinki. Written informed consent was obtained from all included patients. 
This study is registered in ClinicalTrials.gov, number NCT01789411.
Von Willebrand factor measurement
Blood samples were drawn from the arterial sheath prior to the coronary angiography 
procedure. The blood samples were transported to the clinical laboratory of the Erasmus 
MC for further processing and storage at temperature of -80oC within 2 hours after blood 
collection. VWF antigen (VWF:Ag) levels were determined (N=577) using citrate blood with 
an in-house ELISA using rabbit anti-human VWF antibodies (DakoCytomation, Glostrop, 
Denmark) for catching and tagging. Reference standard plasma was calibrated against the 
international standard (Cryocheck Reference, Kordia, Leiden, The Netherlands) and was 
used as a calibrator. The intra- and inter-assay coefficients of variation were 2.6% and 4.7%.. 
intracoronary ultrasound imaging
Following the standard coronary angiography procedure, IVUS imaging of a non-culprit 
coronary artery was performed. Selection of the non-culprit vessel was predefined in the 
study protocol. The order of preference for selection of the non-culprit vessel was: 1. left 
anterior descending (LAD) artery; 2. right coronary artery (RCA); 3. left circumflex (LCX) 
artery. All IVUS data were acquired with the Volcano s5/s5i Imaging System (Volcano Corp., 
San Diego, CA, USA) using a Volcano Eagle Eye Gold IVUS catheter (20 MHz). An automatic 
pullback system was used with a standard pull back speed of 0.5 mm per second. The baseline 
IVUS images were sent to an independent core laboratory (Cardialysis BV, Rotterdam, the 
Netherlands) for offline analysis. The core laboratory personnel were blinded for baseline 
patient characteristics and clinical outcome data. The IVUS virtual histology analyses were 
performed using pcVH 2.1 and qVH (Volcano Corp., San Diego, CA, USA) software. 
The external elastic membrane and luminal borders were contoured for each frame (median 
interslice distance, 0.40 mm). Extent and phenotype of the atherosclerotic plaque were 
assessed. Plaque burden was defined as plaque and media cross-sectional area divided by 
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external elastic membrane cross-sectional area (FIGURE 1). A coronary lesion was defined 
as a segment with a plaque burden of more than 40% in at least 3 consecutive frames. Three 
types of high-risk lesions were identified: 1. Virtual histology-derived thin-cap fibroatheroma 
(VH-TCFA) lesion, defined as a lesion with presence of >10% confluent necrotic core in direct 
contact with the lumen; 2. lesion with large plaque burden, defined as a lesion with a plaque 
burden of ≥70%; 3. stenotic lesion, defined as a lesion with a minimal luminal area of ≤4.0 
mm2 (Figure 1) (18, 20-22). 
figure 1. Measurement of plaque burden and identification of high risk lesions with intravascular 
ultrasound virtual histology
A: Plaque burden is defined as plaque and media cross-sectional area (green) divided by external 
elastic membrane cross-sectional area (contoured in blue). B: Thin-cap fibroatheroma lesion, defined 
as a lesion with presence of >10% confluent necrotic core (red) in direct contact with the lumen. White 
indicates dence calcium, light green indicates fibrofatty tissue, and dark green indicates fibrous tissue. 
C: Lesion with plaque burden of ≥70%. D: Lesion with a minimal luminal area of ≤4.0 mm2.
Clinical endpoints
Clinical follow-up started at inclusion and lasted 1 year. Post-discharge survival status was 
obtained from municipal civil registries. Post-discharge rehospitalizations were prospectively 
assessed during follow-up. Questionnaires focusing on the occurrence of major adverse 
cardiac events (MACE) were sent to all living patients. Subsequently, hospital discharge 
letters were obtained and treating physicians and institutions were contracted for additional 
information whenever necessary. 
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The primary endpoint was MACE, defined as all-cause mortality, ACS or unplanned coronary 
revascularization. ACS was defined as the clinical diagnosis of ST segment elevation myocardial 
infarction (STEMI), non-STEMI or unstable angina pectoris in accordance with the guidelines 
of the European Society of Cardiology (23). Unplanned coronary revascularization was 
defined as unplanned repeat PCI (either culprit or non-culprit coronary artery) or coronary 
artery bypass grafting (CABG). The secondary endpoint was defined as the composite of all-
cause mortality or ACS. The endpoints were adjudicated by a clinical event committee that 
had no knowledge of the VWF:Ag levels and IVUS data. 
Statistical analysis
The distributions of the continuous variables, including VWF levels and the IVUS 
parameters, were tested for normality by visual examination of the histogram. Normally 
distributed continuous variables are presented as mean ± standard deviation (SD). Non-
normally distributed continuous variables are presented as median and interquartile range 
(IQR). VWF levels were not normally distributed and were therefore natural logarithmically 
(ln) transformed (lnVWF:Ag), where after a normal distribution was acquired. Categorical 
variables are presented as numbers and percentages. We examined associations of plaque 
burden and presence of high-risk coronary lesions with VWF:Ag levels. VWF:Ag levels and 
plaque burden were divided into tertiles. To test for linear association, we used linear 
regression analyses with continuous ln-transformed VWF:Ag level as dependent variable. 
In multivariable analyses, the covariates age, gender, diabetes mellitus, hypertension, 
hypercholesterolemia, smoking and history of myocardial infarction were considered as 
established cardiovascular risk factors and as potential confounders, and were therefore 
entered into the full model. 
Patients lost to follow-up were considered at risk until the date of last contact, at which 
time-point they were censored. Cumulative event rates were estimated according to the 
Kaplan-Meier method. Cox proportional hazards regression analyses were performed to 
evaluate the associations between VWF:Ag levels and study endpoints. Analyses were 
adjusted for age, gender and plaque burden. The final results are presented as crude and 
adjusted hazard ratios (HR) with 95% confidence interval (95% CI). 
We a priori expected that there might be heterogeneity in effect estimates between 
patients with ACS and patients with stable angina pectoris, since VWF:Ag levels are known 
to be elevated in the acute phase of an ACS (24, 25). Therefore, all statistical analyses 
were performed separately for patients with ACS and patients with stable angina pectoris 
at inclusion. Data were analyzed with SPSS software (SPSS 20.0, IBM corp., Armonk, NY, 
USA). All statistical tests were two-tailed and p-values <0.05 were considered statistically 
significant.
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table 1. Baseline characteristics
Patient characteristics ACS patients (n=315) SAP patients (n=262)
Age, years 59.7 ± 11.8 63.6 ± 10.2
Men, n (%) 232 (73.7) 203 (77.5)
Diabetes mellitus, n (%) 40 (12.7) 59 (22.5)
Hypertension, n (%) 138 (43.8) 161 (61.5)
Hypercholesterolemia, n (%) 139 (44.1) 180 (68.7)
Smoking, n (%) 117 (37.1) 50 (19.1)
Positive family history, n (%) 145 (46.0) 155 (59.2)
Previous MI, n (%) 80 (25.4) 104 (39.7)
Previous PCI, n (%) 57 (18.1) 128 (48.9)
Previous CABG, n (%) 7 (2.2) 11 (4.2)
Previous stroke, n (%) 11 (3.5) 15 (5.7)
Peripheral artery disease, n (%) 12 (3.8) 24 (9.2)
History of renal insufficiency, n (%) 13 (4.1) 19 (7.3)
History of heart failure, n (%) 6 (1.9) 13 (5.0)
Von Willebrand Factor, IU/mL 1.73 [1.27-2.31] 1.26 [0.93-1.63]
Procedural characteristics
Coronary artery disease
   No significant stenosis, n (%) 18 (5.7) 25 (9.5)
   1-vessel disease, n (%) 174 (55.2) 133 (50.8)
   2-vessel disease, n (%) 88 (27.9) 78 (29.8)
   3-vessel disease, n (%) 35 (11.1) 26 (9.9)
PCI performed, n (%) 293 (93.0) 214 (81.7)
iVuS segment characteristics
Imaged coronary artery
   Left anterior descending, n (%) 120 (38.1) 88 (33.6)
   Left circumflex, n (%) 110 (34.9) 84 (32.1)
   Right coronary artery, n (%) 85 (27.0) 90 (34.4)
Segment length, mm 44.1 [33.0-54.3] 44.3 [34.3-57.2]
Data are presented as mean ± standard deviation or as median [interquartile range]. 
ACS = acute coronary syndrome; CABG = coronary artery bypass grafting; MI = myocardial infarction; PCI = 
percutaneous coronary intervention; SAP = stable angina pectoris. 
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table 2. Number of patients with incident major adverse cardiac events
number of patients ACS Patients (n=315) SAP Patients (n=262)
Composite of major adverse cardiac events 26 29
   Death from any cause 13 4
      Definite cardiac or unexplained sudden death 6 2
   Acute coronary syndrome 7 7
      Myocardial infarction 4 3
   Unplanned coronary revascularization 6 18
Composite of death or acute coronary syndrome 20 11
ACS = acute coronary syndrome; SAP = stable angina pectoris. 
reSultS
In total 577 patients were included, 315 had an ACS and 262 had a SAP. Patients had a 
mean age of 61.5 years and 75% were men (Table 1). Over half of the patients had single 
vessel disease. SAP patients had a higher prevalence of cardiovascular risk factors than 
ACS patients. ACS patients were more likely to smoke. ACS patients had significantly higher 
VWF:Ag levels than patients with SAP (median 1.73 IU/ml [IQR 1.27-2.31] vs. 1.26 IU/ml 
[0.93-1.63], p<0.001) (Table 1). 
figure 2. Coronary plaque burden of imaged coronary segment in relation to Von Willebrand Factor levels 
Mean ± standard error VWF:Ag levels per tertile coronary plaque burden. ACS = acute coronary 
syndrome; SAP = stable angina pectoris; VWF:Ag = von Willebrand Factor antigen. 
Plaque burden was significantly higher in SAP patients than in ACS patients (39.7 ± 11.0 % 
vs. 36.9 ± 11.8 %, p = 0.005). In SAP patients, higher plaque burden was associated with 
higher VWF:Ag levels (P for trend 0.015) (Figure 2). Also after adjustment for established 
cardiovascular risk factors in multivariable analysis, higher plaque burden remained 
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associated with higher VWF:Ag levels (p = 0.027) in patients admitted with SAP. In ACS 
patients, the coronary plaque burden was not associated with VWF:Ag levels (P for trend 
0.84). VWF:Ag levels were not significantly different between patients with and without 
high risk coronary lesions in both ACS and SAP patients (Figure 3). 
For 575 (99.7%) patients the vital status at 1-year follow-up could be acquired, and the 
response rate to the questionnaires that were sent to all living patients was 93.4%. After 
1 year of follow-up, 55 patients (9.6%) had experienced a MACE (Table 2). The cumulative 
Kaplan-Meier incidences of the 1-year MACE was 8.3% for patients with ACS, and 11.1% 
for patients with SAP. The risk of all-cause death and ACS was significantly associated with 
higher VWF:Ag levels in both ACS patients (HR 7.45, 95% CI 2.15-25.9, P=0.002) and patients 
with SAP (HR 7.07 95% CI 1.40-35.6, P=0.018). Additional adjustment for plaque burden 
did not affect the risk estimate for all-cause death and ACS in ACS patients (HR 7.65 95% 
CI 2.16-27.2), while the risk in SAP patients was slightly lower (HR 4.05 95% CI 0.88-18.7). 
Higher VWF:Ag levels were also significantly associated with a higher incidence of MACE in 
ACS patients (HR 4.14, 95% CI 1.47–11.6, P=0.007), but not in patients with SAP (HR 1.31, 
95% CI 0.52-3.29, p=0.57) (Table 3, Figure 4). Additional adjustment for plaque burden did 
not change the results.
table 3. Associations between von Willebrand Factor level and cardiovascular outcome
ACS patients SAP patients
HR (95%CI)* P HR (95%CI)* P
MACe
   Unadjusted 4.28 (1.61-11.4) 0.004 1.39 (0.56-3.42) 0.48
   Adjusted for age and gender 4.14 (1.47-11.6) 0.007 1.31 (0.52-3.29) 0.57
   Adjusted for age, gender and plaque burden 4.13 (1.47-11.6) 0.007 1.08 (0.43-2.70) 0.87
Composite of death or ACS
   Unadjusted 7.15 (2.21-23.1) 0.001 7.62 (1.58-36.8) 0.011
   Adjusted for age and gender 7.45 (2.15-25.9) 0.002 7.07 (1.40-35.6) 0.018
   Adjusted for age, gender and plaque burden 7.65 (2.16-27.2) 0.002 4.05 (0.88-18.7) 0.073
* Hazard ratio per SD increase in ln-transformed Von Willebrand Factor level.
ACS = acute coronary syndrome; MACE = major adverse cardiac event; SAP = stable angina pectoris.
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figure 3. High risk coronary lesions in relation to Von Willebrand Factor levels
Mean ± standard error VWF:Ag levels between high-risk coronary lesions present or absent. 
ACS = acute coronary syndrome; MLA = minimal luminal area; PB = plaque burden; SAP = stable angina 
pectoris; TCFA = thin-cap fibroatheroma; VWF:Ag = von Willebrand Factor antigen.
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figure 4. Von Willebrand Factor and cardiovascular outcome 
Kaplan-meier curve for the cumulative event-free survival of MACE or death and hospitalization for 
ACS per VWF:Ag above and below the median (1.45 IU/ml). ACS = acute coronary syndrome; SAP = 
stable angina pectoris.
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diSCuSSion
This is the first study that has investigated the association between invasive measured 
coronary atherosclerosis by VH-IVUS and VWF:Ag levels. We have shown that patients with 
an ACS have significantly higher VWF levels than patients with SAP. In patients with SAP, 
coronary plaque burden was positively associated with VWF:Ag levels. In addition, high 
VWF:Ag levels were associated with death and ACS at 12 months follow up and this was also 
observed for all MACE in patients with ACS.
The exact pathophysiologic role of VWF in cardiovascular disease has not been elucidated 
yet. First, it has been hypothesized that VWF may play a causal role in the development of 
atherosclerosis, thereby increasing the risk of CAD. This was suggested by animal studies 
with VWF deficient mice, which showed less development of atherosclerosis (9-11). 
However, human studies, for instance in patients with type 3 von Willebrand disease who 
have a complete deficiency of VWF, could not confirm these findings (12, 14). However, 
these patients may incidentally receive VWF concentrates and some use prophylaxis at 
regular basis and are therefore not completely VWF deficient. It is now suggested that the 
association between atherosclerosis and VWF is mainly driven by the fact that VWF is a 
marker of endothelial damage, which is also observed in atherosclerosis (26, 27). 
In this study we found that patients with ACS had significantly higher VWF:Ag levels 
compared with SAP patients, which is in line with a previous study (24). The finding that 
plaque burden was associated with VWF:Ag levels in SAP patients confirms our previous 
findings that VWF is associated with the extent of atherosclerosis. In our previous study 
in ischemic stroke patients, we observed that a higher calcification volume in the aortic 
arch and carotid arteries was associated with higher VWF:Ag levels (15). The fact that there 
was no association between plaque burden and VWF:Ag levels in ACS patients might be 
explained by the strongly increased VWF:Ag levels in these patients due to an acute phase 
response, which is well known for VWF (2, 25). 
We observed no association between several types of high-risk coronary lesions, including 
thin-cap fibroatheroma lesions, lesions with plaque burden ≥70% or lesions with a minimal 
luminal area ≤4.0mm2 and VWF:Ag levels. High risk lesions are precursors of plaque 
rupture and may thereby account for the occurrence of coronary thrombi (18, 22, 28). Our 
results suggest that although VWF is associated with the extent of atherosclerosis, it is not 
associated with the phenotypic more vulnerable atherosclerotic lesions and might be more 
involved in stable atherosclerosis. However, a previous mice study showed, by molecular 
imaging, that activated VWF was found in atherosclerotic disease with high risk features 
(29). This difference might be explained by the VWF measurement, as only locally activated 
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VWF was measured in the mice study and in our study we measured circulating VWF:Ag 
plasma levels. In addition, a difference in the pathophysiologic mechanism of destabilising 
the plaque between mice and human could also influence the results (30-33). 
Our data on the association between VWF:Ag levels and MACE in ACS patients strengthens 
findings of previous studies suggesting that VWF has a predictive role in cardiovascular 
outcome (34-39). These results were not affected by additional adjustment for plaque 
burden, suggesting a role for VWF in cardiovascular outcome. In SAP patients, we found an 
association between high VWF levels and risk of death or ACS. After additional adjustment 
for plaque burden the association was not significant anymore in SAP patients, which may 
be explained by the small sample size, resulting in reduced power. These data suggest that 
the high VWF levels observed in ACS patients, the most severe CAD patients, at inclusion 
predict MACE at follow-up. However, in the definition of MACE unplanned revascularisation 
was included which may be considered as a weaker end-point and could therefore have 
influenced the adverse outcome risk (40). Overall these data supports the role for VWF in 
the prognosis of patients with a CAD, independent of plaque burden. 
There are some limitations of this study. First, blood was sampled in the acute phase at 
the moment of the coronary angiography. This may explain the higher VWF:Ag levels in 
ACS patients compared with SAP patients. Therefore, this could have influenced our results. 
However, we separated the ACS and SAP patients for all analyses. Secondly, a single non-
culprit coronary vessel was imaged in this study. This may have led to an underestimation 
of the association between the presence of high risk lesions in the overall coronary tree and 
VWF:Ag levels. However, a previous study have shown that culprit and non-culprit lesions 
were equally related to MACE (18). In addition, the spatial resolution of IVUS-VH (150 µm) 
is insufficient to exactly replicate histopathologic definitions of a thin fibrous cap (<65 µm) 
(41). Therefore, IVUS-VH tends to overestimate the number of thin-cap fibroatheroma 
lesions. Nevertheless, the presence of VH-TCFA lesions has been shown to carry prognostic 
information (18, 22). Finally, due to the cross-sectional design our data is not able to 
distinguish whether VWF is causal or a marker of atherosclerosis. 
In conclusion, the extent of coronary atherosclerosis is associated with VWF:Ag levels in 
SAP patients undergoing coronary angiography, but not in ACS patients which might be ex-
plained by the acute phase response. High VWF:Ag levels have a predictive role for adverse 
cardiovascular outcome, and also for MACE in ACS patients, independent of plaque burden. 
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AbStrACt
background
High Von Willebrand Factor (VWF) and low ADAMTS13 levels are associated with 
an increased risk of ischemic stroke and myocardial infarction. One of the candidate 
mechanisms underlying this association may be the increase of VWF levels by atherosclerosis. 
Therefore, we assessed the association between novel imaging biomarkers of the advanced 
atherosclerotic plaque and VWF levels and ADAMTS13 activity.
Methods
In 180 patients of the PARISK-study with a recent TIA or ischemic stroke and a symptomatic 
mild-to-moderate carotid artery stenosis (Plaque-At-RISK; clinicaltrials.gov NCT01208025), 
we measured VWF antigen (VWF:Ag) and ADAMTS13 activity. Imaging biomarkers of carotid 
atherosclerosis were determined by MDCTA (n=158) and MRI (n=169). In this cross-sectional 
analysis, we used linear regression analysis to assess the association between imaging 
biomarkers and VWF:Ag levels and ADAMTS13 activity.
results
Age and blood group were associated with VWF:Ag (β=0.01 IU/ml, p=0.001; β=0.22 IU/ml, 
p<0.001). Age and time between event and blood withdrawal were inversely associated 
with ADAMTS13 (β=-0.60%, p=0.002; β=-0.13%, p=0.008). None of the imaging biomarkers 
were associated with VWF:Ag or ADAMTS13.
Conclusion
In our study, we found no association between imaging biomarkers of advanced athero-
sclerosis and VWF and ADAMTS13 in patients. It remains unclear whether the blood bio-
markers mark widespread atherosclerosis or have a more complex role in atherosclerotic 
plaque development.
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introduCtion
Atherosclerosis of the carotid arteries is an important risk factor for ischemic strokes. With 
improved imaging techniques like multidetector-row computed tomography (MDCTA) and 
magnetic resonance imaging (MRI), atherosclerotic burden can be quantified by for example 
degree of stenosis, maximum vessel wall area or calcification volume; and characteristics 
of the vulnerable – rupture-prone – plaque can be visualized like plaque ulceration, 
intraplaque hemorrhage (IPH) and lipid core (1, 2). Vulnerable plaque rupture is crucial 
in the pathophysiological cascade from atherosclerotic plaque development to thrombus 
formation and eventually ischemic stroke or TIA. 
Von Willebrand Factor (VWF) has an important function in primary hemostasis via its role 
in platelet adhesion and aggregation, and increases as a result of endothelial damage. A 
Disintegrin And Metalloprotease with ThromboSpondin motif repeats 13 (ADAMTS13) 
cleaves large VWF multimers into smaller and less prothrombotic forms. Levels of VWF 
are increased in ischemic stroke patients and the highest levels of VWF are found in large 
vessel disease and cardio-embolic strokes (3, 4). High VWF and low ADAMTS13 levels 
are associated with an increased risk of ischemic stroke and myocardial infarction (5-7). 
One of the candidate mechanisms underlying the association between VWF and ischemic 
stroke may be atherosclerosis. Previous studies suggest that atherosclerosis (and not only 
thrombus formation) is a determinant of VWF levels (8). On the other hand, in vitro and in 
vivo studies suggest that VWF might contribute to the pathogenesis of atherosclerosis (9). 
In addition, studies on animals with a VWF deficiency suggest that VWF deficiency has a 
protective effect against atherosclerosis and VWF may be a determinant of atherosclerosis 
(9-11). When taking all these studies together, the data on this topic are inconclusive (9, 12, 
13). We expect that, due to the role of ADAMTS13 in the metabolism of VWF, atherosclerosis 
might play a role in the association between ADAMTS13 and ischemic events as well. 
The aim of our study was to evaluate the association between novel imaging biomarkers 
of the atherosclerotic plaque and VWF and ADAMTS13 in patients with a recent TIA or 
ischemic stroke and a symptomatic mild-to-moderate carotid artery stenosis to help clarify 
the association between atherosclerosis, VWF and ADAMTS13. 
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MetHodS
Study population
Patients were derived from the PARISK-study (Plaque-At-RISK; clinical trials.gov 
NCT01208025); details of the study design have been previously described (14). The 
PARISK-study is a prospective multicenter cohort study using non-invasive plaque imaging 
to identify patients with an ipsilateral mild-to-moderate carotid artery stenosis (30-69%) 
with an increased risk of recurrent stroke. All included patients had a recent TIA, including 
amaurosis fugax, or minor stroke in the carotid artery territory prior to inclusion. Institutional 
Review Board approval was obtained and all patients gave written informed consent.
Between September 2010 and December 2014, 240 patients were included in the PARISK-
study; 180 patients had either a MDCTA (n=158) or MRI (n=169) of the carotid arteries, and 
had an available blood sample.
MdCtA and 3t Mri data acquisition and analysis
Standardized, previously described, contrast-enhanced MDCTA and multi-sequence 
contrast-enhanced MRI protocols were used (14). All imaging studies were evaluated by 
trained readers blinded for clinical data and other imaging tests (15).
MDCTA images were reviewed using dedicated 3D analysis software (Leonardo and syngo.
via; Siemens, Erlangen, Germany). First, image quality was rated on a 3-point scale; poor (not 
eligible for analysis), moderate and good (eligible for analysis) (15). The most severe stenosis 
in the symptomatic carotid bifurcation and internal carotid artery was measured according 
to the ECST criteria, perpendicular to the central lumen line (16). Additionally, we defined 
plaque ulceration as an extension of contrast material of >1mm into the atherosclerotic 
plaque on at least 2 orthogonal planes (17, 18). Finally, a custom-made plug-in for the freely 
available Image J software (National Institutes of Health, Bethesda, Maryland) was used to 
quantify calcifications in the symptomatic carotid artery within 3 cm proximal and distal to 
the bifurcation. We used a threshold of 600 HU to differentiate calcifications from contrast 
material in the lumen; calcification volume was expressed in cubic millimeters. A detailed 
description of the measurements is provided elsewhere (19).
MR images were evaluated with dedicated vessel wall analysis software (Vesselmass, 
Department of Radiology, Leiden University Medical Center, Netherlands). Image quality was 
rated on a 5-point scale; low SNR (not eligible for analysis) to marginal and high SNR (eligible 
for analysis) (15, 20). MR images were automatically registered by delineating the lumen and 
outer vessel wall of the symptomatic carotid artery. Registration was manually corrected if 
needed. Plaque components of the symptomatic carotid artery (lipid, calcifications, IPH) 
were manually segmented. Fifteen transverse adjoining slices of 2 mm each covering the 
entire plaque were annotated. Maximum vessel wall area and plaque component volumes 
of the symptomatic carotid artery were derived from these annotations.
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blood sampling, VWf levels and AdAMtS13 activity measurements
Citrated blood was centrifuged at 2000 g for 10 minutes; then the plasma was centrifuged 
at 14000 g for 10 minutes and stored in aliquots at -80ºC. VWF:Antigen (VWF:Ag) levels 
were measured with an in-house ELISA, using polyclonal rabbit anti-human VWF antibodies 
(Dakocytomation, Glostrup, Denmark) for catching and tagging. ADAMTS13 activity 
was measured using the Fluorescence Resonance Energy Transfer Substrate VWF 73 
(FRETS-VWF73) (21). The inter- and intra-assay coefficient of variation for VWF:Ag levels 
and ADAMTS13 activity were 8.7% and 1.9% (VWF:Ag); 13.1% and 2.9% (ADAMTS13), 
respectively. 
Statistical analysis
In this cross-sectional analysis, linear regression models were used to investigate the 
association between imaging biomarkers of the symptomatic carotid artery and VWF:Ag 
levels or ADAMTS13 activity, respectively. VWF:Ag levels were not normally distributed and 
therefore log-transformed. All quantitative imaging biomarkers were divided into tertiles. 
Adjustments were made for age and gender (model 1), and additionally for cardiovascular 
risk factors (model 2; age, gender, current smoking, hypertension, hypercholesterolemia, 
diabetes mellitus, cardiovascular history, BMI). In the analyses with VWF:Ag, we also adjusted 
for blood group. The analyses were repeated after adding interval event-blood withdrawal 
to the covariates. Statistical analyses were performed using STATA software (version 13.1, 
StataCorp, College Station, Texas). P<0.05 was considered statistically significant.
 
reSultS
Baseline clinical characteristics, VWF:Ag levels, ADAMTS13 activity and imaging 
characteristics are shown in Table 1. Mean age was 68 years, 74% were male and prevalence 
of cardiovascular risk factors was high. We found a median VWF:Ag level of 1.45 IU/ml [1.10 - 
1.81] and a mean ADAMTS13 activity of 98.6% (± 22.8%). There was no correlation between 
VWF:Ag levels and ADAMTS13 activity (R=0.06, P=0.42). Mean symptomatic carotid artery 
stenosis (ECST) was 55 ± 15 %. 
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table 1. Clinical characteristics, blood measurements and imaging biomarkers*
Clinical characteristic (n=180)
Age (years) 68 ± 9
Male 133 (74%)
Current smoking 39 (22%)
BMI 26.7 ± 4.4
Hypertension 127 (71%)
Hypercholesterolemia 139 (77%)
Diabetes Mellitus 44 (24%)
History of CVD and PAD 85 (47%)
Classification event
TIA
Stroke
Amaurosis fugax
77 (43%)
80 (44%)
23 (13%)
blood measurements (n=180)
Interval event-blood withdrawal (days) 47 [32-67]
VWF:Ag (IU/ml) 1.45 [1.10-1.81]
ADAMTS13 activity (%) 98.6 ± 22.8
Blood group non-O 106 (59%) Imaging biomarkers (symptomatic artery)
Degree of stenosis (ECST) (%)† 55 ± 15
MdCtA (n=158)
Interval event–MDCTA (days) 32 [12-54]
Presence plaque ulceration 43 (27%)
Presence calcifications 142 (90%)
Calcification volume (mm3) 25.9 [5.1-80.7]
Mri (n=169)
Interval event–MRI (days) 47 [30-67]
Maximum vessel wall area (mm2) 72.7 [57.2-88.1]
Presence IPH 66 (39%)
IPH volume (mm3) 0.0 [0.0-39.7]
Presence lipid 106 (63%)
Lipid volume (mm3) 26.2 [0-146.0]
* Data are mean ± SD, absolute numbers of patients (%), or median [25th–75th percentile]; † If MDCTA was absent, 
degree of stenosis was assessed at MRI (n=22); CVD, cardiovascular disease; PAD, peripheral arterial disease; TIA, 
transient ischemic attack; ECST, European Carotid Surgery Trial; IPH, intraplaque hemorrhage
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Increasing age was associated with higher VWF:Ag levels (β= 0.01IU/ml/year, p=0.001) and 
individuals with blood group non-O had higher VWF:Ag levels compared with individuals 
with blood group O (β= 0.22 IU/ml, p<0.001). None of the other clinical characteristics were 
significantly associated with VWF:Ag levels. Age was inversely associated with ADAMTS13 
activity (β= -0.60%/year, p=0.002). We also found an inverse association between the time 
from event to blood withdrawal and ADAMTS13 activity (β= -0.13%/day, p=0.008). None of 
the other clinical characteristics were associated with ADAMTS13 activity. 
  None of the qualitative and quantitative measures of atherosclerosis were associated with 
VWF:Ag levels or ADAMTS13 activity in model 1 and 2 (Table 2). Additional adjustment for 
interval event–blood withdrawal did not change the results.
table 2. Imaging characteristics and VWF:Ag levels  and ADAMTS13 activity 
Characteristic VWf (model 1)* AdAMtS13 (model 1)*
beta [95% Ci] P value beta [95% Ci] P value
Degree of stenosis (ECST)† -0.02 [-0.09;0.04] 0.53 -2.29 [-6.30;1.71] 0.26
Maximum vessel wall area† -0.03 [-0.11;0.05] 0.41 2.50 [-2.11;7.10] 0.29
Calcification volume† 0.00 [-0.07;0.08] 0.91 -1.87 [-6.44;2.71] 0.42
Lipid volume† -0.05 [-0.12;0.02] 0.14 1.43 [-2.76;5.62] 0.50
IPH volume† -0.04 [-0.10;0.02] 0.18 0.70 [-3.11;4.51] 0.72
Plaque ulceration -0.12 [-0.24;0.01] 0.08 0.56 [-7.40;8.52] 0.89
* Adjusted for age and gender; additionally for blood group non-O in case of VWF; † in tertiles; ECST, European 
Carotid Surgery Trial; IPH, intraplaque hemorrhage
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diSCuSSion
This study does not show associations between novel imaging biomarkers of atherosclerosis 
and VWF:Ag levels or ADAMTS13 activity in patients with a recent TIA or ischemic stroke and 
a symptomatic mild-to-moderate carotid artery stenosis.
The strength of our study is that we characterized the carotid atherosclerotic plaque using 
two image modalities (MDCTA and MRI) and assessed atherosclerotic burden as well as 
vulnerable plaque characteristics. Furthermore, this is the first study investigating the 
relationship between novel imaging biomarkers with VWF:Ag levels and ADAMTS13 activity. 
A limitation of our study was the cross-sectional design, which precludes the unraveling 
of cause and effect. We had a median delay of 47 days between clinical event and blood 
sampling/imaging, which might have influenced the association via a change in plaque 
composition and VWF levels (22). VWF is known to be increased in the acute phase of an 
event (23). However, imaging and blood sampling were performed at the same moment 
and we found no significant correlation between the interval event-blood withdrawal and 
VWF:Ag. We found a slight correlation between the interval event-blood withdrawal and 
ADAMTS13 activity, however this might be a chance finding. Nonetheless, adjustment for 
the interval did not influence the association between imaging and blood biomarkers. 
In a previous study, we found a strong correlation between calcification volume in the 
aortic arch and carotid arteries and VWF levels in patients with an ischemic stroke or TIA. 
In accordance to literature we also found in this previous study significantly higher VWF 
levels in patients with large artery atherosclerosis compared to other etiological subtypes 
of TIA or stroke (3, 4, 24). No previous studies are known investigating the association 
between ADAMTS13 and atherosclerosis. In the current study, all patients had a carotid 
artery stenosis and we assessed plaque volume as well as vulnerable plaque characteristics; 
no associations were found between any of the novel imaging biomarkers and VWF and 
ADAMTS13. It might be that VWF levels are differently associated with plaque volume 
measurements than with vulnerable plaque characteristics. For instance, in acute coronary 
syndrome patients, the presence of atherosclerosis measured by IVUS was associated with 
VWF:Ag levels, but VWF:Ag levels were not associated with high risk, prone-to-rupture 
atherosclerotic lesions (25). However, due to the clear role of VWF in thrombus formation 
and the less clear role of VWF and ADAMTS13 in atherosclerotic plaque development, we 
expected to find the opposite. It seems that neither the local disturbance of blood flow 
nor the disruptive plaque surface in the carotid bifurcation causes an increase in VWF or a 
decrease in ADAMTS13. It may be that the systemic alteration of the endothelial layer due 
to widespread atherosclerotic disease causes the change in VWF. If this is the case, blood 
coagulation markers are then a marker of a widespread atherosclerotic disease and not 
a modifiable risk marker for secondary prevention. However, a complex role of VWF and 
ADAMTS13 in atherosclerotic plaque development cannot be ruled out.   
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ConCluSionS
Imaging biomarkers of atherosclerosis were not associated with VWF:Ag levels or ADAMTS13 
activity in patients with a recent TIA or ischemic stroke and a symptomatic mild-to-moderate 
carotid artery stenosis. Whether the blood biomarkers are simply a marker of widespread 
atherosclerosis or have a more complex role in atherosclerotic plaque development, remains 
unclear. 
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AbStrACt
background
ADAMTS13 (A Disintegrin and Metalloprotease with TromboSpondin motif repeats 13) has 
antithrombotic properties because it cleaves Von Willebrand factor (VWF) in smaller, less 
active multimers. The aim of our study was to investigate prospectively the association 
between ADAMTS13 activity and ischemic stroke.
Methods
We included 5941 individuals ≥ 55 years without a history of stroke or Transient Ischemic 
Attack (TIA) of the Rotterdam Study, a population-based cohort study. ADAMTS13 activity 
was measured at inclusion with the FRETS-VWF73 assay and VWF antigen (VWF:Ag) 
levels by ELISA. We assessed the association between ADAMTS13 activity, VWF:Ag levels 
and ischemic stroke by Cox proportional hazard analysis. The added value of ADAMTS13 
activity above the traditional risk factors for ischemic stroke risk prediction was examined 
by the c-statistic and the net reclassification improvement index (NRI). All individuals were 
followed for incident stroke or TIA.
results
Over a median follow-up time of 10.7 years (56403 total person years), 461 participants 
experienced a stroke, 306 of which ischemic. After adjustment for cardiovascular risk factors, 
individuals with ADAMTS13 activity in the lowest quartile had a higher risk of ischemic stroke 
(absolute risk 7.3%) than those in the reference highest quartile (absolute risk 3.8%; HR 
1.65, 95% CI 1.16–2.32). Adding ADAMTS13 to the model in prediction of ischemic stroke, 
increased the c-statistic by 0.013 (P=0.003) and provided 0.058 (95% CI -0.002–0.119) NRI. 
Conclusion
Low ADAMTS13 activity is associated with the risk of ischemic stroke and improves the 
accuracy of risk predictions for ischemic stroke beyond traditional risk factors.
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introduCtion
Ischemic stroke is a major cause of mortality and morbidity in the Western World 1. Although 
many risk factors have been identified, its pathogenesis remains still largely unclear and 
treatment options are still limited. The discovery of new risk factors might thus support the 
development of new preventive measures and treatment strategies. 
ADAMTS13, part of the family of A Disintegrin and Metalloprotease with TromboSpondin 
motif 2,3, has antithrombotic properties by cleaving ultralarge Von Willebrand Factor (VWF) 
multimers into smaller forms4. Ultralarge VWF multimers are the most procoagulant forms 
leading to platelet adhesion and aggregation and finally thrombus formation. Several studies 
have reported an association between high VWF levels and the risk of ischemic stroke 5-7. 
The importance of ADAMTS13 in circulation is exemplified by patients who develop 
thrombotic thrombocytopenic purpura (TTP) due to a severe deficiency of ADAMTS13, 
resulting in reduced cleavage of high molecular weight VWF multimers. This leads to an 
increase of these procoagulant VWF multimers, which in turn can result in microthrombus 
formation, frequently leading to disturbances of the cerebral circulation or other organs. In 
TTP patients microthrombi may lead to focal neurological deficit, seizures and even coma 8. 
The importance of circulating ADAMTS13 was also shown in animal models. Several animal 
studies have indicated a pathogenic role of ADAMTS13 in the development or progression 
of ischemic stroke. Studies in which focal cerebral ischemia was experimentally induced 
showed larger cerebral infarctions in ADAMTS13-deficient mice than in wild-type mice 9-11.
These data and small case-control studies suggest that ADAMTS13 plays a role in 
cardiovascular disease, but no prospective studies have yet established the relationship 
between the VWF cleavage protease ADAMTS13 and the risk of ischemic stroke (IS)7,12-
15.To investigate the role of ADAMTS13 and VWF in the pathogenesis of ischemic stroke, 
we investigated prospectively the longitudinal association of ADAMTS13 activity, and its 
interaction with VWF and the risk of ischemic stroke in a large population based cohort 
of nearly 6000 individuals above the age of 55. We also examined whether addition of 
ADAMTS13 activity to the traditional risk factors would lead to improvements in ischemic 
stroke risk prediction. 
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MAteriAl And MetHodS
Study design and study population
We included participants from the Rotterdam Study (RS), a prospective population-based 
cohort study among individuals of 55 years and older living in a suburb in the city of Rotterdam, 
the Netherlands16,17. The study started in 1990 (RS-I). In 1999, additional individuals who had 
turned 55 years or had moved into the study district since the start of the study were added 
to the cohort (RS-II). All participants visited the research center every 3 to 4 years, where 
established cardiovascular risk factors are assessed. For this study, we used data obtained 
from participants at the third examination of the original cohort (RS-I-3, 1997-1999) and the 
first examination of the extended cohort (RS-II-1, 2000-2001). Protocols for the original and 
the extended cohort were similar. Previous findings of the Rotterdam Study are summarized 
in table 6 (online supplement). The Rotterdam Study has been approved by the medical 
ethics committee according to the Population Study Act Rotterdam Study, executed by the 
Ministry of Health, Welfare and Sports of the Netherlands. A written informed consent was 
obtained from all participants. 
Assessment of stroke and TIA
History of stroke and TIA was determined during the baseline interview and verified in 
medical records. After enrollment in the Rotterdam Study, participants were continuously 
monitored for incident strokes and TIAs through automated linkage of the study database 
with files from general practitioners, the municipality, and nursing home physicians. 
Additional information was obtained from hospital records. Potential strokes were reviewed 
by research physicians, and verified by an experienced stroke neurologist (P.J.K.). Events 
were structured based on this information and a diagnosis was made based on the 
criteria independent of the diagnosis of the initial caregivers. Subarachnoid hemorrhages 
and retinal strokes were excluded. Strokes were classified as ischemic, hemorrhagic or 
unspecified. Ischemic stroke was diagnosed if a CT or MRI scan carried out within four weeks 
after the event ruled out other diagnoses. A hemorrhagic stroke was diagnosed if a relevant 
hemorrhage was shown on CT or MRI scan. If no neuroimaging was performed, the stroke 
was classified as unspecified. TIA was defined by focal symptoms that started suddenly and 
improved within seconds with a maximum duration of 24 hours. 
Baseline characteristics
At inclusion in the study (RS-I-3 and RS-II-1), a detailed interview was taken from all 
participants, as well as an extensive set of examinations, including a physical examination 
and blood sampling. Blood pressure was calculated as the mean of two measurements 
using a random-zero sphygmomanometer at the right brachial artery while the individual 
was in a sitting position. Antihypertensive drugs was defined as the use of antihypertensive 
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medication indicated for the treatment of high blood pressure (≥ grade 1 hypertension 
according to World Health Organization criteria18). Grade 1 hypertension was defined as 
systolic >140 mmHg or a diastolic blood pressure >90 mmHg. Grade 2 hypertension was 
defined as systolic >160 mmHg or a diastolic blood pressure >100 mmHg. Antithrombotic 
medication was defined as the use of vitamin K antagonists, platelet aggregation inhibitors, 
and direct thrombin inhibitors. Diabetes mellitus was defined as the use of blood glucose-
lowering medication and/or a fasting serum glucose level ≥ 7.0 mmol/L. Lipid reducing agents 
was defined as the use of statins. Total cholesterol and high-density lipoprotein cholesterol 
were measured using an automated enzymatic procedure. Body mass index was calculated 
as the weight (in kilograms) divided by the square of the height (in meters). Smoking status 
was defined as current, former and no smoking. Blood group antigen phenotypes were 
reconstructed by haplotypes analysis of 4 single nucleotide polymorphisms, rs687289, 
rs507666, rs8176704, and rs8176749, which collectively serve as tagging SNPs for the O, A1, 
A2, and B allele. 
ADAMTS13 activity measurements
ADAMTS13 activity was measured in a kinetic assay using the Fluorescence Resonance 
Energy Transfer Substrate VWF 73 (FRETS-VWF73) as previously described19. Samples were 
measured against a reference curve of serial dilutions of normal human plasma defined 
to have an ADAMTS13 activity of 1 U/ml. Normal ADAMTS13 activity is 100% with a range 
between 50% and 150%20,21. 10% of the samples were retested and all were within 25% 
variation. 
VWF antigen (VWF:Ag) levels were determined with an in-house ELISA, using polyclonal 
rabbit anti-human VWF antibodies (DakoCytomation, Glostrup, Denmark) for catching and 
tagging. 
Statistical analysis
Data on baseline characteristics are shown as mean and standard deviation for continuous 
variables and as counts and percentages for categorical variables. The association between 
ADAMTS13 and baseline characteristics was assessed by univariate and multivariable linear 
regression and presented as beta-coefficients. Beta-coefficients represent the change in 
ADAMTS13 activity with an increase of 1 unit of the specific variable. In case of categorical 
variables, this means that having the characteristic is associated with a change of beta in 
ADAMTS13 activity compared with participants who did not have the characteristic. To 
assess proportional hazards assumption, we tested the log minus log plots. The association 
between ADAMTS13 and stroke, was performed by Cox proportional hazards regression 
analysis using ADAMTS13 quartiles, derived from the whole cohort. We examined the 
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association of ADAMTS13 activity with all strokes (hemorrhagic, ischemic and unspecified), 
ischemic strokes, TIA and all cerebrovascular events (TIA and all strokes). Analyses with stroke 
were censored for TIA occurring before the stroke and analyses with TIA were censored for 
stroke. Consequently, participants were followed from inclusion to stroke, TIA, death, last 
health status update where they were known to be free of stroke or TIA, or January 1, 2012, 
whichever came first. Follow-up was complete until January 1, 2012, for 95.4% of potential 
person years22. The total number of person years was 56,403. A curve with cumulative 
incidence of TIA and all strokes during follow-up was constructed for each of the ADAMTS13 
activity quartiles. For the interaction between VWF:Ag and ADAMTS13 and the risk of stroke, 
we performed a Cox proportional hazard regression analysis with addition of an interaction 
term to the model. For the association between ADAMTS13 and VWF with the risk of stroke, 
a combination of ADAMTS13 activity ≤ and > the 25th percentile and VWF:Ag levels ≥ and 
< the 75th percentile were used. We adjusted all analyses for age and sex, and additionally 
for antithrombotic agents, antihypertensive drugs, diabetes mellitus, lipid reducing agents, 
BMI, smoking, total cholesterol, HDL cholesterol, systolic blood pressure, and diastolic blood 
pressure. 
To address the additional predictive value of ADAMTS13 in ischemic stroke risk prediction, we 
formed 2 models. The first model consisted of the variables included in the recent American 
Heart Association Pooled Cohort Equation; age, sex, systolic blood pressure, treatment for 
hypertension, total and high density lipoprotein cholesterol, smoking and diabetes 23. The 
second model additionally included quartiles of ADAMTS13 activity. We then compared the 
two models using likelihood ratio chi-square test for global model fit, c-statistic for model 
discrimination, and net reclassification improvement index (NRI). Discrimination refers to 
the ability of the model to assign a higher risk to individuals who will develop an event 
compared to the individuals who will not. NRI specifies the amount of correct reclassification 
of individuals with event and individuals without event after extension of the model with 
ADAMTS13. The NRI estimates were based on the 10-year ischemic stroke risk categories of 
<5%, 5% to 7.5%, and >7.5%24.
Missing values of these covariates (0-4.7%) were imputed five times using a multiple 
imputation method including all covariates. Statistical analyses were performed on all five 
different datasets and pooled into one final result using SPSS software. Data were analyzed 
with SPSS version 21 (SPSS 21.0. IBM, Somers, NY, USA) and R, version 3.1.2. All statistical 
tests were two-tailed and p-values <0.05 were considered statistically significant. 
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reSultS
The Rotterdam Study started with 7,983 participants (out of 10,215 invitees) and was 
extended with an additional 3,011 participants (out of 4,472 invitees). We included all 
participants of whom blood was sampled (n = 6494). All participants with a history of stroke 
(n = 257) or TIA (n = 296) at the moment of blood sampling (1997 – 2001) were excluded 
from the analysis. A total of 5941 individuals over 55 years were included in this study. Over 
a median follow-up time of 10.7 years (IQR 7.9 – 11.6) and 56403 total person years, 461 
individuals experienced a stroke, 306 of which (66%) ischemic stroke, 48 (10%) hemorrhagic 
and 107 (23%) unspecified stroke. A TIA occurred in 315 individuals during follow-up. 
The mean age of all individuals was 69 years (± 8.1) and 57% was female (Table 1). The 
mean ADAMTS13 activity in the total cohort was 91.9 ± 17.8%. The mean time between 
ADAMTS13 activity measurement and the occurrence of stroke or TIA were 5.80 and 5.46 
years, respectively.
Baseline characteristics and ADAMTS13 activity
ADAMTS13 activity was associated with age and sex, also after adjustment for cardiovascular 
risk factors. In this cohort we observed a decrease of 5.68% in ADAMTS13 activity per 10 
year increase of age (Beta coefficient 5.68%, P<0.001) and we found 8.6% higher ADAMTS13 
activity in women vs. men (P<0.001; table 2). Several cardiovascular risk factors were also 
associated with ADAMTS13 activity, including diabetes mellitus, cholesterol, and smoking 
(Table 2). 
ADAMTS13 activity and the risk of stroke
Compared with individuals in the highest quartile of ADAMTS13 activity, individuals with 
an ADAMTS13 activity within the lowest quartile had an increased risk of all strokes after 
adjustment for age and sex (absolute risk lowest quartile 11.0%, highest quartile 5.3%; HR 
1.52 95% CI 1.15–2.02) and there was no statistically significant change after additional 
adjustment for cardiovascular risk factors (HR 1.49 95% CI 1.12–2.00) (Table 3). There was no 
graded response effect from quartile 4 to quartile 1. Taking ADAMTS13 activity as a continuous 
variable (per SD decrease), we found an increased risk for stroke (HR 1.12 95% CI 1.01-1.24) 
(Table 3). For ischemic stroke (absolute risk 7.3%) the HR was 1.65 (95% CI 1.16–2.32). The 
risk for ischemic stroke was also increased when taking ADAMTS13 as a continuous variable 
(HR 1.19 95% CI 1.05–1.34). Individuals in the lowest quartile of ADAMTS13 activity had also 
an increased risk of TIA (absolute risk 6.8%) and all cerebrovascular events (absolute risk 
17.8%) (HR 1.64 95% CI 1.17–2.31; HR 1.56 95% CI 1.25–1.94). These results were similar 
for all outcomes if we adjusted additionally for prevalent coronary heart disease (Table 7, 
online supplement) and for blood group. The cumulative incidence of TIA and all strokes per 
ADAMTS13 quartile over the total follow-up period is shown in figure 1. 
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table 1. Baseline characteristics of the total study population
n = 5941 total cohort
n (%) or mean ± Sd
Age (years) 69.0 ± 8.1
Female sex 3401 (57.2%)
Smoking
   Current 1020 (17.3%)
   Former 2907 (49.4%)
BMI (kg/m2) 27.0 ± 4.1
Use of antithrombotic medication 952 (16.8%)
Use of antihypertensive drugs 1314 (23.2%)
Use of lipid reducing agents 716 (12.6%)
Presence of diabetes Mellitus 599 (10.2%)
Total cholesterol (mg/dL)¹ 224.7 ± 37.7
HDL cholesterol (mg/dL)¹ 53.8 ± 14.9
Hypertension
Systolic blood pressure (mmHg) 143 ± 21
Diastolic blood pressure (mmHg) 77 ± 11
Grade I hypertension 2309 (39.1%)
Grade II hypertension 879 (14.9%)
Blood group O 2288 (45.3%)
ADAMTS13 activity (%) 91.89 ± 17.8
¹ SI conversion factors. To convert total cholesterol and HDL cholesterol to mmol/L, multiply values by 0.0259. 
ADAMTS13 activity and VWF:Ag levels
There was no relevant correlation between VWF:Ag levels and ADAMTS13 activity, 
although it was significant (R²0.01, P<0.001). Individuals who had both the lowest 
ADAMTS13 activity (≤25 percentile) and the highest VWF:Ag levels (≥75 percentile) had an 
increased risk of all strokes (absolute risk 13.5%) and ischemic stroke (absolute risk 9.1%) 
compared to the remaining individuals (HR 1.49 95%CI 1.11–2.01; HR 1.71 95% CI 1.19-
2.45, respectively) (Table 4). These data did not change when we additionally adjusted 
for prevalent coronary heart disease (Table 8, online supplement). When comparing 
individuals with a low ADAMTS13 activity and high VWF:Ag to individuals with a high 
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table 2. Association between ADAMTS13 and baseline characteristics
univariate
beta-coefficient (95% Ci)
P-value Multivariablebeta-
coefficient (95% Ci)
P-value
Every 10 year increase of age -5.23 (-5.77 - -4.68) <0.001 -5.68 (-6.28 - -5.09) <0.001
Female sex 7.19 (6.29 – 8.08) <0.001 8.60 (7.64 – 9.55) <0.001
Antihypertensive drugs 0.35 (-0.75 – 1.45) 0.53 -0.24 (-1.31 – 0.84) 0.668
Lipid reducing agents 1.62 (0.20 – 3.05) 0.026 2.12 (0.69 – 3.54) 0.004
Antithrombotic medication -4.52 (-5.76 - -3.28) <0.001 -1.64 (-2.90 - -0.38) 0.011
Diabetes mellitus 4.10 (2.59 – 5.61) <0.001 5.17 (3.72 – 6.62) <0.001
Total cholesterol (mg/dL) 0.05 (0.04 – 0.06) <0.001 0.03 (0.02 – 0.04) <0.001
HDL cholesterol (mg/dL) -0.02 (-0.05 – 0.02) 0.315 -0.12 (-0.15 - -0.08) <0.001
Every 10 mmHg increase in 
systolic blood pressure 
-0.11 (-0.33 – 0.10) 0.302 0.19 (-0.08 – 0.46) 0.162
Every 10 mmHg increase in 
diastolic blood pressure 
0.57 (0.16 – 0.98) 0.006 -0.11 (-0.61 – 0.40) 0.679
BMI (kg/m2) 0.30 (0.19 – 0.41) <0.001 -0.04 (-0.15 – 0.07) 0.472
Current smoking -3.17 (-4.37 - -1.98) <0.001 -4.95 (-6.09 - -3.82) <0.001
Univariate and multivariable linear regression analysis, beta-coefficient represents the change in ADAMTS13 
activity with 95% confidence interval per unit increase of the selected variable. 
ADAMTS13 activity and low ischemic stroke (absolute risk 9.1%) (HR 2.94 95% CI 1.49–5.78; 
HR 3.51 95% CI 1.60–7.70, respectively) (Table 9, online supplement). Formal statistical testing 
did not reveal a significant interaction between VWF:Ag levels and ADAMTS13 activity in 
the association with all strokes, nor with ischemic stroke (P=0.93 and P=0.78, respectively).
Added predictive value of ADAMTS13 activity in ischemic stroke risk prediction
Table 5 summarizes the added value of ADAMTS13 for the prediction of ischemic stroke 
above the traditional risk factors. Addition of ADAMTS13 to the model including the 
traditional risk factors, improved the model fit; i.e. the Likelihood ratio test statistics (X 2) 
increased from 123.7 to 136.9 (P=0.013). The model including ADAMTS13 also increased the 
c-statistic by 0.013 (P=0.003) in prediction of ischemic stroke. Addition of ADAMTS13 to the 
traditional risk factor model provided an NRI of 0.058% (95%CI -0.002 - 0.119) for the total 
population. Among subjects in the 5%-7.5%, which can be considered an intermediate risk 
category for ischemic stroke, the NRI was 0.212 (95% CI 0.048 - 0.376 ), composed of NRI of 
13.5% for events and 7.7% for non-events. Adding VWF to the model including traditional 
risk factors and ADAMTS13 did not provide any improvement in risk prediction. 
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figure 1. Number of events per ADAMTS13 quartile
Number of all cerebrovascular events (TIA and all strokes) per quartile of ADAMTS13 activity. Cut-off 
points (%) of ADAMTS13 activity quartiles were: ≤80.73%, 80.74 – 91.44%, 91.45 – 102.26%, and ≥ 
102.27%.
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table 3. Cox proportional hazard regression analysis between ADAMTS13 quartiles and stroke
ADAMTS13 level Mean ADAMTS13  
activity (95% CI)
Number of  
cases / Total 
number at risk 
Absolute 
risk (%)
Model 1
HR (95% CI)
Model 2
HR (95% CI)
All strokes (n= 461)
quartile 1 70.3 (69.8 – 70.8) 163 / 1486 11.0 1.52 (1.15 – 2.02) 1.49 (1.12 – 2.00)
quartile 2 86.3 (86.2 – 86.5) 108 / 1485 7.2 1.10 (0.82 – 1.47) 1.08 (0.80 – 1.45)
quartile 3 96.6 (96.4 – 96.7) 111 / 1485 7.5 1.18 (0.88 – 1.58) 1.17 (0.88 – 1.57)
quartile 4 114.4 (113.8 – 114.9) 79 / 1485 5.3 1 (ref) 1 (ref)
Per Sd decrease 1.13 (1.02 - 1.24) 1.12 (1.01 – 1.24)
ischemic strokes  
(n= 306)
quartile 1 70.3 (69.8 – 70.8) 109 / 1486 7.3 1.61 (1.15 – 2.26) 1.65 (1.16 – 2.32)
quartile 2 86.3 (86.2 – 86.5) 70 / 1485 4.7 1.07 (0.75 – 1.53) 1.08 (0.75 – 1.54)
quartile 3 96.6 (96.4 – 96.7) 71 / 1485 4.8 1.12 (0.79 – 1.60) 1.13 (0.80 – 1.62)
quartile 4 114.4 (113.8 – 114.9) 56 / 1485 3.8 1 (ref) 1 (ref)
Per Sd decrease 1.18 (1.04 – 1.33) 1.19 (1.05 – 1.34)
tiA (n= 315)
quartile 1 70.3 (69.8 – 70.8) 101 / 1486 6.8 1.55 (1.11 – 2.18) 1.64 (1.17 – 2.31)
quartile 2 86.3 (86.2 – 86.5) 78 / 1485 5.3 1.20 (0.85 – 1.69) 1.25 (0.89 – 1.76)
quartile 3 96.6 (96.4 – 96.7) 77 / 1485 5.2 1.19 (0.84 – 1.67) 1.21 (0.86 – 1.71)
quartile 4 114.4 (113.8 – 114.9) 59 / 1485 4.0 1 (ref) 1 (ref)
Per Sd decrease 1.17 (1.03 – 1.24) 1.19 (1.05 – 1.34)
Any cerebrovascular event (n= 776)
quartile 1 70.3 (69.8 – 70.8) 264  / 1486 17.8 1.54 (1.24 – 1.91) 1.56 (1.25 – 1.94)
quartile 2 86.3 (86.2 – 86.5) 186 / 1485 12.5 1.14 (0.91 – 1.42) 1.15 (0.92 – 1.44)
quartile 3 96.6 (96.4 – 96.7) 188 / 1485 12.7 1.18 (0.95 – 1.48) 1.19 (0.95 – 1.48)
quartile 4 114.4 (113.8 – 114.9) 138 / 1485 9.3 1 (ref) 1 (ref)
Per Sd decrease 1.14 (1.06 – 1.23) 1.15 (1.06 – 1.24)
Model 1 adjusted for age and sex
Model 2 additionally adjusted for antithrombotic medication, antihypertensive drugs, diabetes mellitus, lipid 
reducing agents, BMI, smoking, total cholesterol, HDL cholesterol, systolic blood pressure and diastolic blood 
pressure. All strokes indicates ischemic, hemorrhagic and unspecified strokes. Any cerebrovascular event indicates 
all strokes and TIA. Cut-off points (%) for quartiles were: ≤80.73%, 80.74 – 91.44%, 91.45 – 102.26%, and ≥ 102.27%
.
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table 4. Cox proportional hazard regression analysis between ADAMTS13 and VWF and stroke
AdAMtS13 and VWf:Ag level Number of cases / 
Total number at risk
Absolute 
risk (%)
Model 1
HR (95% CI)
Model 2 
HR (95% CI)
All strokes (n= 461)
VWF < p75 and ADAMTS13 > p25 223 / 3395 6.6 1 (ref) 1 (ref)
VWF ≥ p75 and ADAMTS13 > p25 76 / 1055 7.2 0.91 (0.70 – 1.19) 0.92 (0.71 – 1.20)
VWF < p75 and ADAMTS13 ≤ p25 101 / 1032 9.8 1.24 (0.97 – 1.58) 1.24 (0.97 – 1.60)
VWF ≥ p75 and ADAMTS13 ≤ p25 61 / 451 13.5 1.53 (1.14 – 2.06) 1.49 (1.11 – 2.01)
ischemic strokes (n= 306)
VWF < p75 and ADAMTS13 > p25 153 / 3395 4.5 1 (ref) 1 (ref)
VWF ≥ p75 and ADAMTS13 > p25 44 / 1055 4.2 0.83 (0.59 – 1.16) 0.83 (0.59 – 1.17)
VWF < p75 and ADAMTS13 ≤ p25 68 / 1032 6.6 1.31 (0.98 – 1.76) 1.34 (1.00 – 1.81)
VWF ≥ p75 and ADAMTS13 ≤ p25 41 / 451 9.1 1.72 (1.20 – 2.47) 1.71 (1.19 – 2.45)
tiA (n= 315)
VWF < p75 and ADAMTS13 > p25 156 / 3395 4.6 1 (ref) 1 (ref)
VWF ≥ p75 and ADAMTS13 > p25 58 / 1055 5.5 1.06 (0.78 – 1.44) 1.06 (0.78 – 1.44)
VWF < p75 and ADAMTS13 ≤ p25 72 / 1032 7.0 1.44 (1.08 – 1.92) 1.49 (1.11 – 1.98)
VWF ≥ p75 and ADAMTS13 ≤ p25 29 / 451 6.4 1.27 (0.84 – 1.91) 1.29 (0.85 – 1.95)
Any cerebrovascular event (n= 776)
VWF < p75 and ADAMTS13 > p25 379 / 3395 11.2 1 (ref) 1 (ref)
VWF ≥ p75 and ADAMTS13 > p25 134 / 1055 12.7 0.97 (0.80 – 1.19) 0.97 (0.80 – 1.19)
VWF < p75 and ADAMTS13 ≤ p25 173 / 1032 16.8 1.32 (1.10 – 1.59) 1.34 (1.11 – 1.61)
VWF ≥ p75 and ADAMTS13 ≤ p25 90 / 451 20.0 1.44 (1.13 – 1.83) 1.43 (1.12 – 1.82)
Model 1 adjusted for age and sex
Model 2 additionally adjusted for antithrombotic medication, antihypertensive drugs, diabetes mellitus, lipid 
reducing agents, BMI, smoking, total cholesterol, HDL cholesterol, systolic blood pressure and diastolic blood pressure
All strokes indicates ischemic, hemorrhagic and unspecified strokes. 
Any cerebrovascular event indicates all strokes and TIA. 
ADAMTS13 ≤ 25 percentile represents ≤ 80.72%, VWF ≥ 75 percentile ≥ 1.58 IU/ml. 
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table 5. Additional predictive information after extending the traditional risk factor model with 
ADAMTS13 in prediction of  ischemic stroke  
Model fit Model discrimination
Models likelihood ratio test Statistics (X 2) C-Statistic (95% Ci)
traditional risk factor model 123.7 0.694 (0.665, 0.723)
traditional risk factor model + AdAMtS13 136.9 a   0.707 (0.678, 0.735) a
reclassification after addition of AdAMtS13 to the traditional risk factors, total population (n=5941)
Subjects with event (%) b Subjects without event (%) b nri (95% Ci) c
up
15.0%
down
9.4%
Up
8.8%
Down
9.0% 0.058 (-0.002, 0.119)
reclassification after addition of AdAMtS13 to the traditional risk factors, among the 5%-7.5% risk category (n=1179)
Subjects with event (%) b Subjects without event (%) b
up
33.3%
down
19.8%
Up
20.3%
Down
28.0%
nri (95% Ci) c
0.212 (0.048, 0.376)
X2, Chi-square statistic; CI, confidence interval; NRI, net reclassification improvement.
The traditional risk factor model is composed of the variables included in the American Heart Association Pooled 
Cohort Equation; age, sex, systolic blood pressure, treatment for hypertension, total and high density lipoprotein 
cholesterol, smoking, and diabetes. 
a P-value <0.01 for the increase in model fit and for the increase in the c-statistic after addition of ADAMTS13 to 
the traditional risk factors.  
b Percentages of subjects with or without an event who move to a higher or lower risk category after adding 
ADAMTS13 to the traditional risk factors. The risk categories are based on 10-year ischemic stroke risk <5%, 5%–
7.5%, and >7.5%.
c NRI is estimated as ([number of events reclassified higher minus number of events reclassified lower]/number 
of events) + 
([number of nonevents reclassified lower minus number of nonevents reclassified higher]/number of nonevents).
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diSCuSSion
In this prospective cohort study of nearly 6000 elderly individuals with a median follow-
up of 10.7 years (56403 total person years), we observed an association between baseline 
ADAMTS13 activity and the development of ischemic stroke. Individuals with low ADAMTS13 
activity had a higher risk of experiencing an ischemic stroke than individuals with high 
ADAMTS13 activity. 
The association between ADAMTS13 levels and ischemic stroke has previously been 
investigated in small case-control studies 12-15. Although these studies also suggested that 
low ADAMTS13 levels are associated with an increased risk of stroke, they all had a cross-
sectional design. Therefore prospectively designed cohort studies, like the Rotterdam Study, 
are necessary to assess the role of ADAMTS13 as a risk factor for stroke. 
The association between low ADAMTS13 activity and ischemic stroke risk is likely to 
be explained by less cleavage of high molecular weight multimers of VWF, which are 
the most prothrombotic forms. This results in more large procoagulant VWF multimers 
and consequently a prothrombotic state and may lead to thrombus formation at sites 
of endothelial damage and especially at sites with high shear stress, as in the arterial 
circulation. Nearly all individuals in the lowest ADAMTS13 quartile had ADAMTS13 
activity in the normal range (50 – 150%)20. Nonetheless, our study clearly suggests that 
moderately reduced ADAMTS13 activity is associated with an increased risk of thrombotic 
complications, even though the levels are not as low as characteristic for TTP patients. We 
did not find a graded response effect from quartile 4 to quartile 1, and also previous case-
control studies failed to find a graded pattern with decreasing ADAMTS13 quartiles 14,15,25. 
This suggests that there is more a low level-threshold rather than a clear dose association 
for ADAMTS13 and ischemic stroke. For the association of continuous ADAMTS13 activity 
(per SD decrease) and stroke, we estimated whether the risks were influenced by outliers 
of ADAMTS13 activity by excluding the lowest and highest 1% and 2.5%. These data showed 
comparable risk estimates as shown in table 3 suggesting that there is not an important 
influence of outliers. High VWF:Ag levels have shown to be associated with the risk of 
stroke in previous studies 5-7. To investigate whether stroke is also dependent upon the 
interaction between VWF and ADAMTS13, we analyzed groups based on the combination 
of ADAMTS13 activity and VWF:Ag levels. Individuals with low ADAMTS13 activity and 
high VWF levels had the highest risk of ischemic stroke, suggesting that ADAMTS13 and 
VWF are independent risk factors. This finding is similar to that of two recent case-control 
studies in patients with cardiovascular disease 12,13.We observed no association between 
VWF:Ag levels and ADAMTS13 activity, which is consistent with previous reports 12,13,25,26. 
This might be explained by the fact that the ADAMTS13 activity levels measured in our study 
participants are apparently high enough for cleavage of plasma VWF. However, locally at the 
site of vessel damage the reduced ADAMTS13 activity may lead to reduced cleavage  
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of secreted large multimers of VWF and thereby contribute to local thrombus formation 13. 
A causal role of ADAMTS13 in the outcome of stroke has recently been suggested in patients 
with a congenital deficiency of ADAMTS13 (Upshaw Schulman syndrome) and in animal 
studies. These patients without ADAMTS13 also suffer from ischemic stroke events 27,28. In 
addition, two independent groups reported larger infarctions in ADAMTS13-deficient mice 
in whom ischemic stroke was induced experimentally9-11. Additionally, abolishment of the 
ADAMTS13 gene strongly accelerates atherosclerosis in a murine model 29,30, suggesting a 
role of ADAMTS13 in the progression of atherosclerosis. Infusion of recombinant human 
ADAMTS13 in wild-type mice with cerebral ischemia before reperfusion, reduced the infarct 
size and improved the functional outcome9. These studies suggest that recombinant human 
ADAMTS13, may have a role as therapeutic agent in ischemic stroke patients 31, however this 
should be addressed in future clinical studies. 
The measurement of ADAMTS13 in a large population based cohort of nearly 6000 
individuals allowed us to study the association between ADAMTS13 activity and several 
baseline characteristics and provides more insight in the pathophysiology of ADAMTS13. 
We observed a strong age dependency of ADAMTS13, indicating lower ADAMTS13 activity 
in the elderly population. In our population of individuals above 55 years, the mean 
ADAMTS13 activity was 91.9%. ADAMTS13 activity was significantly lower in individuals of 
increasing age which is consistent with other smaller studies19,26,32,33. Although both age and 
ADAMTS13 activity are associated with the risk of stroke, we found that ADAMTS13 activity 
was associated with an increased risk of stroke also independent of age. Interestingly 
other studies have revealed that even in children, low levels of ADAMTS13 are associated 
with stroke15. In addition, we found an association between ADAMTS13 activity and sex. 
ADAMTS13 activity was higher in women than in men, as previously reported19,33. We also 
observed that patients with diabetes had a higher activity of ADAMTS13. This is in contrast 
with a previous study that showed lower ADAMTS13 activity in patients with diabetes 
mellitus compared with controls 34. However, in that study a positive association between 
glycemic control, measured as HbA1c, and ADAMTS13 activity was reported. The authors 
suggested that this might be explained in these patients by the higher level of metabolic 
stress that increases the hepatic production and release of ADAMTS13 as a compensatory 
mechanism34. We observed also a weak association between use of lipid reducing agents 
and ADAMTS13. In addition, we found a positive association with total cholesterol, which 
confirms a previous study26. Although ADAMTS13 activity was associated with multiple 
characteristics and drugs, the association between ADAMTS13 activity and ischemic stroke 
found in our study was independent of these variables. 
The initial step in evaluation of a new marker is to examine if the marker could predict 
development of future events. While providing a significant evidence of association is 
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necessary, the key aspect is to show that a new risk marker improves predictions over the 
standard clinical risk assessment tools. When added to the traditional risk factors (age, 
sex, systolic blood pressure, treatment for hypertension, total and high density lipoprotein 
cholesterol, smoking, and diabetes)23, ADAMTS13 improved the ischemic stroke risk 
predictions, as measured by an increase in model discrimination and moderate reclassification 
in the overall population and in persons categorized as having a risk between 5% to 7.5% by 
traditional cardiovascular risk factors, as depicted in table 5. This is of importance because 
in these patients preventive treatment is suggested to be considered24. To allow for a more 
precise and clinically relevant interpretation of the contribution of ADAMTS13 activity to 
stroke risk prediction, we repeated the analysis for different traditional risk factors including 
systolic blood pressure, total and HDL cholesterol, smoking, and diabetes. We added each 
traditional risk factor to the model already containing other traditional risk factors and 
assessed improvements in model fit, discrimination and reclassification for each traditional 
risk factor (data not shown). Our results confirmed that the contribution of ADAMTS13 to 
stroke risk prediction is comparable to those of systolic blood pressure, HDL cholesterol and 
smoking.
Addition of VWF to the model did not improve the risk prediction. This might be explained by 
the fact that ADAMTS13 has a more important role in the prediction of stroke than VWF:Ag 
levels. We previously already published that the role of VWF:Ag in predicting stroke in this 
elderly population study was not very strong 5. 
The strength of our study is that this is a prospective study with nearly 6000 individuals on 
the role of ADAMTS13 in ischemic stroke with a long follow-up of 10.7 years in a population 
that is representative for the Dutch population. A limitation of our study is that 23% of 
the incident strokes had to be classified as unspecified due to the lack of cerebral imaging. 
These strokes mainly occurred in the early phase of the study when patients were often not 
referred to the hospital. As 80-90% of all strokes are ischemic 35,36, most of the unspecified 
strokes in our study will also be of ischemic origin. Another limitation is that ischemic stroke 
could only be subclassified in etiologic subgroups in a limited number of ischemic stroke 
patients. This limited our ability to study the importance of ADAMTS13 activity as a risk 
factor of various subtypes of ischemic stroke. We measured ADAMTS13 activity only at 
baseline as this is an observational study, and it would be of interest how ADAMTS13 levels 
change over time. Furthermore, a marker of stroke severity like the modified Rankin Score, 
was not determined in our study. Therefore we could not investigate whether ADAMTS13 
activity is associated with stroke severity. However, a TIA is considered to be a less severe 
stroke and we found similar risk estimates of the association between ADAMTS13 activity 
and TIA or ischemic stroke. This suggests that there is no association between ADAMTS13 
activity and stroke severity. Our study was performed in a population of predominantly 
Caucasians of 55 years and older that live in a middle income district of Rotterdam, which 
limits the generalizability of our results. We did not take into account any competing 
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morbidity and mortality in the analyses or clinical variables during follow-up. Maybe we 
could have obtained more insight on the association between ADAMTS13 and stroke if 
multiple measurements over time would have been available.
In conclusion, low ADAMTS13 activity was significantly associated with the risk of 
ischemic stroke, independently of age, sex, and established cardiovascular risk factors 
over a median of 10.7 years of follow-up. Addition of ADAMTS13 activity improved the 
accuracy of risk predictions for ischemic stroke beyond the traditional risk factors.
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Stroke was defined according to WHO criteria as a syndrome of rapidly developing clinical 
signs of focal (or global) disturbance of cerebral function, with symptoms lasting 24 h or 
longer or leading to death, with no apparent cause other than of vascular origin. (see also 
Wieberdink et al. 2012 Eur J Epidemiol. 2012 Apr;27(4):287-95 and Hatano S. et al. Bull 
World Health Organ. 1976;54(5):541-53). 
Transient ischemic attacks were attacks of sudden neurological symptoms that completely 
resolved within 24 hours, with no clear evidence for the diagnosis of migraine, epilepsy, 
Ménière disease, hyperventilation, cardiac syncope, hypoglycaemia, or orthostatic 
hypotension (Bos et al. JAMA 2007 Dec 26;298(24):2877-85).
table 6. Previous findings on markers and stroke in the Rotterdam Study
Marker findings references
Age Stroke incidence increases with age Hollander M. et al. J Neurol Neurosurg. 2003. 
Wieberdink R.G. et al. Eur J Epidemiol. 20120
Sex Stroke incidence is higher in men Hollander M. et al. J Neurol Neurosurg. 2003. 
Total cholesterol Total cholesterol is not significantly  
associated with an increased risk of stroke
Hollander M. et al. Circulation, 2002. 
HDL cholesterol HDL cholesterol is not significantly 
associated with an increased risk of stroke
Hollander M. et al. Circulation, 2002.
Bos M.J. et al. PLoS Med. 2014. 
Diabetes Mellitus Diabetes Mellitus is associated with an 
increased risk of stroke
Hollander M. et al. Circulation, 2002.
Bos M.J. et al. PLoS Med. 2014.
Hypertension Hypertension is associated with an 
increased risk of stroke
Bos M.J. et al. PLoS Med. 2014.
Vermeer S.E. et al. Stroke, 2002. 
Smoking Smoking is associated with an increased 
risk of stroke
Bos M.J. et al. PLoS Med. 2014.
Vermeer S.E. et al. Stroke, 2002.
BMI BMI is not significantly associated with an 
increased risk of stroke
Bos M.J. et al. PLoS Med. 2014.
Atrial fibrillation Atrial fibrillation is associated with an 
increased risk of stroke
Hollander M. et al. Circulation, 2002.
Bos M.J. et al. PLoS Med. 2014.
Left ventricular 
hypertrophy
LVH is associated with an increased risk 
of stroke
Bots M.L. et al. J Epidemiol Community 
Health, 2002.
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table 7. Cox proportional hazard regression analysis between ADAMTS13 quartiles and stroke
 additionally adjusted for prevalent coronary heart disease
AdAMtS13 level number of cases /  
total number at risk
Hr (95% Ci)
All strokes (n= 461)
Quartile 1 163 / 1486 1.52 (1.14 – 2.03)
Quartile 2 108 / 1485 1.08 (0.80 – 1.46)
Quartile 3 111 / 1485 1.17 (0.87 – 1.57)
Quartile 4 79 / 1485 1 (ref)
Per SD decrease 1.13 (1.02 – 1.25)
ischemic strokes (n= 306)
Quartile 1 109 / 1486 1.67 (1.19 – 2.36)
Quartile 2 70 / 1485 1.08 (0.75 – 1.55)
Quartile 3 71 / 1485 1.13 (0.79 – 1.62)
Quartile 4 56 / 1485 1 (ref)
Per SD decrease 1.20 (1.06 – 1.35)
tiA (n= 315)
Quartile 1 101 / 1486 1.65 (1.17 – 2.32)
Quartile 2 78 / 1485 1.26 (0.90 – 1.78)
Quartile 3 77 / 1485 1.21 (0.86 – 1.71)
Quartile 4 59 / 1485 1 (ref)
Per SD decrease 1.19 (1.05 – 1.34)
Any cerebrovascular event (n= 776)
Quartile 1 264  / 1486 1.57 (1.26 – 1.96)
Quartile 2 186 / 1485 1.15 (0.92 – 1.45)
Quartile 3 188 / 1485 1.19 (0.95 – 1.48)
Quartile 4 138 / 1485 1 (ref)
Per SD decrease 1.15 (1.07 – 1.25)
Adjusted for age, sex, antithrombotic medication, antihypertensive drugs, diabetes mellitus, lipid reducing agents, 
BMI, smoking, total cholesterol, HDL cholesterol, systolic blood pressure, diastolic blood pressure, and prevalent 
coronary heart disease. 
All strokes indicates ischemic, hemorrhagic and unspecified strokes. 
Any cerebrovascular event indicates all strokes and TIA. 
Cut-off points (%) for quartiles were: ≤80.73%, 80.74 – 91.44%, 91.45 – 102.26%, and ≥ 102.27%
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table 8. Cox proportional hazard regression analysis between ADAMTS13 and VWF and stroke 
additionally adjusted for prevalent coronary heart disease
AdAMtS13 and VWf:Ag level number of cases / 
total number at risk
Hr (95% Ci)
All strokes (n= 461)
VWF < p75 and ADAMTS13 > p25 223 / 3395 1 (ref)
VWF ≥ p75 and ADAMTS13 > p25 76 / 1055 0.91 (0.70 – 1.18)
VWF < p75 and ADAMTS13 ≤ p25 101 / 1032 1.26 (0.99 – 1.61)
VWF ≥ p75 and ADAMTS13 ≤ p25 61 / 451 1.51 (1.12 – 2.04)
ischemic strokes (n= 306)
VWF < p75 and ADAMTS13 > p25 153 / 3395 1 (ref)
VWF ≥ p75 and ADAMTS13 > p25 44 / 1055 0.81 (0.58 – 1.14)
VWF < p75 and ADAMTS13 ≤ p25 68 / 1032 1.36 (1.01 – 1.82)
VWF ≥ p75 and ADAMTS13 ≤ p25 41 / 451 1.73 (1.20 – 2.48)
tiA (n= 315)
VWF < p75 and ADAMTS13 > p25 156 / 3395 1 (ref)
VWF ≥ p75 and ADAMTS13 > p25 58 / 1055 1.06 (0.78 – 1.43)
VWF < p75 and ADAMTS13 ≤ p25 72 / 1032 1.50 (1.12 – 2.00)
VWF ≥ p75 and ADAMTS13 ≤ p25 29 / 451 1.26 (0.83 – 1.91)
Any cerebrovascular event (n= 776)
VWF < p75 and ADAMTS13 > p25 379 / 3395 1 (ref)
VWF ≥ p75 and ADAMTS13 > p25 134 / 1055 0.96 (0.79 – 1.18)
VWF < p75 and ADAMTS13 ≤ p25 173 / 1032 1.35 (1.12 – 1.63)
VWF ≥ p75 and ADAMTS13 ≤ p25 890 / 451 1.43 (1.12 – 1.82)
Adjusted for age, sex, antithrombotic medication, antihypertensive drugs, diabetes mellitus, lipid reducing agents, 
BMI, smoking, total cholesterol, HDL cholesterol, systolic blood pressure, diastolic blood pressure, and prevalent 
coronary heart disease. 
All strokes indicates ischemic, hemorrhagic and unspecified strokes. 
Any cerebrovascular event indicates all strokes and TIA. 
ADAMTS13 ≤ 25 percentile represents ≤ 80.72%, VWF ≥ 75 percentile ≥ 1.58 IU/ml.
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table 9. Cox proportional hazard regression analysis between low ADAMTS13, high VWF and stroke
ADAMTS13 and VWF:Ag level Number of cases / 
Total number at risk
Absolute 
risk (%)
Model 1
HR (95% CI)
Model 2 
HR (95% CI)
All strokes (n= 461)
VWF ≤ p25 and ADAMTS13 ≥ p75 14 / 430 3.3 1 (ref) 1 (ref)
VWF ≥ p75 and ADAMTS13 ≤ p25 61 / 451 13.5 2.76 (1.42 – 5.38) 2.94 (1.49 – 5.78)
ischemic strokes (n= 306)
VWF ≤ p25 and ADAMTS13 ≥ p75 11 / 430 2.6 1 (ref) 1 (ref)
VWF ≥ p75 and ADAMTS13 ≤ p25 41 / 451 9.1 3.04 (1.41 – 6.56) 3.51 (1.60 – 7.70)
tiA (n= 315)
VWF ≤ p25 and ADAMTS13 ≥ p75 19 / 430 4.4 1 (ref) 1 (ref)
VWF ≥ p75 and ADAMTS13 ≤ p25 29 / 451 6.4 1.59 (0.79 – 3.19) 1.55 (0.76 – 3.14)
Any cerebrovascular event (n= 776)
VWF ≤ p25 and ADAMTS13 ≥ p75 33 / 430 7.7 1 (ref) 1 (ref)
VWF ≥ p75 and ADAMTS13 ≤ p25 90 / 451 20.0 2.10 (1.31 – 3.36) 2.16 (1.34 – 3.49)
Model 1 adjusted for age and sex 
Model 2 additionally adjusted for antithrombotic medication, antihypertensive drugs, diabetes mellitus, lipid 
reducing agents, BMI, smoking, total cholesterol, HDL cholesterol, systolic blood pressure and diastolic blood pressure
All strokes indicates ischemic, hemorrhagic and unspecified strokes. 
Any cerebrovascular event indicates all strokes and TIA. 
ADAMTS13 ≤ 25 percentile represents ≤ 80.72%, VWF ≥ 75 percentile ≥ 1.58 IU/ml. 
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SuMMAry
background
The metalloprotease ADAMTS13 cleaves high molecular weight von Willebrand factor 
multimers into smaller, less procoagulant forms. Low ADAMTS13 activity is associated with 
an increased risk of ischemic stroke but its pathogenic role in coronary heart disease is 
unclear. 
We aimed to determine the association between ADAMTS13 activity and the risk of coronary 
heart disease in a large prospective population-based cohort study. 
Methods
5688 participants of the Rotterdam Study, a population-based cohort study among 
individuals ≥ 55 years without a history of coronary heart disease (CHD) were included. 
ADAMTS13 activity was measured by the FRETS-VWF73 assay and VWF:Ag levels by ELISA. 
We assessed the association between ADAMTS13 activity, VWF:Ag levels and coronary 
heart disease using Cox proportional hazard regression analysis, adjusting for cardiovascular 
risk factors. 
results
Over a median follow-up time of 9.7 years, 456 individuals suffered from coronary heart 
disease. A low ADAMTS13 activity (quartile 1) was associated with an increased CHD risk 
(HR 1.42, 95%CI 1.07 – 1.89) compared with the reference highest quartile. 
Conclusions
Low ADAMTS13 activity is associated with an increased risk of coronary heart disease in the 
elderly, independently of VWF and established cardiovascular risk factors. 
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introduCtion
ADAMTS13, A Disintegrin and Metalloprotease with ThromboSpondin motif repeats 
13(1-3), cleaves large Von Willebrand Factor (VWF) multimers into smaller, less procoagulant 
forms (4). The important physiological function of ADAMTS13 is evident from patients with 
thrombotic thrombocytopenic purpura (TTP), characterized by a complete deficiency of 
ADAMTS13. A deficiency of ADAMTS13 results into reduced cleavage of the most active 
high molecular weight (HMW) multimers, resulting in increased microthrombi formation. 
Patients with TTP suffer from microthrombi that may lead to focal microangiopathy, renal 
insufficiency, cerebral ischemia and myocardial infarction (5). 
Recently, we have shown the association between low ADAMTS13 activity and increased risk 
of ischemic stroke (6). As ischemic stroke and coronary heart disease (CHD) have multiple 
shared risk factors and as in both diseases atherosclerosis plays a role, we hypothesized 
that there is also an association between ADAMTS13 activity and CHD. This hypothesis 
is supported by the observation that ADAMTS13-deficient mice have larger myocardial 
infarctions upon induction of myocardial ischemia, compared with wild type mice (7-9). In 
addition, small case-control studies have suggested that ADAMTS13 may also play a role 
in CHD (10, 11). This suggests a role for ADAMTS13 in myocardial ischemia. Prospective 
cohort studies on the association between ADAMTS13 and CHD are lacking. Therefore, 
we investigated prospectively the association between ADAMTS13 activity and the risk of 
coronary heart disease in a large population cohort (Rotterdam Study) among individuals 55 
years and older. 7
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MAteriAlS And MetHodS
Study design and study population
Participants were included from the Rotterdam Study (RS), a population-based cohort study 
among individuals of 55 years and older living in a suburb of Rotterdam, the Netherlands 
(12). In 1990, the study started with 7,983 individuals (out of 10,215 invitees) (RS-I) and 
was extended in 1999 with an additional 3,011 individuals (out of 4,472 invitees) (RS-II), 
who moved into the study district or became 55 years since the start of the study. Every 
3 to 4 years, participants visited the research center for detailed evaluations including the 
assessment of established cardiovascular risk factors. For this study, we used data obtained 
from participants at the third examination of the original cohort (RS-I-3, 1997-1999) and the 
first examination of the extended cohort (RS-II-1, 2000-2001). We included all participants 
of whom blood was sampled (N= 6452) and excluded participants with a history of CHD 
or stroke at the moment of blood sampling (1997 – 2001) (N= 764). The Rotterdam Study 
has been approved by the medical ethics committee according to the Population Study Act 
Rotterdam Study, executed by the Ministry of Health, Welfare and Sports of the Netherlands. 
Written informed consent was obtained of all participants.  
AdAMtS13 activity and VWf:Ag levels measurements
ADAMTS13 activity was measured in a kinetic assay using the Fluorescence Resonance 
Energy Transfer Substrate VWF 73 (FRETS-VWF73) as previously described (13). Samples 
were measured against a reference curve of serial dilutions of pooled normal human plasma 
(George King Biomedical Inc) defined to have an ADAMTS13 activity of 1 U/ml. 
VWF antigen (VWF:Ag) levels were determined with an in-house ELISA, using polyclonal 
rabbit anti-human VWF antibodies (DakoCytomation, Glostrup, Denmark) for catching and 
tagging. 
Assessment of coronary heart disease
History of CHD and stroke in all participants was determined during the baseline interview 
and verified in medical records. After enrollment in the Rotterdam Study, participants were 
continuously monitored for incident CHD through automated linkage of the study database 
with files from general practitioners, the municipality, and nursing home physicians. 
Additional information was obtained from hospital records. Incident coronary heart 
disease was defined as myocardial infarction (MI) and CHD mortality. Myocardial infarction 
was defined as pathology findings of an acute MI within 28 days of death, or a rise/fall in 
cardiac biomarkers and/or objective indicative ECG changes, and preferably the presence 
of symptoms or signs (e.g. cardiac pain, cardiogenic shock). CHD mortality was defined as 
definite fatal MI, definite fatal CHD and possible fatal CHD (14).
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other measurements
At inclusion in the study (RS-I-3 and RS-II-1), a detailed interview was taken from all 
participants, as well as an extensive set of examinations, including a physical examination and 
blood sampling. All determinants at inclusion of the study (1997 – 2001) were used as baseline 
characteristics. Blood pressure was calculated as the mean of two measurements using a 
random-zero sphygmomanometer at the right brachial artery while the individual was in a 
sitting position. Antithrombotic medication was defined as the use of vitamin K antagonists, 
platelet aggregation inhibitors, and direct thrombin Xa inhibitors. Antihypertensive drugs 
was defined as the use of antihypertensive medication indicated for the treatment of high 
blood pressure (≥ grade 1 hypertension according to World Health Organization criteria 
(15)). Diabetes mellitus was defined as the use of blood glucose-lowering medication and/
or a fasting serum glucose level ≥ 7.0 mmol/L. Lipid reducing agents was defined as the 
use of statins. Total cholesterol and high-density lipoprotein cholesterol were measured 
using an automated enzymatic procedure. Body mass index was calculated as the weight 
(in kilograms) divided by the square of the height (in meters). Smoking status was defined 
as current, former and no smoking. Blood group antigen phenotypes were reconstructed by 
haplotypes analysis of 4 single nucleotide polymorphisms, rs687289, rs507666, rs8176704, 
and rs8176749, which collectively serve as tagging SNPs for the O, A1, A2, and B allele. 
Previous studies have shown an association between cardiovascular risk factors and 
coronary heart disease in the Rotterdam Study (16-18). 
Statistical analysis
Data on baseline characteristics are shown as mean and standard deviation for continuous 
variables and as counts and percentages for categorical variables. The association between 
ADAMTS13 and CHD events was calculated using Cox proportional hazards regression 
analysis using ADAMTS13 quartiles and additionally  per 1 SD of ADAMTS13 decrease. 
Individuals who developed a stroke before the CHD event, were censored for stroke. All 
participants were followed from inclusion to MI, death, last health status update where 
they were known to be free of CHD, or January 1, 2012, whichever came first. To assess 
proportional hazards assumption, we tested the log minus log plots.  A Kaplan Meier 
cumulative hazard curve was assessed for each of the ADAMTS13 quartiles and compared 
by using the log-rank test. For the association between ADAMTS13 activity, VWF:Ag levels 
and the risk of CHD events, combinations of the ADAMTS13 and VWF quartiles were made. 
Participants with an ADAMTS13 activity above the 25th percentile and a VWF:Ag level below 
the 75th percentile were used as the reference. Participants with an ADAMTS13 activity 
below the 25th percentile and a VWF:Ag level above the 75th percentile were supposed to 
have the highest risk of CHD. ADAMTS13 activity was multiplied by VWF:Ag levels to use 
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as an interaction term and added to the multivariate cox regression including ADAMTS13 
activity and VWF:Ag levels. We also performed a ‘Youden Index’ analysis. The ‘Youden 
Index’ is a summary measure of the ROC curve and gives a cut-off by a trade-off between 
sensitivity and specificity of ADAMTS13 in prediction of CHD risk. We adjusted all analyses 
for age and sex, and additionally for antithrombotic agents, antihypertensive drugs, diabetes 
mellitus, lipid reducing agents, smoking, total cholesterol, HDL cholesterol, and systolic 
blood pressure. Missing values of these covariates (0-4.9%) were imputed five times using 
a multiple imputation method including all covariates. Statistical analyses were performed 
on all five datasets and pooled into one final result using SPSS software. Data were analyzed 
with SPSS version 21 (SPSS 21.0. IBM, Somers, NY, USA). All statistical tests were two-tailed 
and p-values <0.05 were considered statistically significant. 
figure 1. Kaplan-Meier curve 
Kaplan-Meier curve for the cumulative hazard of CHD events per quartile of ADAMTS13 activity. Cut-off 
points (%) for quartiles were: ≤ 80.92%, 80.93 - 91.44%, 91.45 - 102.21%, and ≥ 102.22%
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reSultS
In total, we included 5688 individuals who were free from coronary heart disease and stroke 
at baseline. Over a median follow-up time of 9.7 years, 456 individuals (8.0%) experienced 
a cardiovascular event of whom 230 individuals died due to CHD and 226 individuals 
experienced a myocardial infarction. The mean age of all individuals was 68.9 years (± 8.2) 
and 59.7% was female (Table 1). The mean ADAMTS13 activity in the total population was 
91.9%(± 17.6). There was no relevant correlation between ADAMTS13 activity and VWF:Ag 
levels (R -0.10, P<0.001).
table 1. Baseline characteristics
n = 5688 total cohort
n (%) or mean ± Sd
Age (years) 68.9 ± 8.2
female sex 3398 (59.7%)
Smoking  
   Current 1000 (17.8%)
   former 2687 (47.7%)
bMi (kg/m2) 27.0 ± 4.1
Antithrombotic medication 752 (13.9%)
Antihypertensive drugs 1250 (23.1%)
lipid reducing agents 535 (9.9%)
diabetes Mellitus 545 (9.7%)
total cholesterol (mmol/l) 5.9 ± 1.0
Hdl cholesterol (mmol/l) 1.4 ± 0.4
Systolic blood pressure (mmHg) 143 ± 21
diastolic blood pressure (mmHg) 77 ± 11
blood group o 2189 (45.5%)
AdAMtS13 activity (%) 91.93 ± 17.64
VWf:Ag (iu/ml) 1.31 ± 0.58
Data are presented as N (%) or mean ± SD
Individuals in the lowest quartile of ADAMTS13 had a 42% higher risk of CHD compared 
with individuals in the highest quartile of ADAMTS13 (HR 1.42, 95%CI 1.07 – 1.89; Table 2), 
independent of cardiovascular risk factors. Also in Kaplan Meier survival analysis, individuals 
in the lowest quartile of ADAMTS13 had the highest hazard compared with the other 
quartiles and this increased risk was consistent over time (Figure 1). The risk of CHD 
increased with 1.12 fold per decrease of 1 SD of ADAMTS13 activity, when ADAMTS13 was 
entered as continuous variable in the model (per SD decrease HR 1.12, 95%CI 1.01 – 1.24). 
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Individuals with a combination of the highest VWF:Ag level and the lowest ADAMTS13 activity, 
had an increased risk of developing CHD compared with individuals with lower VWF:Ag 
levels and higher ADAMTS13 activity (HR 1.43, 95%CI 1.04 - 1.96, Table 3). Individuals with a 
low ADAMTS13 activity and a VWF:Ag level below the 75th percentile had an almost similar 
risk estimate as individuals with a low ADAMTS13 and a high VWF:Ag level (above the 75th 
percentile; HR 1.32, 95% CI 1.03 - 1.68). After additionally adjustment for blood group in 
these associations, the risk estimates changed slightly (Table 3). There was no interaction 
between ADAMTS13 activity and VWF:Ag levels in the association with CHD events (P=0.95).
table 2. Cox proportional hazard regression analysis between ADAMTS13 quartiles and CHD
AdAMtS13 activity Mean AdAMtS13 
activity (95% Ci)
number of cases / 
total number at risk
Model 1
Hr (95% Ci)
Model 2
Hr (95% Ci)
CHD event (N= 456)
quartile 1 70.5 (70.1 – 71.0) 156 / 1425 1.30 (0.98 – 1.72) 1.42 (1.07 – 1.89)
quartile 2 86.4 (86.2 – 86.5) 116 / 1419 1.05 (0.79 – 1.39) 1.10 (0.83 – 1.47)
quartile 3 96.6 (96.4 – 96.7) 99 / 1421 0.96 (0.72 – 1.29) 1.00 (0.75 – 1.34)
quartile 4 114.3 (113.7 – 114.9) 85 / 1422 1 (ref) 1 (ref)
Per Sd decrease 1.08 (0.98 – 1.20) 1.12 (1.01 – 1.24)
Model 1 adjusted for age and sex 
Model 2 additionally adjusted for antithrombotic medication, antihypertensive drugs, diabetes mellitus, lipid 
reducing agents, smoking, total cholesterol, HDL cholesterol, and systolic blood pressure.
table 3. Cox proportional hazard regression analysis between ADAMTS13 and VWF and CHD
ADAMTS13 and VWF:Ag level Number of cases / 
total number at risk
Model 1
HR (95% CI)
Model 2
HR (95% CI)
Model 3
HR (95%  CI)
CHD event (N= 453)
VWf < p75 and AdAMtS13 > p25 221 / 3240 1 (ref) 1 (ref) 1 (ref)
VWf ≥ p75 and AdAMtS13 > p25 77 / 1015 0.97 (0.74 – 1.26) 0.98 (0.76 – 1.28) 0.95 (0.71 – 1.27)
VWf < p75 and AdAMtS13 ≤ p25 103 / 998 1.22 (0.96 – 1.55) 1.32 (1.03 – 1.68) 1.40 (1.08 – 1.81)
VWf ≥ p75 and AdAMtS13 ≤ p25 52 / 425 1.41 (1.03 – 1.93) 1.43 (1.04 – 1.96) 1.31 (0.92 – 1.87)
Model 1 adjusted for age and sex
Model 2 additionally adjusted for antithrombotic agents, antihypertensive drugs, diabetes mellitus, lipid reducing 
agents, smoking, total cholesterol, HDL cholesterol, and systolic blood pressure. 
Model 3 additionally adjusted for blood group.
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diSCuSSion
We have shown in this large prospective population cohort study that individuals with low 
ADAMTS13 activity have an increased risk of coronary heart disease events. 
Our finding provides clarity on the existence of the relationship between ADAMTS13 and 
CHD. This association is likely to be explained by less cleavage of high molecular weight 
multimers of VWF, which are the most procoagulant forms. This results in more (ultra-)large 
procoagulant VWF multimers and consequently a prothrombotic state leading to thrombus 
formation at sites of endothelial damage and high shear stress.
The available literature was confusing, since previous case-control studies have shown 
conflicting results on the association between ADAMTS13 and CHD (19-23). This can be 
explained by the fact that most of these studies included a small number of patients. In 
addition, our recently published meta-analysis showed an increased but not statistically 
significant risk of CHD in individuals with a low ADAMTS13 (10). Maino et al. performed a 
meta-analysis based on individual patient data and found that in individuals with ADAMTS13 
levels <5% of normal, there was an increased risk of acute myocardial infarction (11). These 
data may suggest that there is more a low level threshold rather than a clear dose association 
of ADAMTS13 and CHD, as was also suggested for ischemic stroke (6). Nearly all individuals 
in our study in the lowest ADAMTS13 quartile had ADAMTS13 activity in the normal range 
(50 – 150%) (24). Nonetheless, our study clearly shows that moderately reduced ADAMTS13 
activity is associated with an increased risk of thrombotic complications, even though the 
levels are not as low as characteristic for TTP patients. However, in our study we showed 
a graded response effect from quartile 4 to quartile 1 suggesting that with decreasing 
ADAMTS13 activity the CHD risk is increasing. Additionally, we performed a Youden Index 
analysis showing the highest sensitivity with activity levels of ADAMTS13 of around 69.7, 
which is almost equal to the mean levels of ADAMTS13 activity in the first quartile (Table 2: 
70.5%). Accordingly, in the ‘Youden Index’ analysis, the first quartile of ADAMTS13 appeared 
to carry the highest sensitivity in the association between ADAMTS13 and CHD risk. 
The important role of ADAMTS13 in cardiovascular disease has previously been shown in 
experimental animal studies showing larger myocardial infarctions in ADAMTS13 deficient 
mice compared with wild type mice (7-9). These studies suggest a major role of ADAMTS13 
in myocardial infarction. These studies also showed that infusion of recombinant human 
ADAMTS13, reduced the infarct size in wild type mice with myocardial ischemia before 
reperfusion (7, 9). This suggests that ADAMTS13 may also have a therapeutic role in CHD 
patients. However, future large prospective cohort studies are needed to determine the 
exact role of ADAMTS13 in CHD. 
When we compared the association of ADAMTS13 with CHD, with the association we 
previously reported with stroke, it is suggested that the influence of ADAMTS13 is more 
prominent in ischemic stroke than in CHD (HR 1.65, 95% CI 1.16 - 2.32; HR 1.42, 95%CI 
1.07 – 1.89; respectively) (6, 10). A major difference between stroke and CHD is that there 
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is wide variety in etiology of ischemic stroke (25) with thromboembolism being the most 
frequent cause, while in CHD the major cause is atherosclerosis. A previous review on 
hypercoagulability also found that hypercoagulability is a stronger risk factor for ischemic 
stroke than myocardial infarction (26). This suggests a general more pronounced role for 
coagulation-related risk factors for ischemic stroke than CHD. 
Previously, we found an association between high VWF levels and CHD in the Rotterdam 
(27). To investigate whether VWF and ADAMTS13 interact in determining CHD risk, we 
analyzed the risk of CHD using groups based on a combination of ADAMTS13 activity and 
VWF levels. In individuals with a low ADAMTS13 activity and a high VWF level, the risk 
of CHD was increased compared with the reference group and we found no interaction 
between VWF levels and ADAMTS13 activity. Thereby this study suggests that ADAMTS13 
and VWF are both independent risk factors, which has also been shown in previous studies 
(6, 11, 19). This might be explained by the fact that ADAMTS13 activity levels measured in 
our study participants are apparently high enough for cleavage of plasma VWF. This has 
also been shown previously in ADAMTS13 heterozygote individuals that they had normal 
VWF multimer patterns in plasma. However, locally at sites of endothelial damage the 
reduced ADAMTS13 activity may lead to reduced cleavage of secreted large multimers of 
VWF and thereby contribute to local thrombus formation. Individuals with a low ADAMTS13 
activity and a VWF:Ag level below the 75th percentile had an almost similar risk estimate as 
individuals with a low ADAMTS13 and a high VWF:Ag level (above the 75th percentile). This 
suggests that ADAMTS13 could be a more prominent risk factor for CHD than VWF, however 
further studies are needed to evaluate the independent roles and interaction between 
ADAMTS13 and VWF. As it is known that individuals with blood group O have 25% lower 
VWF levels (28), we additionally adjusted for blood group in these associations. We found 
similar risk estimates, although the association between low ADAMTS13 and high VWF:Ag 
level with the risk of CHD was not statistically significant after additional adjustment. 
We have shown an association between low ADAMTS13 and an increased risk of CHD in a 
large prospective cohort study with a long follow-up (median 9.7 years). A limitation of our 
study is that only individuals of 55 years and older were included and therefore whether these 
results can be extended to younger populations remains unclear. In addition, we measured 
ADAMTS13 activity at baseline to determine the subsequent CHD risk, to understand more 
about underlying mechanisms future studies should perform multiple measurements of 
ADAMTS13 over time. Although we adjusted for all cardiovascular risk factors, the possibility 
of residual confounding cannot be ruled out and thereby influencing the results. 
In conclusion, this large prospective cohort study shows that low ADAMTS13 activity is 
associated with an increased risk of coronary heart disease among individuals of 55 years 
and older, independently of VWF and established cardiovascular risk factors. 
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AbStrACt
background
Von Willebrand Factor (VWF) is a plasma protein that plays a major role in platelet adhesion 
and aggregation. Large VWF multimers are cleaved into smaller, less coagulant forms by 
the metalloprotease ADAMTS13. Previous studies have shown that high VWF and low 
ADAMTS13 levels are associated with cardiovascular disease, but whether these factors are 
associated with mortality is unclear. Our aim is to establish the association between VWF 
antigen (VWF:Ag) levels,  ADAMTS13 activity, and mortality.
Methods
We included 6130 participants of the Rotterdam Study, a population-based cohort study 
among individuals ≥ 55 years. We determined the association between ADAMTS13 activity, 
VWF:Ag levels and all-cause mortality and cardiovascular mortality by Cox proportional 
hazard regression analysis. 
results
Over a median follow-up time of 11.3 years and a total of 90635 person years, 1868 of 
the 6130 individuals died (30.5%), of whom 442 due to cardiovascular disease (23.7%). 
In individuals with low ADAMTS13 activity, the risk of cardiovascular mortality (HR 1.46, 
95%CI 1.09 -1.96) was higher than in individuals with high ADAMTS13 activity. The risk of 
cardiovascular mortality (HR 1.29, 95%CI 0.98 – 1.70) was higher in individuals with the 
highest VWF:Ag levels than in those with the lowest. In individuals with both low ADAMTS13 
activity and high VWF:Ag levels, the risk of cardiovascular mortality (HR 1.73 95%CI 1.28 – 
2.35) was also higher. 
Conclusions
In this large prospective cohort study, ADAMTS13 activity and VWF:Ag levels are both 
associated with an increased risk of all-cause and cardiovascular mortality. 
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introduCtion
VWF is a multimeric glycoprotein that plays a major role in platelet adhesion and aggregation 
(1). Large VWF multimers are highly procoagulant and are cleaved by its metalloprotease 
ADAMTS13 (A Disintegrin And Metalloprotease with ThromboSpondin motif repeats 
13) in smaller, less procoagulant forms (2). In case of a deficiency of ADAMTS13, large 
VWF multimers are not cleaved, resulting in more high molecular VWF multimers in the 
circulation. This is characteristic for thrombotic thrombocytopenic purpura (TTP) (3) in 
which patients suffer from microangiopathies, kidney failure and neurological symptoms 
due to the formation of microthrombus in the circulation. 
Cardiovascular disease is one of the leading causes of death in the Western world (4). 
We recently showed in the Rotterdam study that high Von Willebrand Factor (VWF) and 
low ADAMTS13 levels are associated with an increased risk of cardiovascular disease, 
including coronary heart disease and ischemic stroke (5-8). Although VWF and ADAMTS13 
are associated with cardiovascular disease, it is not clear yet whether these factors are 
associated with mortality. 
Some prospective studies have shown an association between VWF levels and mortality 
(9-13). Most of these studies have shown a significant association between high VWF 
levels and a worse cardiovascular health (9, 10, 12, 13), but almost all studies have focused 
on the cardiac specific mortality (9-11) and only two studies have focused on the total 
cardiovascular mortality due to coronary heart disease or stroke (12, 13). Studies on the 
association between ADAMTS13 and all-cause mortality are lacking. 
We aimed to investigate the association between VWF levels, ADAMTS13 activity and all-
cause or cause-specific mortality, especially cardiovascular mortality. 
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MAteriAlS And MetHodS
Study design and study population
This study is part of the Rotterdam Study, a prospective population-based cohort study among 
individuals of 55 years and older who are all living in Ommoord, a suburb of Rotterdam, 
The Netherlands (14). Of the 10,215 eligible individuals, 7,983 agreed to participate at the 
start of the study in 1990 (RS-1). In 1999 the study was extended with 3,011 individuals 
(out of 4,472 invitees) who moved into the study district or became 55 years since the 
start of the study. All participants were asked to visit the study center every 3 to 4 years to 
assess established cardiovascular risk factors. The Rotterdam Study has been approved by 
the Medical Ethics Committee of the Erasmus MC and by the Ministry of Health, Welfare 
and Sport of the Netherlands, implementing the Population Studies Act: Rotterdam Study. 
Written informed consent was obtained from all participants. For this study, we used the 
data of the participants in the third examination of the original cohort (RS-I-3) and the first 
examination of the extended cohort (RS-II-1). We included all participants who were alive at 
baseline and of whom blood was sampled (N= 6511). Patients who died within 3 years after 
blood sampling were excluded from the analyses (N= 381) as an already existing disease at 
moment of blood sampling may have influenced ADAMTS13 activity and VWF levels. 
Von Willebrand factor and AdAMtS13 measurements
VWF antigen (VWF:Ag) levels were determined with an in-house ELISA. Polyclonal rabbit 
anti-human VWF antibodies were used for catching and tagging (DakoCytomation, Glostrup, 
Denmark). ADAMTS13 activity was measured in a kinetic assay with the previously described 
Fluorescence Resonance Energy Transfer Substrate VWF 73 (FRETS-VWF73) (15). All samples 
were measured against a reference curve of serial dilutions of normal human plasma 
(Cryocheck normal reference plasma, Presizion Biologic, Dartmouth, USA).
Assessment of mortality
Information on mortality was continuously reported through automatic linkage of general 
practitioner files. Additionally, municipal records were checked on a monthly basis. 
Information on cause of death was obtained from general practitioners and hospital 
records. Research physicians reviewed all information and coded all events according to the 
International Classification of Diseases, 10th edition (ICD-10). Deaths due to cardiovascular 
disease were coded as I21 or I64. A consensus panel adjudicated the final cause of death 
according to ICD-10 codes using standardized definitions (16). If the cause of death was 
coded as C01-C97, the cause of death was labeled as cancer related mortality. Chronic 
Obstructive Pulmonary Disease (COPD) related mortality was coded as J43-J44. Participants 
were followed from date of entry in the study until date of death, lost to follow-up or January 
1st, 2012, whichever came first. 
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Baseline characteristics
Of all participants, data was collected by structured interviews and physical examination. 
In a subset of participants blood was sampled. Blood pressure was measured as the mean 
of two readings using a random-zero sphygmomanometer in sitting position. The use of 
antihypertensive drugs was defined as the use of antihypertensive medication indicated for 
the treatment of high blood pressure (≥ grade 1 hypertension according to World Health 
Organization Criteria (17)). Antithrombotic medication was defined as the use of vitamin K 
antagonists, platelet aggregation inhibitors, and direct thrombin inhibitors. Diabetes mellitus 
was defined as fasting serum glucose level ≥ 7.0 mml/L and/or the use of blood glucose 
lowering medication (18). Lipid lowering agents was defined as the use of statins. Total 
cholesterol and high-density lipoprotein cholesterol were measured using an automated 
enzymatic procedure. Body mass index was calculated as the weight (in kilograms) divided 
by the square of the height (in meters). Smoking status was defined as current, former or 
no smoking at baseline.  
Statistical analysis
Mean and standard deviation or counts and percentages were used to describe baseline 
characteristics. Log minus Log plots were drawn to determine proportional hazards 
assumption. Cox proportional hazard regression analysis was used to assess the association 
between ADAMTS13, VWF and mortality. For these analyses quartiles of ADAMTS13 activity 
and VWF:Ag levels were used. A Kaplan Meier curve was constructed using ADAMTS13  and 
VWF quartiles adjusted for age and sex. For the combination of ADAMTS13 activity and 
VWF levels, we used the 25 percentile for ADAMTS13 and the 75 percentile as cut-off for 
VWF. All analyses were adjusted for age and sex and additionally for use of antithrombotic 
agents, antihypertensives, diabetes mellitus, lipid reducing agents, BMI, current smoking, 
total cholesterol, HDL cholesterol, systolic blood pressure and diastolic blood pressure and 
finally additionally adjusted for prevalent cardiovascular disease. Missing values of all these 
covariates (0-4.7%) were imputed five times using a multiple imputation method including 
all covariates. Statistical analyses were performed on all five datasets and pooled into one 
final result using SPSS software. Data were analyzed using SPSS version 21 (SPSS 21.0 IBM, 
Somers, NY, USA). All statistical tests were two-tailed and a p value of <0.05 was considered 
statistically significant.
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reSultS
In total, 6130 individuals were included in this study. The mean age of the included 
individuals was 69 ± 8.0 years and 57% was female. The median VWF:Ag level was 1.19 [IQR 
0.92 – 1.58] IU/ml and the mean ADAMTS13 activity was 91.8 ± 17.6%. During the median 
follow-up time of 11.3 years, 1868 (30.5%) individuals died, 442 of them (23.7%) due to 
cardiovascular disease, 518 (27.7%) due to cancer, and 59 (3.2%) due to COPD. 
After adjusting for confounders, the risk of all-cause mortality was significantly higher in 
individuals in the lowest ADAMTS13 quartile than in individuals with the highest ADAMTS13 
(HR 1.46, 95%CI 1.26 – 1.69, Table 2). The risk of cardiovascular mortality was also increased 
in individuals with the lowest ADAMTS13 activity (HR 1.46, 95%CI 1.09 – 1.96). The risks of 
cancer related mortality and COPD related mortality were 1.30 and 1.91, but not statistically 
significant (HR 1.30, 95%CI 0.99 – 1.71; HR 1.91, 95%CI 0.69 – 5.32, respectively).
table 1. Baseline characteristics
N = 6130 Total cohort
N (%) or mean ± SD
Age (years) 68.9 ± 8.0
Female sex 3520 (57.4%)
Smoking
   Current 1057 (17.4%)
   Former 3019 (49.6%)
BMI (kg/m2) 27.0 ± 4.1
Antithrombotic medication 1194 (20.4%)
Hypertension 1406 (24.1%)
Lipid reducing agents 785 (13.4%)
Diabetes Mellitus 623 (10.3%)
Total cholesterol (mmol/l) 5.8 ± 1.0
HDL cholesterol (mmol/l) 1.4 ± 0.4
Systolic blood pressure (mmHg) 143 ± 21
Diastolic blood pressure (mmHg) 77 ± 11
Blood group O 2360(45.3%)
ADAMTS13 activity (%) 91.76 ± 17.59
VWF:Ag level (IU/ml), median [IQR] 1.19 [0.92-1.58]
In individuals in the highest VWF quartile, the risk of all-cause mortality was increased 
compared with individuals in the lowest quartile of VWF (HR 1.21, 95%CI 1.06 – 1.38, Table 3). 
When we analyzed the different mortality causes, the risk estimate of cardiovascular 
related mortality (HR 1.29, 95%CI 0.98 – 1.70) was similar to the risk of all-cause mortality. 
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table 2. Cox proportional hazard regression analysis between ADAMTS13 quartiles and mortality
ADAMTS13 activity Number of cases / 
total number at risk
Model 1
HR (95% CI)
Model 2
HR (95% CI)
Model 3 
HR (95% CI)
All-cause mortality  
(N= 1868)
Quartile 1 679 / 1530 1.50 (1.30 – 1.73) 1.46 (1.26 – 1.69) 1.46 (1.26 – 1.69)
Quartile 2 490 / 1531 1.21 (1.04 – 1.40) 1.18 (1.02 – 1.38) 1.20 (1.03 – 1.39)
Quartile 3 412 / 1530 1.13 (0.97 – 1.32) 1.12 (0.96 – 1.31) 1.13 (0.97 – 1.31)
Quartile 4 287 / 1530 1 (ref) 1 (ref) 1 (ref)
Cardiovascular mortality 
(N= 442)
Quartile 1 171 / 1514 1.41 (1.06 – 1.89) 1.46 (1.09 – 1.96) 1.46 (1.09 – 1.96)
Quartile 2 98 / 1525 0.92 (0.68 – 1.25) 0.93 (0.68 – 1.27) 0.95 (0.69 – 1.29)
Quartile 3 100 / 1525 1.05 (0.78 – 1.43) 1.07 (0.79 – 1.45) 1.07 (0.79 – 1.46)
Quartile 4 73 / 1523 1 (ref) 1 (ref) 1 (ref)
Model 1 adjusted for age and sex 
Model 2 additionally adjusted for antithrombotic medication, hypertension, diabetes mellitus, lipid reducing 
agents, BMI, smoking, total cholesterol, HDL cholesterol, systolic blood pressure and diastolic blood pressure
Model 3 additionally adjusted for prevalent cardiovascular disease 
No association was observed between VWF:Ag levels and COPD mortality (HR 1.07, 95%CI 
0.83 – 1.37) and cancer mortality (HR 1.02, 95%CI 0.80 – 1.30). 
The lowest ADAMTS13 and the highest VWF quartiles were both associated with the lowest 
event-free survival after adjustment for age and sex (Figure 1). 
In individuals with both high VWF:Ag and low ADAMTS13 activity (N=448), the risk of all-
cause mortality was strongly increased compared to individuals with both low VWF:Ag and 
high ADAMTS13 activity (Table 4). We additionally investigated whether individuals with 
both high VWF:Ag levels and low ADAMTS13 activity had an even stronger risk of mortality. 
Of these 448 individuals 247 individuals died (55.1%) during follow-up compared to 22.6% in 
the group individuals with low VWF:Ag levels and high ADAMTS13 activity. Individuals with 
both high VWF and low ADAMTS13 had a 58% increased risk of all-cause mortality (HR 1.58, 
95%CI 1.36 – 1.84). Also, the risk of cardiovascular mortality was increased most strongly in 
individuals with both low ADAMTS13 and high VWF (HR 1.73, 95%CI 1.28 – 2.35). The risks 
of cancer related mortality and COPD related mortality were both not increased with the 
combination of low ADAMTS13 and high VWF (HR 1.16, 95%CI 0.84 – 1.60; HR 1.32 95%CI 
0.54 – 3.22).
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table 3. Cox proportional hazard regression analysis between VWF quartiles and mortality
VWF:Ag levels Number of cases / 
total number at risk
Model 1
HR (95% CI)
Model 2
HR (95% CI)
Model 3
HR (95% CI)
All-cause mortality (N= 
1863)
Quartile 1 366 / 1558 1 (ref) 1 (ref) 1 (ref)
Quartile 2 414 / 1537 0.99 (0.86 – 1.14) 0.99 (0.86 – 1.14) 0.99 (0.86 – 1.14)
Quartile 3 451 / 1495 0.96 (0.84 – 1.11) 0.97 (0.84 – 1.11) 0.97 (0.84 – 1.11)
Quartile 4 632 / 1530 1.21 (1.06 – 1.38) 1.21 (1.06 – 1.38) 1.21 (1.06 – 1.38)
Cardiovascular mortality 
(N= 439)
Quartile 1 80 / 1551 1 (ref) 1 (ref) 1 (ref)
Quartile 2 95 / 1526 1.03 (0.77 – 1.39) 1.04 (0.77 – 1.41) 1.03 (0.76 – 1.38)
Quartile 3 109 / 1486 1.04 (0.77 – 1.39) 1.04 (0.78 - 1.39) 1.05 (0.78 – 1.40)
Quartile 4 155 / 1523 1.30 (0.99 – 1.71) 1.29 (0.98 – 1.70) 1.29 (0.98 - 1.70)
Model 1 adjusted for age and sex 
Model 2 additionally adjusted for antithrombotic medication, hypertension, diabetes mellitus, lipid reducing 
agents, BMI, smoking, total cholesterol, HDL cholesterol, systolic blood pressure and diastolic blood pressure
Model 3 additionally adjusted for prevalent cardiovascular disease
table 4. Cox proportional hazard regression analysis between ADAMTS13 and VWF and mortality
ADAMTS13 and VWF:Ag level Number of 
cases / 
total number 
at risk
Model 1
HR (95% CI)
Model 2
HR (95% CI)
Model 3
HR (95% CI)
Mortality (N = 1862)
VWF < p75 and ADAMTS13 > p25 798 / 3502 1 (ref) 1 (ref) 1 (ref)
VWF ≥ p75 and ADAMTS13 > p25 385 / 1080 1.23 (1.09 – 1.39) 1.24 (1.10 – 1.41) 1.24 (1.10 – 1.40)
VWF < p75 and ADAMTS13 ≤ p25 432 / 1081 1.33 (1.18 – 1.50) 1.31 (1.16 – 1.48) 1.31 (1.16 – 1.48)
VWF ≥ p75 and ADAMTS13 ≤ p25 247 / 448 1.60 (1.38 – 1.86) 1.57 (1.35 – 1.82) 1.58 (1.36 – 1.84)
Cardiovascular mortality (N= 439)
VWF < p75 and ADAMTS13 > p25 174 / 3486 1 (ref) 1 (ref) 1 (ref)
VWF ≥ p75 and ADAMTS13 > p25 95 / 1078 1.35 (1.05 – 1.74) 1.35 (1.05 – 1.74) 1.33 (1.03 – 1.72)
VWF < p75 and ADAMTS13 ≤ p25 110 / 1070 1.51 (1.18 – 1.94) 1.57 (1.22 – 2.01) 1.54 (1.20 – 1.97)
VWF ≥ p75 and ADAMTS13 ≤ p25 60 / 443 1.73 (1.28 – 2.34) 1.72 (1.27 – 2.33) 1.73 (1.28 – 2.35)
Model 1 adjusted for age and sex
Model 2 additionally adjusted for antithrombotic agents, antihypertensives, diabetes mellitus, lipid reducing agents, 
BMI, current smoking, total cholesterol, HDL cholesterol, systolic blood pressure and diastolic blood pressure
Model 3 additionally adjusted for prevalent cardiovascular disease
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figure 1. Kaplan meier curves for VWF:Ag levels and ADAMTS13 activity
Kaplan Meier curve for the cumulative survival for all-cause mortality per quartile of ADAMTS13 activity 
(A) and VWF:Ag levels (B) adjusted for age and sex. Kaplan Meier curve for the cumulative survival for 
cardiovascular mortality per quartile of ADAMTS13 activity (C) and for VWF:Ag levels (D) adjusted for 
age and sex. Cut-points for ADAMTS13 quartiles were: ≤70.99%, 71.00 – 90.80%, 90.81 – 111.51%, and 
≥111.52%. Cut-points for VWF quartiles were: ≤0.56, 0.57 – 1.09, 1.10 – 1.82, and 1.83 IU/L
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diSCuSSion
In this large prospective cohort study with a median follow-up time of 11.3 years and a 
total of 90635 person years, ADAMTS13 activity and VWF:Ag levels were associated with 
an increased  risk of mortality and specifically cardiovascular mortality. These risks were 
independent of prevalent cardiovascular disease and established cardiovascular risk factors. 
We found an association between low ADAMTS13 activity and the risk of all-cause and 
cardiovascular mortality. Recently, we have shown that low ADAMTS13 activity is associated 
with an increased risk of ischemic stroke and coronary heart disease (8, 19), but no studies 
on the association with mortality have been performed to date. We found that individuals 
with low ADAMTS13 activity (< 80.7%) had a 1.46 fold higher risk of mortality than individuals 
with high ADAMTS13 activity. In individuals with the lowest ADAMTS13, the risk estimates 
of all-cause and cardiovascular mortality (HR 1.46 for both) were similar, suggesting that the 
risk of all-cause mortality might be driven by an increased risk of cardiovascular disease.
We found an increased risk of all-cause mortality in individuals with the highest VWF:Ag 
levels. In addition, there was a borderline significant association between cardiovascular 
mortality and high VWF:Ag levels, although the risk estimate was higher compared 
with all-cause mortality. This might be explained by the smaller number of cases in this 
subgroup. These results indicate that ADAMTS13 activity may play a more prominent role in 
cardiovascular disease in our elderly study population. Previous studies using the Rotterdam 
Study have already found a higher cardiovascular risk in individuals with a low ADAMTS13 
activity than with a high VWF:Ag level (5, 8, 20). The association between VWF levels and 
cardiovascular mortality has been reported before (9-13). However, these studies only 
investigated cardiac specific or cardiovascular mortality and no studies are performed yet 
on the association with all-cause mortality and cause specific mortality. 
 In a model with both low VWF levels and high ADAMTS13 activity, we found that 
individuals with a high VWF:Ag level and low ADAMTS13 activity have an increased risk 
of all-cause and cardiovascular mortality up to 1.73 fold, although this was only a small 
subgroup of individuals (24.1 and 7.3%, respectively). This finding suggests that VWF and 
ADAMTS13 could be independent risk factors and might have an additive effect, which was 
also shown before (8). 
The risks of cancer and COPD related mortality were not increased in individuals with either 
high VWF:Ag levels or low ADAMTS13 activity, although the risk of cancer related mortality 
was borderline significant in individuals with the lowest ADAMTS13 activity. Cancer and COPD 
are both common causes of mortality. Previous studies have shown a relation between high 
VWF levels and cancer (21-24), COPD (25, 26), or inflammation (27) and also an association 
between ADAMTS13 and inflammation was shown before (28-30). This would suggest that 
there may be an association between high VWF levels, low ADAMTS13 and cancer or COPD 
related mortality. However, the lack of this association suggests that ADAMTS13 and VWF 
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are influenced by other mechanisms such as inflammation in patients with COPD or cancer, 
and their effect might be explained by alternative factors. 
So far, this is the first study that investigated the association between VWF:Ag levels, 
ADAMTS13 activity and the risk of all-cause and cardiovascular mortality in a population 
that is representative for the Dutch population. We had a long follow-up time of 11.3 years 
in which many individuals died (30.5%). However, only 59 participants died due to COPD 
related mortality which was too small to have sufficient power to evaluate the association. 
Moreover, VWF and ADAMTS13 could have been influenced by an already existing disease 
at the moment of blood sampling. Therefore, we excluded all individuals who died within 
the first 3 years after blood sampling to reduce this influence. Our study was performed in a 
population of predominantly Caucasians of 55 years and older that live in a middle income 
district of Rotterdam. This limits the generalizability of our results, especially for younger 
individuals. 
In conclusion, we observed in this large prospective cohort study with a long follow-up 
time, an association between high VWF levels, low ADAMTS13 activity and all-cause or 
cardiovascular mortality. This risk increased up to 1.73 fold when using both high VWF and 
low ADAMTS13. 
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AbStrACt.
background
Physical stress triggers the endothelium to release von Willebrand Factor (VWF) from the 
Weibel Palade bodies. Since VWF is a risk factor for arterial thrombosis, it is of great interest 
to discover determinants of VWF response to physical stress. We aimed to determine the 
main mediators of the VWF increase by exhaustive physical exercise. 
Methods
105 healthy individuals (18-35 years) were included in this study. Each participant performed 
an incremental exhaustive exercise test on a cycle ergometer. Respiratory gas exchange 
measurements were obtained while cardiac function was continuously monitored. Blood 
was collected at baseline and directly after exhaustion. VWF antigen (VWF:Ag) levels, VWF 
collagen binding (VWF:CB) levels, ADAMTS13 activity and common variations in Syntaxin 
Binding Protein-5 (STXBP5, rs1039084 and rs9399599), Syntaxin-2 (STX2, rs7978987) and 
VWF (promoter, rs7965413) were determined. 
results
The median VWF:Ag level at baseline was 0.94 IU/mL [IQR 0.8-1.1] and increased with 47% 
[IQR 25-73] after exhaustive exercise to a median maximum VWF:Ag of 1.38 IU/mL [IQR 1.1-
1.8] (p<0.0001). VWF:CB levels and ADAMTS13 activity both also increased after exhaustive 
exercise (median increase 43% and 12%, both p<0.0001). The strongest determinants of 
the VWF:Ag level increase are performance related (p<0.0001). We observed a gender 
difference in VWF:Ag response to exercise (females 1.2 IU/mL; males 1.7 IU/mL, p=0.001), 
which was associated by a difference in performance. Genetic variations in STXBP5, STX2 
and the VWF promoter were not associated with VWF:Ag levels at baseline nor with the 
VWF:Ag increase.  
Conclusions
VWF:Ag levels strongly increase upon exhaustive exercise and this increase is strongly 
determined by physical fitness level and the intensity of the exercise, while there is no clear 
effect of genetic variation in STXBP5, STX2 and the VWF promoter. 
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introduCtion
Blood coagulation changes in response to physical exercise (1-6). One of the major players 
in blood coagulation is von Willebrand factor (VWF), a multifunctional glycoprotein that 
initiates primary haemostasis. Ultralarge very active VWF multimers are cleaved by A 
Disintegrin and Metalloprotease with ThromboSpondin motif repeats 13 (ADAMTS13) into 
smaller, less prothrombotic forms. It is well known that levels of VWF increase steeply 
upon intense physical exercise (7). To date it is not fully understood which mediators, both 
non-genetic and genetic, affect VWF response to stress. However, it is of great interest to 
discover new determinants of the excretion mechanism of VWF molecules, since high VWF 
levels have been associated with venous thrombosis (8) and arterial thrombosis (9-11). 
VWF is mainly synthesized by endothelial cells and marks endothelial cell activation (12, 
13). The majority of the freshly synthesized VWF molecules are constitutively released into 
the circulation. A small part of especially large VWF multimers - harbouring the greatest 
haemostatic potential - is stored in Weibel Palade Bodies of endothelial cells (14-17). 
Numerous agonists initiate the release from these storage granules, including hypoxia, 
epinephrine, histamine, thrombin, fibrin, and vasopressin (18, 19). 
Plasma VWF levels have a wide biological variation, since numerous lifestyle factors, 
environmental factors, and genetic factors continuously influence VWF levels in the 
circulation (19). Previous studies among human twins have demonstrated that more than 
half of the variability in VWF levels is caused by genetic variations in the genome (20, 21). 
The most important genetic determinant is ABO blood group (22). In addition, recently six 
new genetic loci have been discovered using a hypothesis-free approach with genome-wide 
association studies (23). Two of the newly identified genetic loci, Syntaxin Binding Protein-5 
(STXBP5) and Syntaxin-2 (STX2), are of specific interest, since their encoding proteins 
interact with SNARE complex proteins, such as SNAP23 and syntaxin-4, which have been 
shown to be involved in Weibel Palade Body (WPB) exocytosis, a well-known mechanism for 
the secretion of VWF molecules by endothelial cells (24). Another genetic modulator is the 
VWF promoter in which four single nucleotide polymorphisms (SNPs) have been identified, 
that are associated with VWF levels (25, 26). 
We aimed to identify important mediators, including lifestyle factors, environmental factors, 
and common genetic variations in the STXBP5, STX2 and VWF promoter genes, of VWF 
response to incremental exhaustive exercise in a large group of young healthy individuals. 
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MAteriAl And MetHodS
Ethics Statement
The study was approved by the medical ethical committee at Erasmus University Medical 
Center and written informed consent was obtained from all participants at inclusion. 
Study participants
For the “RESPOnse” (Role of SNARE protein genes in the regulation of von Willebrand Factor 
concentration and other coagulation factors) study, we included 105 healthy individuals, 
who were between 18 to 35 years of age and of North-European ancestry. Exclusion criteria 
were known cardiovascular risk factors, including hypertension, hypercholesterolemia, 
diabetes, obesity (BMI > 30 kg/m2), and a positive family history of cardiovascular disease. 
In addition, participants never had a thrombotic event or coagulation disorder, were non-
smokers, had no known malignancies, no liver or renal dysfunction, did not use medication 
that may influence VWF levels and were not pregnant. Oral contraceptives use was allowed 
in this study. Subjects were requested to abstain from caffeinated and alcoholic beverages 
twelve hours prior to the test and to avoid heavy or high-intensity physical exercise and 
sports activities on the day of the test.
Baseline measurements 
At baseline, all patients received a questionnaire on current health status and physical 
condition. We measured weight using a calibrated digital scale (SECA GmbH & co, model 861) 
and height using a wall mounted telescopic height rod (SECA GmbH & co, model 220). Blood 
pressure was measured in an upright sitting position with a calibrated sphygmanometer 
(Welch Allyn, model Maxi-Stabil 3) and left upper-arm adjusted cuff size (WelchAllyn, 
FlexiPort reusable blood pressure cuff). Also, before the start of the cycle ergometer test, we 
performed a rest electrocardiogram (ECG) to exclude abnormalities in electric conduction 
through the heart, arrhythmias etc. All participants declared to be in good health and none 
of them had medical contra-indications for participation in the study. 
Cycle ergometer maximal test
Each participant performed an incremental exercise test until exhaustion, performed on a 
cycle ergometer (Ergoline, ER800, Lode, the Netherlands) using a linearly increasing (12 or 
18.5 W min-1) ramp protocol. These slopes were chosen to achieve exhaustion within 8-12 
minutes as recommended by Zhang et al (27). Participants started with a warming-up phase 
of 4 minutes without resistance. They were instructed to pedal at a frequency between 
60 and 80 rotations per minute (rpm). The loaded phase was terminated when pedalling 
frequency dropped below 60 rpm and was followed by cooling-down for at least 2 minutes. 
Cardiac function was monitored using a 12-lead electrocardiogram with heart rate (HR) 
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being recorded continuously. Respiratory gas exchange measurements were performed 
continuously by using a computerized metabolic cart (Oxycon Pro, Carefusion, the 
Netherlands) that was calibrated before each test. Maximal whole-body oxygen uptake 
capacity was defined in the present study as VO
2
 remaining unchanged or increasing less 
than 1 ml/min/kg for 30 sec or more despite an increment in work load (28). VO
2
 is the 
capacity to transport and use oxygen during exercise and is a measure for physical fitness. 
The ventilatory threshold (VT1) was determined by an increase in ventilation (Ve)/VO
2
 
but without a concomitant increase in Ve/VCO
2
. The ventilatory threshold represents 
the moment at which metabolism changes from aerobic to anaerobic. Two experienced 
exercise physiologists reviewed the plots averaged over 30 sec of the Ve/VO
2 
and Ve/VCO
2
 
and determined VT1 values. In case of disagreement, the opinion of a third investigator was 
sought. The metabolic equivalent (METs) score is calculated by the VO2 max and VO2 VT1 
values (1 MET = 3.5 ml/min/kg VO2). A METs score (calculated by the VO2 max) above 10 
represents activities associated with significant exertion. A METs score calculated by the 
VO2 VT1 represents the intensity to sustain activities for 1 hour and is a measurement of 
the physical fitness of an individual. The power output (W) was assessed to establish the 
workload capacity of the participant. Power output is dependent on physical fitness, but 
also on talent. Finally, maximum respiratory exchange ratio (RER) at peak power output was 
determined. The RER is a ratio between the amount of carbon dioxide (CO
2
) exhaled and 
the amount of oxygen (O2) inhaled per breath. Together with the maximum achieved heart 
rate as percentage of age-predicted heart rate (i.e. 208-0.7*age) (29), the maximum RER is 
a measure for the intensity of the test.
Blood sampling
Venous blood was drawn from the forearm before and directly after exhaustion (within 1 
minute) via a cannula in the antecubital vein using a Vacutainer system (Becton-Dickinson, 
Plymouth, UK). The first 2 ml of blood was discarded at every time point. Blood for 
coagulation measurements was collected in 3.2% trisodium citrate (9:1 vol/vol). Citrated 
blood was centrifuged within 1 hour at 3500 rpm for 10 min at 4°C. Plasma was additionally 
centrifuged at 14 000 rpm at room temperature and stored in aliquots at -80°C. For DNA 
isolation we stored the buffy coats of the remaining citrated blood at -20°C until use. 
Genomic DNA was isolated according to standard salting-out procedures and stored at 4°C 
for genetic analysis. 
Laboratory measurements
VWF antigen (VWF:Ag) was determined with an in-house ELISA with polyclonal rabbit anti-
human VWF antibodies and horseradish peroxidase conjugated anti-human VWF antibodies 
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(DakoCytomation, Glostrop, Denmark) for catching and tagging, respectively.
VWF collagen binding (VWF:CB) was determined with an in-house ELISA using collagen 
bovine antibodies and horseradish peroxidase conjugated anti-human VWF antibodies 
(DakoCytomation, Glostrop, Denmark) for catching and tagging, respectively.
ADAMTS13 activity was measured by a Fluorescence Resonance Energy Transfer Substrate 
(FRETS) assay using a fluorescent VWF peptide consisting of 73 amino acids (FRETS-VWF73). 
Plates were read with BioTek’s microplate reader (BioTek). The intra-assay coefficients of 
variation for VWF:Ag, VWF:CB and ADAMTS13 were 1.9%, 4.5% and 3.6%, respectively. The 
inter-assay coefficients of variation for VWF:Ag, VWF:CB and ADAMTS13 were 8.3%, 7.9% 
and 7.5%, respectively.
Genotyping
The STXBP5 gene spans 182 kbps and is located in the q24 region of chromosome 6. Initially, 
we obtained data from the International HapMap project (phase II November 2008 http://
www.hapmap.org) on the linkage disequilibrium (LD) pattern and selected haplotype-
tagging single-nucleotide polymorphisms (ht-SNPs) using Haploview software (version 3.11; 
www.broad.mit.edu/mpg/haploview/index/php). For the STXBP5 and STX2 genes blocks of 
haplotypes with a frequency of ≥ 3% were defined in order to select these ht-SNPs. We took 
potential functionality into consideration by preferentially selecting non-synonymous ht-
SNPs or SNPs that are located in known regulatory elements. We considered only SNPs that 
were present in a Caucasian population. Of these ht-SNPs, three were significantly associated 
with VWF:Ag levels in our previous study among young patients with arterial thrombosis 
and healthy controls (30). Therefore, we selected and genotyped only these three SNPs 
in STXBP5 (rs1039084 and rs9399599) and in STX2 (rs7978987) for our current study. The 
polymorphisms in STXBP5, rs1039084 and rs9399599, are in high linkage disequilibrium with 
rs9390459, which had the highest genome wide significance level for VWF plasma levels in 
the meta-analysis of the CHARGE consortium (D’ = 1.00, R2 = 0.87 for rs9399599 and D’= 
0.96, R2 = 0.86 for rs1039084) (phase II November 2008 http://www.hapmap.org). Also, 
rs7978987 in STX2 had a highly significant P value of 3.82 x 10-11 in this meta-analysis(23). 
The gene encoding VWF is approximately 180 kb in length, contains 52 exons and is located 
on chromosome 12. Four SNPs in this gene have been identified, which are in strong linkage 
disequilibrium and segregate as two haplotypes (25, 31). We have selected and genotyped 
one of these SNP’s (rs7965413). 
Genotyping was done using Custom TaqMan Genotyping Assays (Applied Biosystems, 
Foster City, CA, USA). Endpoint fluorescence was measured on the ABI 7900HT instrument 
(Applied Biosystems, Foster City, CA, USA) and clustered according to genotype using SDS 
2.1 software (Applied Biosystems, Foster City, CA, USA). Genotyping was successful for each 
SNP in on average 97% of all subjects.
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Statistical Analysis
Data on baseline characteristics are presented as means and standard deviations for 
continuous variables and as counts and percentages for categorical data. Since VWF:Ag 
levels were skewed, these data were natural logarithmically transformed (lnVWF:Ag) and 
presented as median and interquartile range (IQR). Mann-Whitney tests were used for 
unpaired two-group comparisons of non-parametric data. 
The association between baseline characteristics and performance related determinants 
with lnVWF:Ag increase were assessed with linear regression models. Logistic regression 
was used to assess the relationship between VWF:Ag response and baseline characteristics, 
using VWF:Ag response as categorical variable. VWF:Ag increase was divided into two 
categories: low response with a VWF:Ag increase below the median (<0.40 IU/mL) and high 
response with a VWF:Ag increase above the median (≥ 0.40 IU/mL). Gender differences 
in performance-related determinants were assessed with univariate analysis of variance 
(ANOVA). The power output and the VO
2
 were adjusted for weight and presented as the 
value per kg. 
Allele frequencies of the VWF polymorphisms were calculated by genotype counting. For 
each SNP, the deviation from the Hardy-Weinberg equilibrium was tested by means of a 
Chi-squared test with one degree of freedom. We used linear regression analyses with 
additive genetic models to determine the association between genetic variations in VWF 
and lnVWF:Ag levels. We had a power of 0.80 to detect a difference of 0.2 between carriers 
of the minor allele and carriers of the common allele, assuming a minor allele frequency of 
0.40. Beta-coefficients represent the increase in lnVWF:Ag levels per coded allele. Statistical 
analyses were performed with SPSS for Windows, version 20.0 (SPSS Inc, Chicago, USA). A 
two-sided value of p < 0.05 was considered statistically significant.
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reSultS
In the current study, 105 healthy individuals were included. Baseline characteristics are 
shown in table 1. The mean age was 24 years and 61% were female. Blood pressure (mean 
114/70 mmHg) and BMI (mean 23 kg/m2) were within the normal range. Of all subjects, 
86 (82%) used alcoholic beverages. Of all female participants, 33 women (52%) used oral 
contraceptives, seven women (11%) had an intra-uterine device (MirenaÒ), and two women 
(3%) had a Nuva ringÒ. 
The median VWF:Ag level at baseline was 0.94 IU/mL and increased with 47% after exhaustive 
exercise to a median maximum VWF:Ag of 1.38 IU/mL (p < 0.0001) (table 1, figure 1). The 
median VWF:CB level at baseline was comparable with the VWF:Ag level, 0.93 IU/mL, and 
increased with 43% to a median maximum of 1.36 IU/mL (p < 0.0001). The absolute increase 
in VWF:Ag and VWF:CB levels was highly correlated (R 0.81, p < 0.0001). The VWF:CB / 
VWF:Ag ratio was 1.00 at baseline and was decreasing to 0.96 at maximum exercise. 
ADAMTS13 levels also increased after exhaustive exercise with 12% (Table 1, Figure 1). 
There was no correlation between the absolute increase in VWF:Ag level and ADAMTS13 (R 
0.06, p = 0.57). 
Baseline characteristics were not associated with baseline VWF:Ag levels (table 2). As 
expected, blood group non-O was associated with higher baseline VWF:Ag levels (geometric 
mean of VWF:Ag for blood group O: 0.82 ± 0.03 IU/mL and for non-O: 1.08 ± 0.05 IU/mL). 
Sex, systolic blood pressure, and diastolic blood pressure were significantly associated with 
the VWF:Ag level response (table 2 and figure 2). Alcohol consumption, defined as any 
amount of glasses per week, was borderline significantly associated with a lower VWF:Ag 
response (p = 0.06). The strongest determinant was sex. In a multivariate model including 
sex, blood pressure, and alcohol consumption, only sex remained significantly associated 
with VWF:Ag levels (beta-coefficient for males 0.79 [95% CI 0.52;1.06], p < 0.0001). 
At baseline, we observed no difference in VWF:Ag levels between males and females 
(median [IQR]: females 0.95 IU/mL [0.78;1.12] and males 0.91 IU/mL [0.74;1.11], p = 0.50). 
At exhaustion, males had significantly higher VWF:Ag levels than females (females 1.22 IU/
mL [1.06;1.58] and males 1.66 IU/mL [1.24;2.05], p = 0.001). OAC use was not associated 
with the VWF:Ag level response to exercise. 
Next, we investigated the association between performance related determinants and 
the VWF:Ag response (table 3A). All performance-related determinants were significantly 
associated with the increase in VWF:Ag levels, but not with the baseline VWF:Ag levels. 
The strongest performance related determinants (p < 0.0001) were the peak power output 
per kg bodyweight, the ratio between the power output at the ventilatory threshold and 
the peak power output in Watt, VO
2 
peak per kg and the maximum RER at peak power 
output. Physical fitness, as represented by the VO
2
 VT1/max and power output VT1/max, 
was negatively associated with the VWF:Ag increase. In addition, a multivariate regression 
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table 1. Baseline characteristics
n = 105
Age (years) 24.3 ± 4.4
Female sex, N (%) 64 (61%)
Systolic blood pressure (mmHg) 114 ± 12
Diastolic blood pressure (mmHg) 70 ± 9
Heart rate (bpm) 76 ± 10
BMI (kg/m2) 23 ± 2
Oral contraceptives (% of total women) 33 (52%)
Blood group O, N (%) 54 (51%)
METs score (max) 12.4 ± 2.4
METs score (VT1) 8.6 ± 1.9
VWF:Ag baseline (IU/mL), median (IQR) 0.94 (0.77-1.12)
VWF:Ag maximum (IU/mL), median (IQR) 1.38 (1.10-1.84)
VWF:Ag absolute increase (IU/mL), median (IQR) 0.40 (0.23-0.70)
VWF:Ag relative increase (%), median (IQR) 47 (25-73)
VWF:CB baseline (IU/mL), median (IQR) 0.93 (0.75-1.17)
VWF:CB maximum (IU/mL), median (IQR) 1.36 (1.11-1.68)
VWF:CB absolute increase (IU/mL), median (IQR) 0.37 (0.17-0.67)
VWF:CB relative increase (%), median (IQR) 43 (19-69)
ADAMTS13 baseline (U/ml), median (IQR) 1.28 (1.11-1.42)
ADAMTS13 maximum (U/ml), median (IQR) 1.46 (1.24-1.58)
ADAMTS13 absolute increase (U/ml), median (IQR) 0.15 (0.07-0.24)
ADAMTS13 relative increase (%), median (IQR) 12 (6-19)
VWF:CB / VWF:Ag ratio baseline, median (IQR) 1.00 (0.91-1.10)
VWF:CB / VWF:Ag ratio maximum, median (IQR) 0.96 (0.89-1.05)
Summary statistics for continuous variables are presented as mean ± standard deviation. Categorical data are 
summarized as percentages. VWF:Ag, VWF:CB and ADAMTS13 levels and the VWF:CB / VWF:Ag ratio are presented 
as median and interquartile range (IQR). 
was performed. However, strong multicolinearity was observed between all performance-
related variables. Therefore, we selected variables that showed the least correlation with 
each other for the multivariate model. To this end, we used two models with different 
combinations of variables. Nevertheless, multicolinearity could not be excluded completely, 
whereby the results of the multivariate regression analysis should still be interpreted with 
care. Next, we added sex to model I and model II, which resulted in the loss of the significant 
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association between sex and VWF:Ag increase (Model I: β = 0.27 [95% CI -0.04;0.58], p = 0.09; 
model II: β = 0.23 [95% CI -0.84;0.54], p = 0.15). Additionally, when stratifying for sex the 
association between performance related determinants and the increase in VWF:Ag levels 
remained. In table 3B the performance-related values are presented for males and females 
separately. Physical fitness (VO
2
 VT1/max and power output VT1/max) was slightly higher 
in females than in males. The intensity of the test and the endurance of the participant, as 
represented by the VO2 peak, peak power output, and the maximum RER, were higher in 
males than in females. There was no difference in test duration between males and females. 
When excluding women with oral contraceptives the results of the study did not change.
Finally, we investigated the association between genetic variations in STXBP5, STX2 and VWF 
promoter on VWF:Ag response to exercise (table 4). There was no significant association 
between genetic variations and VWF:Ag levels at baseline, at exhaustion, nor an association 
with the absolute VWF:Ag increase. Also, ABO blood group, the most important genetic 
determinant of VWF:Ag levels, was not associated with the VWF:Ag level response to 
exercise. There was also no significant difference in the association between VWF increase 
and genetic variation between individuals with blood group O and individuals with blood 
group non-O (data not shown). 
table 2. Association between baseline characteristics and VWF:Ag levels
 baseline VWf:Ag levels
beta-coefficient [95% Ci]
P-value Absolute VWf:Ag increase
beta-coefficient [95% Ci]
P-value
Age 0.01 [-0.004; 0.02] 0.18 -0.03 [-0.06;0.01] 0.14
Male sex -0.02 [-0.14;0.10] 0.73 0.79 [0.54;1.04] < 0.0001
Systolic blood pressure 0.001 [-0.01;0.01] 0.93 0.02 [0.003;0.03] 0.02
diastolic blood pressure -0.004 [-0.11;0.002] 0.21 0.02 [0.001;0.03] 0.04
BMI -0.002 [-0.03;0.02] 0.90 0.02 [-0.05;0.08] 0.60
Alcohol consumption -0.10 [-0.26;0.05] 0.18 -0.36 [-0.74;0.01] 0.06
blood group non-o 0.28 [0.17;0.39] < 0.0001 -0.10 [-0.39;0.19] 0.48
oral contraceptives -0.04 [-0.21;0.14] 0.67 -0.23 [-0.59;0.14] 0.22
Univariate linear regression analysis, beta-coefficient represents the increase of lnVWF:Ag levels with 95% confidence 
interval per unit increase of the selected variable. 
9
172 Chapter 9
ta
bl
e 
3.
 P
er
fo
rm
an
ce
-r
el
at
ed
 d
et
er
m
in
an
ts
 o
f V
W
F:
A
g 
in
cr
ea
se
 a
nd
 m
ea
n 
di
ffe
re
nc
es
 b
et
w
ee
n 
m
al
es
 a
nd
 fe
m
al
es
A u
ni
va
ri
at
e
β 
[9
5%
 C
i]
M
ul
ti
va
ri
at
e
M
od
el
 i 
β 
[9
5%
 C
i]
M
ul
ti
va
ri
at
e
M
od
el
 ii
β 
[9
5%
 C
i]
B M
al
es
n
 =
 4
1
fe
m
al
es
n
 =
 6
4
P-
va
lu
e
Pe
ak
 P
ow
er
 o
ut
pu
t 
pe
r 
kg
0.
57
 [0
.4
2;
0.
72
]*
0.
51
 [0
.3
6;
0.
65
]*
4.
4 
± 
0.
1
3.
4 
± 
0.
1
< 
0.
00
01
W
att
s 
pe
r 
kg
 V
t1
0.
42
 [0
.1
7;
0.
66
]†
2.
8 
± 
0.
1
2.
3 
± 
0.
1
< 
0.
00
01
W
att
s 
V
t1
/ 
W
att
s 
m
ax
-2
.5
7 
[-
3.
95
;-
1.
20
]*
-1
.0
2 
[-
2.
36
;0
.3
3]
63
 ±
 1
67
 ±
 1
0.
04
Vo
2 p
ea
k 
pe
r 
kg
0.
05
 [0
.0
3;
0.
06
]*
0.
04
 [0
.0
3;
0.
06
]*
50
.2
 ±
 1
.0
39
.2
 ±
 0
.8
< 
0.
00
01
Vo
2 V
t1
 p
er
 k
g
0.
03
 [0
.0
1;
0.
05
]†
33
.9
 ±
 0
.9
27
.9
 ±
 0
.7
< 
0.
00
01
Vo
2 V
t1
 /
 V
o
2 p
ea
k
-2
.1
4 
[-
3.
55
;-
0.
72
]†
-0
.4
1 
[-
1.
66
;0
.8
3]
68
 ±
 2
72
 ±
 1
0.
05
1
M
ax
 r
es
pi
ra
to
ry
 e
xc
ha
ng
e 
r
ati
o 
3.
75
 [2
.0
1;
5.
49
]*
2.
52
 [0
.7
9;
4.
25
]†
2.
49
 [0
.9
0;
4.
07
]†
1.
18
 ±
 0
.0
1
1.
13
 ±
 0
.0
1
0.
00
1
te
st
 d
ur
ati
on
0.
09
 [0
.0
3-
0.
15
]†
18
.1
 ±
 0
.3
18
.2
 ±
 0
.3
0.
90
Li
ne
ar
 re
gr
es
si
on
 a
na
ly
si
s 
w
it
h 
na
tu
ra
l l
og
 V
W
F:
A
g 
as
 d
ep
en
de
nt
. B
et
a-
co
effi
ci
en
t r
ep
re
se
nt
s 
th
e 
in
cr
ea
se
 in
 ln
V
W
F:
A
g 
pe
r u
ni
t i
nc
re
as
e 
of
 th
e 
se
le
ct
ed
 v
ar
ia
bl
e.
* 
p 
< 
0.
00
01
, 
† 
p 
< 
0.
01
. 
A
 P
er
fo
rm
an
ce
 r
el
at
ed
 d
et
er
m
in
an
ts
 o
f V
W
F:
A
g 
in
cr
ea
se
 in
 t
he
 t
ot
al
 p
op
ul
ati
on
B 
G
en
de
r 
di
ff
er
en
ce
s 
in
 p
er
fo
rm
an
ce
-r
el
at
ed
 d
et
er
m
in
an
ts
173Performance related factors are the main determinants of the von Willebrand Factor response to exhaustive 
physical exercise
table 4. VWF:Ag levels per genotype of polymorphisms in STXBP5, STX2 and VWF promoter
 N baseline (iu/ml) exhaustion (iu/ml) Absolute difference (iu/ml)
rs1039084 (StXbP5)     
GG 33 0.94 ± 0.06 1.45 ± 0.08 0.52 ± 0.06
AG 44 1.02 ± 0.05 1.56 ± 0.07 0.54 ± 0.05
AA 25 0.96 ± 0.06 1.42 ± 0.10 0.46 ± 0.06
P for trend  0.44 0.44 0.67
rs9399599 (StXbP5)     
AA 32 0.89 ± 0.06 1.40 ± 0.09 0.51 ± 0.06
At 45 1.05 ± 0.05 1.59 ± 0.07 0.54 ± 0.05
tt 25 0.96 ± 0.06 1.41 ± 0.10 0.45± 0.06
P for trend  0.11 0.18 0.56
rs7978987 (StX2)     
GG 48 0.98 ± 0.05 1.43 ± 0.07 0.45 ± 0.05
AG 45 0.98 ± 0.05 1.55 ± 0.07 0.57 ± 0.05
AA 12 0.94 ± 0.09 1.42 ± 0.14 0.47 ± 0.09
P for trend  0.94 0.43 0.18
rs7965413 (VWf promoter)
AA 47 1.01 ± 0.05 1.48 ± 0.07 0.47 ± 0.05
AG 40 0.94 ± 0.05 1.43 ± 0.08 0.49 ± 0.05
GG 13 1.03 ± 0.09 1.61 ± 0.13 0.58 ± 0.09
P for trend 0.55 0.50 0.55
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In this study among 105 healthy young subjects, VWF:Ag levels increased significantly upon 
incremental exhaustive exercise (mean METs score (max) >10) with a median increase of 
47%. The VWF:Ag response was highly variable and was strongly dependent on performance-
related and physical fitness-related determinants. Neither baseline characteristics nor the 
studied genetic determinants of VWF:Ag levels affected the extent of VWF:Ag response to 
physical exercise. 
VWF:CB levels increased after exhaustive exercise in the same proportion as VWF:Ag levels. 
ADAMTS13 levels at baseline were in the high normal range. This study included young 
and healthy individuals and a previous study also showed higher levels in young individuals 
(3). ADAMTS13 levels increased after exhaustion, although it was to a lower extent than 
VWF levels. A previous study showed similar results as ADAMTS13 increased after exercise 
in patients with von Willebrand disease type 2B (3). However, in another study in healthy 
individuals there was no difference in ADAMTS13 between baseline and immediately after 
exercise (3, 5). In addition, ADAMTS13 decreased after infusion of desmopressin, which 
induces a release of large VWF multimers into the circulation, in healthy individuals (32). 
However, all these studies included only low number of patients. 
As the average maximal achieved heart rate as a percentage of age-predicted maximum 
heart rate was 97 ± 6%, together with a plateauing of oxygen uptake and a mean RER of 
1.15 ± 0.08, our test protocol can be considered as an exhaustive cycle ergometer test in our 
subjects (33, 34). 
In our study, the VWF:Ag levels increase upon exercise was the highest in individuals with 
the lowest physical fitness, although this was not significant after multivariate analysis, 
and in individuals with the most intensive exercise. Intensive physical exercise is associated 
with more recruitment of capillaries in the muscle and additionally an increase in vascular 
conductance in muscle composed predominantly of fast-twitch oxidative (type IIa) and fast-
twitch glycolytic (type IIb) fibers (37). This results in more endothelial exposure to shear stress 
and adrenergic stimulation, which may explain the increased release of VWF upon exercise. 
The highest VWF:Ag response in individuals with the lowest physical fitness underlines 
the hypothesis that frequent physical exercise has a positive effect on cardiovascular risk. 
This is in contrast with a previous study which showed no difference in VWF:Ag increase 
upon exercise between resistance trained and untrained individuals (35). However, in 
this study only a small number of individuals were included (N=20). For a long time it has 
been anticipated that regular physical exercise has a favourable effect on many biological 
mechanisms, thereby improving health and fitness. Regular physical exercise is associated 
with a decreased all-cause mortality and with a reduced cardiovascular risk (38). The 
positive effects of physical exercise on cardiovascular disease development may be induced 
by alterations in haemostasis that lead to a hypocoagulable state. This hypocoagulable 
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state is achieved by a compensatory exhaustion of platelets in physically active individuals 
and underlines the beneficial effects of exercise on long-term prevention of cardiovascular 
disease (39). In our study, the baseline VWF:Ag levels were not associated with physical 
fitness or intensity of the test. This observation is in line with previous findings that showed 
that levels of coagulation factor VII (FVII), VWF, and FVIII at rest were similar in professional 
athletes and controls (40). There are multiple factors which could have influenced our 
results, including the type of sport and the training status of the participants, which are 
known to influence e.g. capillary density and in vivo endothelial function in skeletal muscle. 
However, the majority of our subjects participated in recreational type of sports activities 
and can be regarded as a representative sample of healthy active individuals.
STXBP5 and STX2 are two novel genetic loci that have been associated with VWF:Ag levels 
in the general population (23). In addition, genetic variation within these genes affects 
VWF:Ag levels in young patients with a first event of arterial thrombosis (30). Considering 
the involvement of the STXBP5 and STX2 encoding proteins in the regulated secretion of 
VWF molecules, our hypothesis was that genetic variants within these genes would affect 
the release of VWF molecules, but not the steady state levels, which are determined by 
the constitutive pathway. To this end, we included young individuals below the age of 35 
years to exclude the presence of extensive atherosclerosis, which is related to endothelial 
dysfunction and consequent higher VWF:Ag levels. Their baseline VWF:Ag levels therefore 
represent a steady state situation. To provoke release of VWF molecules from Weibel Palade 
Bodies in our study, all participants performed exhaustive physical exercise, which induces 
beta-adrenergic receptor activation (41) and subsequent endothelial cell activation. Genetic 
variation in STXBP5 and STX2 was not associated with VWF:Ag levels at baseline, though we 
had sufficient power to detect the previously observed effect of these genetic variants. The 
VWF:Ag increase upon exercise was also not affected by genetic variation in STXBP5 and 
STX2 . This finding was in contrast to our hypothesis. 
In addition, we genotyped a common variation in the VWF promoter gene. Previous studies 
have shown an association between this genetic variation and VWF:Ag levels at baseline 
(25, 31). However, other studies have failed to show an effect of this polymorphism on 
VWF levels under normal conditions (42-44). Despite the fact that the influence of genetic 
variation in the VWF promoter on VWF levels has never been studied in arterial thrombosis 
or at stress before, we hypothesized that a genetic variation in this gene would affect the 
expression of VWF at physical exercise resulting in a difference in VWF plasma levels. In 
our study, we could not find a significant association between baseline VWF:Ag levels and 
genetic variations in the VWF promoter gene, probably caused by a relatively small study 
population. Furthermore, the VWF:Ag increase upon exercise was also not associated with 
the VWF promoter. This suggests that, in contrast to our hypothesis, the VWF release is not 
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depending on genetic variations in the VWF promoter at exhaustive physical exercise. 
The negative results of the influence of genetic variation on VWF increase may be caused by 
the fact that genetic variations in STXBP5 and STX2 may not be involved in WPB exocytosis. 
In addition, VWF is also stored in alpha-granules of platelets and the contribution of platelet 
VWF to plasma levels upon exercise is not known (45). Therefore, VWF release from platelet 
alpha-granules during exercise cannot be excluded and might explain the negative results 
of the role of genetic variations involved in Weibel Palade Body exocytosis. Furthermore, 
we observed that the VWF:Ag increase was highly variable and strongly dependent on 
physical fitness and the intensity of the exercise performed. Consequently, the effect of 
environmental factors may have been stronger than the genetic effect. 
Another important genetic determinant of VWF:Ag levels is blood group (46). Individuals 
with blood group O have 25% lower VWF:Ag levels than individuals with blood group 
non-O, because the presence of blood group A and B antigens on VWF molecules leads to 
a decreased clearance of VWF molecules (47). Furthermore, blood group non-O has been 
associated with an increased risk of CHD (48-50). Ribeiro et al. observed that males with 
blood group non-O (N = 8) had higher post-exercise VWF:Ag levels than males with blood 
group O (N = 8), although the rise of VWF:Ag was not statistically significantly different 
between the groups (51). In our study, subjects with blood group non-O had higher levels at 
exhaustion (median [IQR], 1.60 IU/mL [1.2-2.0]), than subjects with blood group O (1.29 IU/
mL [1.1-1.6], p = 0.03). However, blood group was not associated with the VWF:Ag increase 
upon exercise (0.49 IU/mL [0.2-0.8] in non-O versus 0.46 [0.2-0.7] in O, p = 0.34). Assuming 
that exercise induces the release of VWF molecules from its storage granules and the 
clearance does not change during exercise, it was expected that subjects with blood group 
O and subjects with blood group non-O had a similar increase after exercise. In this study, 
we only included young healthy individuals and therefore the results of the study cannot be 
extrapolated to the older population. However, those individuals were included to exclude 
the presence of extensive atherosclerosis which represents a steady state situation. 
In conclusion, we have shown in a large and homogeneous group of young healthy individuals 
that VWF:Ag levels increase strongly upon exhaustive physical exercise and is primarily 
dependent on physical fitness and the intensity of the exercise performed. Genetic variations 
in STXBP5, STX2 and VWF promoter that have previously been identified as important genetic 
determinants of VWF:Ag levels, were not associated with the VWF:Ag response to physical 
exercise. Also, ABO blood group, the most important genetic determinant of VWF:Ag levels 
was not associated with the VWF:Ag increase. These findings suggest that environmental 
factors may be more important than genetic factors in determining the VWF:Ag response 
to stress. 
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The aim of this thesis was to study the role of Von Willebrand Factor (VWF) and A 
Disintegrin And Metalloprotease with ThromboSpondin motif repeats 13 (ADAMTS13) in 
the pathogenesis of cardiovascular disease and to obtain more insight in the underlying 
mechanisms. Firstly, we investigated the association between VWF and atherosclerosis. 
Secondly, we studied the role of ADAMTS13 in cardiovascular disease and thirdly we studied 
the role of ADAMTS13 and VWF as determinants of cardiovascular mortality. 
Von Willebrand factor, atherosclerosis and atherothrombosis
Previous studies have shown that high VWF levels are associated with an increased risk of 
arterial thrombosis, including acute coronary syndrome and ischemic stroke (1-3). It is of 
importance to discover the underlying mechanism of this association in order to understand 
the pathophysiologic role of VWF in cardiovascular disease and to determine whether VWF 
can play a role in the development of arterial thrombosis. The question remains whether VWF 
increases the risk of arterial thrombosis by having a pathogenetic role in the development of 
atherosclerosis or by promoting platelet aggregation and subsequent thrombus formation 
on preexisting atherosclerotic lesions, or that both play a role. Several studies suggest 
that VWF is involved in the development of atherosclerosis (4, 5). VWF is synthesized in 
endothelial cells and released at moments of endothelial dysfunction or damage. VWF is 
therefore an established marker of endothelial dysfunction (4, 6). Endothelial dysfunction is 
one of the first stages of the development of atherosclerosis (7). VWF may therefore also be 
a marker of atherosclerosis, especially in the first and stable stage of atherosclerosis.  
Studies on association between VWF and atherosclerosis
Animal studies have shown less atherosclerosis in VWF deficient animals compared to wild 
type animals (8-10). Besides that this suggests an association between atherosclerosis and 
VWF levels, it also suggests a causal role for VWF in the development of atherosclerosis. 
However, other animal studies showed contradictory results (11, 12). It has become evident 
that reduced atherosclerosis is not caused by VWF deficiency but rather by a polymorphism in 
Apolipoprotein B100 (5, 13). This polymorphism has a major role in determining the severity 
of diet-induced hypercholesterolemia and thereby influences the degree of atherosclerosis. 
Studies in von Willebrand disease (VWD) type 3 patients, who completely lack VWF, found 
similar extent of atherosclerosis compared with controls (14-16). This suggests that in 
humans there is no causal role for VWF in the development of atherosclerosis. Recently, 
Sanders et al showed that VWD patients with moderate or severe VWD, have a lower 
prevalence of arterial thrombosis compared to the general population (17). These studies in 
VWF deficient individuals suggest that VWF has a more prominent role in atherothrombosis 
than in atherosclerosis.
10
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VWF and atherosclerosis
We investigated the association between VWF levels and the extent of atherosclerosis in 
three different studies. All studies had a cross-sectional design and included different study 
populations and had different markers of atherosclerosis. 
VWF and calcification volume
Firstly, we measured in two studies the calcification volume determined using multidetector 
CT angiography, which correlates with the extent of atherosclerosis. Calcifications may be 
present at early stages of atherosclerosis, but also in advanced atherosclerotic lesions which 
consist of a necrotic lipid rich core. In our Erasmus stroke study among 925 ischemic stroke 
and TIA patients, we found a positive association between VWF levels and calcification 
volume measured in the carotid and aortic artery (18). This indicates that there is an 
association between the extent of atherosclerosis measured at these sites and VWF levels. 
However, in the Parisk study among 158 ischemic stroke and TIA patients in which the 
calcification volume was measured in the carotid artery we did not find this association 
(chapter 5). Also a previous cohort study found no association between coronary calcium 
score and VWF levels in healthy individuals (19). These controversial results can be 
explained by a difference in study populations, sample size and type of arteries which were 
used to quantify atherosclerosis. In the Parisk study we found a higher median calcification 
volume, due to the fact that only 10% of patients had no calcification which was lower than 
in the ESS in which we found no calcification in 42% of the patients. This can be explained 
by the fact that we only included patients with a mild to moderate stenosis in the Parisk 
study. Secondly, in the Parisk study we included a relatively small number of patients and 
therefore the study may not have had enough power to detect an association. In addition, 
the previously mentioned cohort study by Folsom et al. included also only a small number 
of 215 healthy individuals. Thirdly, in the Parisk study we had a median time of 46 days 
between event and blood sampling for VWF compared with a median of 5 days in the ESS 
study, which will influence the VWF:Ag levels as VWF levels are known to be increased in 
the acute phase after an event due to an acute phase response (4, 20). There may be a 
difference in the results between the three previous mentioned studies as different groups 
with various extents of atherosclerosis are included. A recent review has shown that 
symptomatic plaques in the carotid artery have a lower calcification percentage compared 
with asymptomatic plaques, suggesting that the calcification percentage is a parameter for 
plaque stability (21). In addition, the absence of calcifications in the coronary artery does 
not mean that there is no atherosclerosis (22). Therefore it would be of interest to use other 
markers of atherosclerosis and to study their association with VWF levels. 
VWF and plaque burden
To further investigate whether VWF levels are associated with the type and extent of 
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atherosclerosis, we measured plaque burden as a marker of atherosclerosis by intravascular 
ultrasound (IVUS) and by multidetector CT angiography (MDCTA) in two different study 
populations of patients with coronary heart disease patients (23) and ischemic stroke 
patients (chapter 5). We found that plaque burden was positively associated with VWF:Ag 
levels in stable angina pectoris (SAP) patients, but not in acute coronary syndrome (ACS) 
patients. This difference may be explained by the strongly increased VWF:Ag levels due to 
the acute phase response in ACS patients, which we did not observe in SAP patients (4, 
20). A recent ACS may lead to such a strong increase of VWF levels that the variability due 
to difference in extent of atherosclerosis cannot be detected. In the Parisk study, plaque 
burden was defined as the degree of stenosis by the European Carotid Surgery Trial (ESCT). 
We found a mean carotic stenosis of 55% (95% CI 30-69%) and plaque burden in the carotid 
artery was not significantly associated with VWF levels. The difference in findings between 
these two studies may be explained by a different study population in which atherosclerosis 
was measured in two different arteries and also the imaging technique of which IVUS is a 
more accurate technique using virtual histology. Additionally, plaque burden was differently 
defined. In the study using IVUS plaque burden was defined as the plaque and media cross-
sectional area divided by the external elastic membrane cross-sectional area. In the Parisk 
study, degree of stenosis was used which has been shown to be less correlated with plaque 
burden (22). Furthermore, In the study using IVUS we measured the plaque burden in a 
non-culprit coronary artery in contrast to the Parisk study in which the culprit carotid artery 
was used. Measurement in a non-culprit artery may even have led to an underestimation 
of the association between plaque burden in the overall coronary tree and VWF:Ag levels. 
Another explanation might be that only the most severe stenosis in the artery was used 
for the analysis in both studies. This could have led to an overestimation of the amount of 
atherosclerosis. 
VWF and high risk lesions
As high risk lesions are vulnerable to rupture and therefore associated with an increased risk 
of MACE, we also investigated whether VWF levels are decreased in the presence of high 
risk lesions and via this route lead to an increased risk of arterial thrombosis (24). We found 
no association between high risk lesions and VWF levels (23)(chapter 5). This surprised us, 
since VWF levels are associated with the extent of atherosclerosis. A possible explanation 
is that local VWF levels may be higher at the site of high risk lesions and that this is not 
reflected by systemic high VWF plasma levels. A previous mice study using molecular imaging 
showed that activated VWF was found in atherosclerotic disease with high risk features (25). 
In this study locally activated VWF was measured and in our studies we measured circulating 
VWF:Ag plasma levels. In addition, a difference in the pathophysiologic mechanism of 
destabilising the plaque between mice and humans could also explain the conflicting results 
between these studies (26-29).  
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VWF an atherothrombosis
The question still remains whether VWF is associated with atherosclerosis or with 
atherothrombosis and thereby with arterial thrombosis. VWF mediates platelet adhesion and 
aggregation and thereby the formation of a thrombus. Rupture of an unstable atherosclerotic 
plaque triggers coagulation and leads to platelet aggregation and thrombus formation (30). 
VWF might therefore also have an influence in this stage of arterial thrombosis. A previous 
histochemical study showed that VWF was present at sites of platelet accumulation in 
coronary thrombi of patients with an acute myocardial infarction (31). In addition, two 
animal studies showed that there is an association between VWF plasma levels and platelet 
aggregation at atherosclerotic sites in the carotid and aortic arteries (32, 33). This suggests 
that there is a role of VWF in atherothrombosis at atherosclerotic plaques, and therefore it 
may be possible that VWF plays a role at a later stage of platelet thrombi without playing a 
major role in the formation of atherosclerosis. 
In concusion, our results suggest that VWF may be associated with the extent of athero-
sclerosis, and not with the phenotypic more vulnerable atherosclerotic lesions. This 
suggests that VWF might be more involved in stable atherosclerosis or with the total extent 
of atherosclerosis. These studies suggest that VWF is more a marker of atherosclerosis than 
a causal factor in the development of atherosclerosis. 
ADAMTS13 activity and cardiovascular disease
ADAMTS13 cleaves high molecular weight VWF multimers into smaller, less coagulant forms 
(34, 35). Low levels of ADAMTS13 result into higher molecular weight VWF multimers and 
a prothrombotic state as observed in Thrombotic Thrombocytopenic Pupura (TTP) which 
is characterized by a severe deficiency of ADAMTS13. Untreated, TTP patients suffer from 
thrombotic complications like ischemic stroke and myocardial infarction and the disease is 
fatal in the majority of untreated patients (36). It has been hypothesized that more subtle 
reduced levels of ADAMTS13 may also lead to more active VWF and therefore be a risk 
factor of thrombosis. This has first been studied in animal models. In these studies reduced 
atherosclerosis was found in ADAMTS13 deficient mice compared to wild type mice (37, 38), 
suggesting that ADAMTS13 is involved in the pathogenesis of atherosclerosis. Additionally, 
ADAMTS13 deficient mice in whom myocardial or cerebral ischemia was induced showed 
a reduced infarct volume compared with wild type mice (39-44). In conclusion, the animal 
studies showed an association between reduced levels of ADAMTS13, atherosclerosis 
and arterial thrombosis. More recently several case-control studies have investigated the 
association between ADAMTS13 levels and arterial thrombosis and indeed these studies 
suggest that individuals  with low ADAMTS13 levels had an increased risk of arterial 
thrombosis (3, 45-47).
We have performed a meta-analysis of these case-control studies and established that low 
ADAMTS13 is associated with an increased risk of ischemic stroke (48). The association with 
coronary heart disease is less clear. Recently, these case-control studies were combined in 
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an individual patient data meta-analysis. This meta-analysis included all individual patient 
data of five different studies and found that only extremely low ADAMTS13 levels (<5% of 
normal) were associated with an increased myocardial infarction risk (49).However, these 
studies were limited by their case-control design. Therefore, there was a need for large 
prospective population based cohort studies to further establish the role of ADAMTS13 in 
arterial thrombosis. In the Rotterdam Study, a prospective cohort study including nearly 6000 
individuals over a median of 10.7 years of follow-up, we found an association between low 
ADAMTS13 activity and an increased risk of both ischemic stroke and coronary heart disease 
(50). This strengthens the hypothesis that low ADAMTS13 is a risk factor for cardiovascular 
disease. We found that individuals in the lowest quartile of ADAMTS13 activity had an 
increased risk of arterial thrombosis. Nearly all individuals in this lowest quartile had an 
ADAMTS13 activity (95% CI 69.8 - 70.8%) in the normal range (50 - 150%)(51). Even though 
the ADAMTS13 levels are not as low as characteristic for TTP patients (<10%), we found an 
increased risk of thrombotic complications in these individuals. There was no graded pattern 
from quartile 1 to quartile 4 in both studies, as was also observed in other studies (45, 52, 
53). An explanation might be that there is a threshold level for ADAMTS13 rather than a 
clear plasma level dose association, indicating that individuals with an ADAMTS13 activity 
below a certain level have a higher risk of arterial thrombosis, as was also suggested in the 
individual patient data meta-analysis using case-control studies (49). Interestingly, recent 
follow-up data of TTP survivors indicates that the risk of stroke is significantly higher in TTP 
survivors with a persistent low ADAMTS13 activity compared with controls, despite the fact 
that they are in remission and do not have signs of microangiopathy, thrombocytopenia, 
and atherosclerosis (54). This also points towards an important role of ADAMTS13 in arterial 
thrombosis, especially in individuals with the lowest level of ADAMTS13 activity (55). 
In the Rotterdam Study, we observed a higher risk of ischemic stroke than of coronary heart 
disease in individuals with low ADAMTS13 activity, although it is difficult to compare these 
diseases. Atherosclerosis is a common underlying cause of a myocardial infarction, whereas 
in ischemic stroke thromboembolism may be more prevalent and many other patients 
have stroke of undetermined etiology. Embolisation of a thrombus may be caused by a 
less stable thrombus and the activity of ADAMTS13 may be of more importance in these 
patients. We found significantly higher VWF:Ag levels in ischemic stroke and TIA patients 
with a cardioembolic origin of stroke compared with small vessel occlusion patients (18). 
This indicates a different role of VWF and of ADAMTS13 in different etiologies of stroke. In 
individuals with an undetermined etiology of ischemic stroke, hypercoagulability may also 
be a risk factor for stroke as has also recently been suggested in a review by Maino et al (56). 
This review included 70 studies in which they compared the effect of multiple coagulation 
factors, as measure of hypercoagulability on the risk of ischemic stroke and myocardial 
infarction. They concluded that there is a more important role for hypercoagulability in 
ischemic stroke than in myocardial infarction. 
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Interaction between ADAMTS13 and Von Willebrand Factor 
ADAMTS13 cleaves VWF into smaller forms leading to less high molecular weight multimers. 
Low ADAMTS13 activity will therefore result into high VWF activity and increase of (ultra) 
large VWF multimers. We found a very weak association between VWF:Ag levels and 
ADAMTS13 activity in our large cohort. This has been previously described (3, 47) and might 
be explained by the fact that mainly the activity of VWF is influenced by ADAMTS13 due to 
proteolysis. As VWF antigen levels represent the VWF plasma concentration this may not be 
influenced by the ADAMTS13 activity. 
Reduced ADAMTS13 levels may lead to increased VWF locally at sites of high shear stress 
or plaque rupture. VWF unfolds at sites of vessel damage and low ADAMTS13 activity 
will lead to reduced cleavage of secreted large multimers of VWF. This finally results in 
the recruitment of platelets and the formation of a thrombus. By cleaving unfolded VWF, 
ADAMTS13 regulates the formation of a platelet plug and thrombus growth. Concluding, 
there may be an association between VWF levels and ADAMTS13 activity locally, but this 
may not be reflected in the VWF:Ag plasma levels in the circulation. 
ADAMTS13, Von Willebrand Factor and outcome of cardiovascular disease
High VWF levels are known to be prothrombotic and it has been hypothesized that high levels 
may lead to more recurrent events or a worse outcome (57-61). To investigate whether high 
VWF levels or low ADAMTS13 activity are associated with an unfavorable outcome after 
event, we performed three different studies. First, in the Rotterdam Study we investigated 
the association between ADAMTS13, VWF and all-cause and cause specific mortality. We 
showed that both low ADAMTS13 activity and high VWF:Ag levels measured in a group of 
elderly (≥ 55 years) individuals of the general population, were associated with an increased 
risk of cardiovascular and all-cause mortality. This is in line with previous studies in which 
an association between high VWF levels and cardiac specific mortality was found (57, 58, 
62). However, only two of these studies have focused on CHD and stroke related mortality 
(63, 64). One study, including 1057 individuals with proven coronary artery disease, found a 
significant association (HR 1.29, 95% CI 1.15 - 1.43) (63). None of these studies investigated 
the association between VWF levels and all-cause mortality. Additionally, no studies on the 
association between ADAMTS13 and mortality had been performed yet. We found that 
ADAMTS13 activity are associated with all-cause mortality, and that the risk estimates for 
cardiovascular mortality were comparable with all-cause mortality suggesting that this is 
mainly driven by cardiovascular mortality. No relationship between cancer related mortality 
and COPD related mortality and ADAMTS13 and VWF levels was observed. 
In the study in patients with stable angina pectoris (SAP) and acute coronary syndrome 
(ACS), we also found an association between VWF:Ag levels and cardiovascular outcome 
(MACE) in ACS patients after 1 year. High VWF levels measured within hours till days after 
the event are associated with a worse outcome after ACS (23). Despite VWF levels are 
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known to be increased in the acute phase of an event (4, 20), our study suggest that the 
VWF levels measured in ACS patients, the most severe CAD patients, shortly after the event 
predict MACE at follow-up.
Lastly, we found an association between high VWF:Ag levels and an unfavorable outcome 
in ischemic stroke and TIA patients as assessed by the modified Rankin Score (mRS) and 
the NIHSS in the ESS (18). This is in agreement with a previous study in hemorrhagic and 
ischemic stroke patients in which high VWF levels were associated with a poor mRS (65).  
In conclusion, these studies suggests that VWF levels and ADAMTS13 activity may be 
determinants of an unfavorable outcome and mortality and that treatment strategies may 
be tailored based on these measurements. Our findings may indicate that patients with 
ischemic stroke or ACS with high VWF:Ag levels or low ADAMTS13 activity may benefit from 
more intensive anticoagulant therapy or monitoring. However, this should be investigated 
in prospective studies. 
Methodological considerations
The association between VWF:Ag levels and markers of atherosclerosis was determined 
in three different cross-sectional studies. A disadvantage of these studies was that 
atherosclerosis and VWF levels were determined at almost the same moment (within 
weeks). This limits the ability to determine the exact role of VWF in atherosclerosis, whether 
it is causally involved or more a marker of atherosclerosis. In addition, we have shown that 
VWF levels increase at moments of exercise, stress and in the acute phase of an event, and 
therefore blood sampling shortly after an event should be reconsidered (66). Measurement 
of these parameters over time may even better predict outcome in these patient groups. 
In the ESS including ischemic stroke and TIA patients, we found that patients with blood 
group O had 30% lower VWF:Ag levels compared with patients with blood group non-O, 
as is also observed in healthy individuals. Interestingly, patients with blood group O had 
a similar calcification volume, a measurement of the extent of atherosclerosis, compared 
with patients with non-O. If VWF would have an important role in the development of 
atherosclerosis, genetic variations which determines VWF levels, like blood group, may have 
influenced the extent of atherosclerosis. The fact that we did not find a difference in the 
calcification volume also suggests that VWF is more a marker of atherosclerosis. Previously 
we already showed that genetic variations that are associated with VWF levels did not 
influence the risk of ischemic stroke (67). Overall these findings suggests that increased 
levels of VWF do not play a major role in the pathogenesis of atherosclerosis and are more 
a marker of atherosclerosis. 
We investigated the role of ADAMTS13 in cardiovascular disease using the Rotterdam Study, 
which is a prospective population based cohort study. The advantage of this prospective 
study is that we were able to longitudinally follow patients to determine if and when they 
become diseased and whether the exposure status at baseline changed the outcome. We 
10
192 Chapter 10
were able to determine the role of ADAMTS13 activity at baseline with cardiovascular 
incidence during nearly 10 year follow-up. However, this study design also has some 
disadvantages. The Rotterdam Study included individuals of 55 years and older. Therefore, 
the results of this study cannot automatically be generalized to a younger population. 
Additionally, it is an observational study and therefore no conclusions can be made upon 
causality of the association. 
Cardiovascular disease, including coronary heart disease and ischemic stroke, is a 
multifactorial disease in which several underlying factors play a role. Since multiple 
determinants are known and are associated with each other, it is difficult to distinguish 
whether a determinant is causally involved. Determinants may be associated with outcome 
due to the association with other factors, called confounding. On the other hand, some 
factors may also be a consequence of the outcome. This makes observational studies 
difficult in proving causality. We also included a risk prediction model, in our study on the 
role of ADAMTS13 activity in ischemic stroke. Risk prediction serves as the basis for clinical 
decision making for initiation of therapy, motivating adherence to lifestyle changes, and 
treatment and raising awareness of the disease. In cardiovascular disease various classical 
risk factors are included in the model which generates a risk score and this can estimate a 
probability to develop a cardiovascular event within a certain time period. Several studies 
have investigated whether newer risk markers can add in this risk prediction (68-71). A 
previous sub study of the Rotterdam Study indicated that VWF was not an additional risk 
predictor in coronary heart disease (68). We found however that ADAMTS13 activity has an 
additive value in the risk prediction of ischemic stroke. Among subjects in the intermediate 
risk category for ischemic stroke, the Net Reclassification Index (NRI) was 0.212 (95% 
CI 0.048 - 0.376). This may be explained by the fact that ADAMTS13 might have a more 
prominent role in arterial thrombosis than VWF, as has been shown before (72, 73). To 
evaluate the clinical value of a risk marker, it is important to consider whether the marker 
changes the risk prediction sufficiently to change recommended therapy. We quantified this 
by calculating the percentage of individuals that are correctly reclassified into risk categories 
with the addition of a new risk marker by the NRI. In this respect, the intermediate risk 
category is the most interesting group as in individuals in this group treatment should be 
considered. In the highest risk category all individuals already receive preventive treatment. 
The NRI was significant in the intermediate risk category, which suggests that ADAMTS13 
activity may be of value in ischemic stroke risk prediction in this subgroup, independent of 
other risk factors. Those individuals with low ADAMTS13 activity in the intermediate group 
have a higher risk of stroke and are therefore candidates for more intensive preventive 
measurements. 
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Clinical implications
The findings of this thesis provide new insights in the role of VWF and ADAMTS13 in risk 
prediction of cardiovascular disease and outcome. However, so far these insights do not 
have direct clinical implications. One of our goals was to determine the association between 
ADAMTS13 activity and cardiovascular disease as this was never studied in prospective 
studies so far. Our findings should be validated in other population based cohort studies. 
Future studies are necessary to further establish the role of ADAMTS13 in cardiovascular 
disease and to see whether ADAMTS13 may be a target for therapy. ADAMTS13 activity was 
found to improve the risk prediction of ischemic stroke independent of classical risk factors. 
This suggests that ADAMTS13 can be used as risk marker of ischemic stroke and CHD. 
However, additional studies need to be determine the role of ADAMTS13 in cardiovascular 
disease risk prediction. 
Recently, several animal studies have shown that rhADAMTS13 infusion may be a treatment 
option in ischemic stroke and myocardial infarction. Wild type mice in which cerebral or 
myocardial ischemia was induced were treated with rhADAMTS13 just before reperfusion. 
These mice developed less extended infarctions compared with wild type mice without 
treatment (39, 42-44). It is not yet known whether increasing ADAMTS13 levels in humans by 
infusion of rhADAMTS13 may be beneficial in the outcome of arterial thrombosis. However, 
this hypothesis first has to be proven in animal studies with cerebral or myocardial ischemia. 
Ultimately, this may result in a new treatment strategy for patients with stroke, of which the 
outcome is still poor. 
In addition, we have found that VWF levels are associated with atherosclerosis in two large 
studies. VWF:Ag levels could maybe be used as a marker of atherosclerosis. Measurements 
of atherosclerosis using CTA or MRI are expensive and additionally CTA exposes individuals 
to radiation which is associated with an increased risk of developing malignancies. Instead 
of this, VWF:Ag measurements are not expensive and can easily be determined. In addition, 
VWF levels were also associated with an unfavorable outcome in ischemic stroke determined 
by a disability score, and also with major adverse cardiovascular events in ACS patients 
and with mortality in elderly individuals. However, future studies have to be performed to 
determine whether VWF is specific enough as a marker. 
Recommendations for future studies
The ultimate goal is to find new risk markers and therapeutic agents for cardiovascular 
disease. We studied for the first time the association between ADAMTS13 activity and 
the risk of cardiovascular disease in a prospective design. Although we found a significant 
association in a large cohort with a long follow-up, additional prospective studies are 
needed to confirm these associations. The ultimate study design would be a prospective 
cohort study with multiple ADAMTS13 activity measurements and determination of clinical 
characteristics during follow-up. 
10
194 Chapter 10
Nowadays ischemic stroke patients are treated with antiplatelet agents and with thrombolysis 
with recombinant tissue plasminogen activator (rt-PA). Recently, studies have shown 
improvement of outcome when patients were treated additionally with thrombectomy. 
However, thrombolysis and thrombectomy have only shown to be effective within 4-6 hours 
after onset of symptoms and still 30-40% of patients have no benefit of this therapy (74-76). 
Therefore, new therapeutic agents are needed. In this thesis we have shown an association 
between ADAMTS13 activity and cardiovascular disease and an additive predictive value of 
ADAMTS13 activity in ischemic stroke risk prediction. Animal studies showed a beneficial 
effect of rhADAMTS13 infusion in experimental models (39, 42, 43). Currently, only mice 
studies have shown reduced infarct volumes in rhADAMTS13 treated mice compared with 
wild type mice (39, 42, 43). This was not associated with an increase of bleeding symptoms. 
Taken together, ADAMTS13 may be a promising new treatment option in cardiovascular 
disease. In the future, phase 1 and 2 studies on feasibility and safety and if successful 
randomized-controlled trials with rhADAMTS13 in humans are necessary to study this drug. 
First, ischemic stroke patients not responding to thrombolysis and thrombectomy could 
be treated with rhADAMTS13. Furthermore, an option for a future study may be more 
intensive prevention of arterial thrombosis in individuals with a ‘lower ADAMTS13 activity’ 
to reduce their risk of developing arterial thrombosis. However, first the threshold of low 
ADAMTS13 activity needs to be determined and strategies to increase ADAMTS13 need 
to be identified. We found in our study that ADAMTS13 activity was higher in individuals 
using statins compared to non statin users. A previous in vitro study showed that simvastatin 
upregulated the ADAMTS13 expression in mice podocytes (77). If ADAMTS13 levels do 
increase after statin treatment this may be an option for primary prevention in individuals 
with low ADAMTS13 activity. 
In addition, it would be of interest to study the association between ADAMTS13 levels with 
the outcome after stroke determined by clinical outcome, stroke severity measured as the 
modified Rankin score (mRS) or the NIHSS and the infarct size. If ADAMTS13 is associated 
with a worse outcome, it would be worthwhile to study ADAMTS13 as a treatment strategy. 
Based on our findings of the predictive role of ADAMTS13 activity in cardiovascular 
disease, studies should be performed to identify determinants of ADAMTS13 levels. We 
have recently performed a Genome Wide Association Study (GWAS) to identify common 
genetic variations that determine ADAMTS13 levels. We found that genetic variations in the 
ADAMTS13 and SUPT3H genes were associated with ADAMTS13 activity (78). Future studies 
can focus on the association between these genetic variations and cardiovascular disease. 
Genetic variations that influences the ADAMTS13 level and are associated with the risk of 
cardiovascular disease may provide additional evidence that ADAMTS13 is involved in the 
development of cardiovascular disease. 
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Von Willebrand Factor (VWF) is an important player in primary hemostasis by mediating 
platelet adhesion and aggregation leading to clot formation. High molecular weight VWF 
multimers are the most procoagulant forms and are cleaved by ADAMTS13 (A Disintegrin 
And Metalloprotease with ThromboSpondin motif repeats 13) into smaller, less coagulant, 
forms. 
Recent studies have shown an association between both high VWF:Ag levels, low ADAMTS13 
levels and arterial thrombosis, including ischemic stroke and acute coronary syndrome. In 
this thesis several studies on VWF, ADAMTS13 and arterial thrombosis have been presented. 
Chapter 1 is a general introduction on the background on the function of VWF and ADAMTS13 
and the pathogenesis of atherosclerosis and cardiovascular disease. 
In chapter 2 we reviewed the available literature on the association between both VWF 
and ADAMTS13 and arterial thrombosis. Additionally, we performed meta-analyses of the 
reported studies. One of our main observations was that high VWF levels are associated 
with both an increased risk of coronary heart disease and ischemic stroke. An association 
between low ADAMTS13 and arterial thrombosis has only been reported in a few small 
case-control studies, therefore it remains unclear whether ADAMTS13 is an independent 
risk factor for arterial thrombosis. We found an increased risk of coronary heart disease with 
low ADAMTS13 levels (lowest tertile or quartile), although this did not reach statistically 
significance. In contrast, we observed a significant association between low ADAMTS13 and 
ischemic stroke (OR 2.72, 95%CI 1.52 – 4.86). Although these studies differed in study design 
and some included only a small number of cases, these studies suggests that both VWF 
and ADAMTS13 are associated with arterial thrombosis. However, the mechanism of the 
association between high VWF levels and arterial thrombosis is still unknown. Therefore, in 
order to obtain more insight in these findings we investigated whether VWF was associated 
with atherosclerosis using three different studies. 
In chapter 3 we determined the association between VWF levels and atherosclerosis in 
patients with ischemic stroke or transient ischemic attack (TIA). In this study we measured 
the extent of atherosclerosis by the calcification volume in both the aortic arch and the 
carotid arteries using a recently developed technique by CT angiography (CTA). We found 
a strong positive association between the calcification volume and VWF:Ag levels in these 
patients. In addition, VWF:Ag levels were significantly higher in patients with a large artery 
atherosclerosis subtype of ischemic stroke compared with other stroke subtypes. The study 
also suggests that VWF may have prognostic value in patients with ischemic stroke, as high 
VWF levels were associated with an unfavorable outcome. 
Next, we investigated the association between atherosclerosis and VWF levels in patients 
with an acute coronary syndrome (ACS) or stable angina pectoris (SAP) by measuring the 
coronary plaque burden using intravascular ultrasound virtual histology (IVUS-VH) (chapter 4). 
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High coronary plaque burden was associated with higher VWF:Ag levels in SAP patients, but 
not in ACS patients. This might be explained by the time of blood sampling in ACS patients 
during the acute phase, which may lead to increased VWF levels. High risk lesions which are 
vulnerable to rupture were not associated with VWF levels. Furthermore, we found that 
high VWF:Ag levels have a predictive role for adverse cardiovascular outcome in SAP and 
ACS patients, and also for major adverse cardiac events (MACE) in ACS patients. 
In chapter 5 we investigated the association between atherosclerosis, VWF:Ag levels and 
ADAMTS13 activity in patients with ischemic stroke with mild to moderate carotid artery 
stenosis. Atherosclerosis was measured by different imaging biomarkers of atherosclerosis 
including calcification volume and plaque ulceration. We found no association between 
the imaging markers of atherosclerosis and VWF:Ag levels and ADAMTS13 activity. This is 
in contrast with the other two previous studies. This might be explained by the specific 
selection of patients in this study since only patients with a mild to moderate carotid artery 
stenosis were included. Our results suggest that VWF is more important in patients with 
advanced atherosclerosis, as we also found the highest VWF:Ag levels in patients with a 
large artery atherosclerosis type of ischemic stroke (chapter 3). On the other hand, VWF 
and ADAMTS13 seem to be associated with the extent of atherosclerosis and not with the 
specific characteristics of atherosclerosis. 
The role of ADAMTS13 in arterial thrombosis was so far only studied in small case-control 
studies and prospective cohort studies are needed. Therefore, we investigated the 
association between ADAMTS13 and ischemic stroke in a large population-based cohort 
study the Rotterdam Study, among individuals of 55 years and older (chapter 6). ADAMTS13 
activity was associated with age, sex and several cardiovascular risk factors in this study. 
We measured VWF levels and ADAMTS13 activity in a total of 5941 individuals. The median 
follow-up time of these individuals was 10.7 years. We showed that low ADAMTS13 activity 
was significantly associated with an increased risk of ischemic stroke (HR 1.65, 95%CI 1.16 
– 2.32) and all strokes (HR 1.49, 95%CI 1.12 – 2.00). In addition, we found that ADAMTS13 
activity improved the accuracy of risk prediction for ischemic stroke beyond the traditional 
risk factors. 
In the same study population as described in chapter 6, we investigated the association 
between low ADAMTS13 activity and coronary heart disease in the Rotterdam Study 
(chapter 7). In total 453 individuals suffered from coronary heart disease. In individuals 
with the lowest quartile of ADAMTS13 activity, the risk of CHD was significantly increased 
compared with individuals with the highest quartile of ADAMTS13 activity (HR 1.42, 95%CI 
1.07 – 1.89). Individuals with low ADAMTS13 activity and high VWF:Ag levels also had an 
increased risk of CHD. 
To study whether ADAMTS13 activity and VWF levels were associated with outcome of 
cardiovascular disease we investigated the role of VWF levels and ADAMTS13 activity on the 
risk of all-cause and cardiovascular mortality in the Rotterdam Study (chapter 8). We found 
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that high VWF:Ag levels and low ADAMTS13 activity were associated with an increased risk 
of all-cause mortality and cardiovascular mortality. We did not find an association between 
VWF, ADAMTS13 and cancer-related mortality or COPD related mortality. 
Physical stress triggers the endothelium to release VWF from Weibel Palade Bodies (WPB). 
Since VWF is a risk factor for arterial thrombosis, it is of great interest to discover determinants 
of VWF response to physical stress. In a study among 105 healthy young individuals, VWF:Ag 
levels increased significantly upon incremental exhaustive exercise (chapter 9). The VWF:Ag 
response was highly variable and was strongly dependent on performance-related and 
physical fitness-related determinants. Genetic variations in STXBP5, STX2 and VWF promoter 
that have previously been identified as genetic determinants of VWF:Ag levels, were not 
associated with the VWF:Ag response to physical exercise. This suggests that environmental 
factors may be more important than genetic factors in determining the VWF:Ag reponse to 
stress. 
In the last chapter (chapter 10) the findings of our studies are discussed. We conclude that 
the extent of atherosclerosis is strongly associated with VWF levels. Furthermore, VWF 
might be a marker of an unfavorable outcome in coronary heart disease and ischemic stroke 
patients. Plaque characteristics, such as high risk lesions, do not seem to be associated with 
VWF levels. Lastly, low ADAMTS13 is strongly associated with an increased risk of arterial 
thrombosis, including ischemic stroke and coronary heart disease. Overall, the studies in 
this thesis provide a better understanding of the role of VWF and ADAMTS13 in arterial 
thrombosis. 
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Von Willebrand factor (VWF) speelt een belangrijke rol in de bloedstolling door het binden 
en plakken van bloedplaatjes. Uiteindelijk leidt dit tot het vormen van een bloedstolsel. 
Hoog moleculair gewichts VWF multimeren zijn de meest actieve vormen die leiden tot 
meer stolselvorming. Deze multimeren worden geknipt door ADAMTS13 (A Disintegrin 
And Metalloprotease with ThromboSpondin motif repeats 13) in kleinere en minder 
actieve vormen. Recentelijk hebben verschillende studies een associatie gevonden tussen 
hoge VWF antigen (VWF:Ag) spiegels, lage ADAMTS13 spiegels en hart- en vaatziekten, 
waaronder het hart- en herseninfarct. In dit proefschrift worden meerdere studies gericht 
op VWF, ADAMTS13 en hart- en vaatziekten gepresenteerd. 
Hoofdstuk 1 is een introductie van de achtergrond van de functies van VWF en ADAMTS13 
en daarnaast de ontstaanswijze van atherosclerose en hart- en vaatziekten. 
In hoofdstuk 2 hebben we de relevante informatie over de associatie tussen zowel VWF als 
ADAMTS13 en hart- en vaatziekten samengevat. Hierin hebben we tevens een meta-analyse 
verricht van de beschikbare studies. Eén van de belangrijkste bevindingen was dat VWF 
spiegels geassocieerd zijn met zowel een verhoogd risico op het acuut coronair syndroom 
als het herseninfarct. Tevens werd in een aantal kleine case-control studies een associatie 
tussen ADAMTS13 en hart- en vaatziekten gevonden dus of ADAMTS13 een onafhankelijke 
risicofactor voor hart- en vaatziekten is blijft nog onduidelijk. Wij vonden in de meta-analyse 
dat lage ADAMTS13 spiegels (laagste tertiel of kwartiel) geassocieerd waren met een 
verhoogd risico op het acuut coronair syndroom, ook al was dit niet statistisch significant. 
Daar tegenover vonden we een significante associatie tussen lage ADAMTS13 spiegels en het 
herseninfarct (OR 2.72, 95%CI 1.52 - 4.86). Ondanks dat deze studies allemaal een andere 
opzet hadden en sommige studies maar een kleine groep mensen geïncludeerd hadden, 
lijkt het er op dat VWF en ADAMTS13 beide geassocieerd zijn met hart- en vaatziekten. 
Het mechanisme tussen hoge VWF spiegels en hart- en vaatziekten is tot op heden nog 
onduidelijk. Daarom wilden wij onderzoeken of VWF geassocieerd is met atherosclerose, 
aderverkalking, om meer inzicht te krijgen in deze bevindingen en hebben we hiervoor drie 
verschillende studies gebruikt. 
In hoofdstuk 3 hebben we gekeken naar de associatie tussen VWF spiegels en atherosclerose 
in patiënten met een herseninfarct of een TIA (Transient Ischemic Attack). Hierin hebben 
we het kalkvolume in zowel de aortaboog als de arterie carotis gemeten als maat van de 
uitgebreidheid van atherosclerose middels een nieuw ontwikkelde techniek met behulp 
van CT angiografie (CTA). We vonden in deze patiëntengroep een sterk positieve associatie 
tussen het kalkvolume en VWF:Ag spiegels. Daarnaast waren VWF:Ag spiegels significant 
hoger in patiënten met uitgebreide atherosclerose ten opzichte van patiënten met een 
herseninfarct met een andere oorzaak. In de studie tonen we aan dat VWF mogelijk ook 
een prognostische waarde kan hebben in patiënten met een herseninfarct, omdat hoge 
VWF spiegels geassocieerd waren met een slechtere uitkomst na het infarct. 
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Tevens hebben we gekeken naar de associatie tussen atherosclerose en VWF spiegels in 
patiënten met een acuut coronair syndroom (ACS) of stabiele angina pectoris (SAP) waarbij 
we de totale plaque in de coronair arterieën hebben gemeten middels intravascular 
ultrasound virtual histology (IVUS-VH) (hoofdstuk 4). Grote plaques in de coronairen waren 
geassocieerd met hogere VWF:Ag spiegels in SAP patiënten, maar niet in ACS patiënten. Dit 
wordt mogelijk verklaard doordat het moment van bloedafname in ACS patiënten acuut na 
het ontstaan van de klachten is, wat waarschijnlijk heeft geleid tot verhoogde VWF spiegels. 
Hoog risico laesies, welke makkelijk kunnen ruptureren en kunnen leiden tot een infarct, 
waren niet geassocieerd met VWF spiegels. Daarnaast vonden we dat hoge VWF:Ag spiegels 
een voorspellende waarde hebben voor een slechtere cardiovasculaire uitkomst in SAP en 
ACS patiënten. In ACS patiënten was dit ook het geval voor een recidief cardiovasculaire 
aandoening (major adverse cardiac event). 
In hoofdstuk 5 hebben we in patiënten met een herseninfarct met een milde tot matige 
stenose van de arterie carotis, de associatie tussen atherosclerose, VWF:Ag spiegels en 
ADAMTS13 activiteit bekeken. Atherosclerose was in deze studie gemeten door middel 
van verschillende beeldvormende biomarkers van atherosclerose waaronder kalkvolume 
en plaque ulceratie. In deze studie vonden we geen associatie tussen de verschillende 
biomarkers en zowel VWF:Ag spiegels als ADAMTS13 activiteit. Dit is in tegenstelling tot de 
andere twee studies. Mogelijk wordt dit verklaard door de specifieke selectie van patiënten in 
deze studie, omdat alleen patiënten met een milde tot matige stenose werden geïncludeerd. 
Concluderend suggereren onze resultaten dat VWF meer geassocieerd is in patiënten met 
een ernstige atherosclerose, omdat we ook vonden dat patiënten met een uitgebreide 
atherosclerose de hoogste VWF:Ag spiegels hadden (hoofdstuk 3). Aan de andere kant lijken 
VWF en ADAMTS13 geassocieerd met de uitgebreidheid van atherosclerose en niet met de 
specifieke karakteristieken van atherosclerose. 
De rol van ADAMTS13 in hart- en vaatziekten was tot nu toe alleen in kleine case-control 
studies onderzocht en daarom waren prospectieve cohort studies nodig. Hierom hebben 
wij de associatie tussen een ADAMTS13 activiteit en het herseninfarct onderzocht in een 
grote populatie gebaseerde cohort studie, de Rotterdam studie, waarin mensen van 55 
jaar en ouder werden geïncludeerd (hoofdstuk 6). ADAMTS13 activiteit was geassocieerd 
met leeftijd, geslacht en meerdere andere cardiovasculaire risicofactoren. We bepaalden 
ADAMTS13 activiteit en VWF spiegels in een totale groep van 5941 mensen. De mediane 
follow-up tijd in deze individuen was 10.7 jaar. We vonden dat een lage ADAMTS13 activiteit 
significant geassocieerd was met een verhoogd risico op het herseninfarct (HR 1.65, 95%CI 
1.16 - 2.32) en tevens met alle beroertes inclusief hersenbloedingen (HR 1.49, 95%CI 
1.12 - 2.00). Daarnaast vonden we dat ADAMTS13 activiteit de risico voorspelling op het 
herseninfarct verbeterde, bovenop de traditionele risicofactoren. 
In dezelfde studie populatie zoals beschreven in hoofdstuk 6, hebben we de associatie tussen 
een lage ADAMTS13 activiteit en coronair hartlijden in de Rotterdam studie onderzocht 
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(Hoofdstuk 7). In totaal 453 individuen ontwikkelde coronair hartlijden in deze studie. 
In mensen met de laagste ADAMTS13 activiteit (laagste 25%) was het risico op coronair 
hartlijden verhoogd ten opzichte van mensen met de hoogste ADAMTS13 activiteit (hoogste 
25%) (HR 1.42, 95%CI 1.07 - 1.89). Individuen met de laagste ADAMTS13 activiteit en de 
hoogste VWF:Ag spiegels hadden ook een verhoogd risico op het ontwikkelen van coronair 
hartlijden. 
Om te onderzoeken of ADAMTS13 activiteit en VWF spiegels geassocieerd zijn met de 
uitkomst van hart- en vaatziekten, hebben we de rol van VWF spiegels en ADAMTS13 
activiteit op het risico op overlijden aan alle ziekten en specifiek cardiovasculair overlijden 
onderzocht in de Rotterdam studie (hoofdstuk 8). Hierbij vonden we dat hoge VWF:Ag 
spiegels en een lage ADAMTS13 activiteit geassocieerd waren met een verhoogd risico 
op overlijden, algemeen en cardiovasculair geassocieerde mortaliteit. We vonden geen 
associatie tussen VWF, ADAMTS13 en kanker gerelateerde mortaliteit of COPD (chronic 
obstructive pulmonary disease) gerelateerde mortaliteit. 
Fysieke stress stimuleert het endotheel zodat VWF vrij komt uit Weibel Palade Bodies (WPB). 
Omdat VWF een risicofactor is voor hart- en vaatziekten, is het interessant om te kijken naar 
de factoren die VWF beïnvloeden op momenten van vrijkomen tijdens fysieke stress. In 
een studie waarbij we 105 gezonde jonge mensen includeerden, vonden we dat VWF:Ag 
spiegels significant stegen bij uitputtende inspanning (hoofdstuk 9). De VWF:Ag respons 
was erg variabel en was sterk afhankelijk van uitvoerings-gerelateerde en fysieke fitheids-
gerelateerde factoren. Genetische variaties in STXBP5, STX2 en de VWF promoter, die eerder 
geïdentificeerd waren als genetische factoren van VWF:Ag spiegels, waren niet geassocieerd 
met de VWF:Ag respons op fysieke inspanning. Dit suggereert dat omgevingsfactoren 
mogelijk een belangrijkere invloed hebben dan genetische factoren in de VWF:Ag respons 
op stress.
In het laatste hoofdstuk (hoofdstuk 10) worden de bevindingen van al onze studies 
beschreven. Concluderend is er een sterke associatie tussen de uitgebreidheid van 
atherosclerose en VWF spiegels. Daarnaast is VWF een marker van een ongunstige uitkomst 
in patiënten met coronair hartlijden en een herseninfarct. Plaque karakteristieken, zoals 
hoog risico laesies, lijken niet geassocieerd met VWF spiegels. Tevens is een lage ADAMTS13 
activiteit sterk geassocieerd met een verhoogd risico op hart- en vaatziekten, inclusief 
coronair hartlijden en het herseninfarct. De studies in dit proefschrift geven een beter 
inzicht in de rol van VWF en ADAMTS13 in hart- en vaatziekten. 
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dAnkWoord
Eén van de laatste pagina’s in het proefschrift, maar meestal het eerst gelezen deel van het 
boekje. Uiteraard wil ik een hoop mensen bedanken die van mijn promotietijd een hele 
leuke en leerzame tijd hebben gemaakt. 
Mijn promoter, beste prof.dr. Leebeek, beste Frank, vanuit een keuzeonderzoek kwam ik 
bij jou terecht. Je bent enthousiast, begaan, gedreven en altijd kritisch. Ik heb veel van je 
geleerd. Ik heb bewondering hoe jij de kliniek en wetenschappelijk onderzoek combineert. 
Bedankt voor alle momenten en voor de mogelijkheid om naar Wenen te gaan voor een 
aantal weken. Het was een erg leuke en leerzame tijd. 
Mijn copromoter, beste dr. de Maat, beste Moniek, als student bij de neurologie werkte ik 
al veel met je samen. Ik heb altijd met veel plezier met je gewerkt en veel van je geleerd. Je 
stond altijd klaar en ik kon altijd binnenlopen voor een statistiek of lab gerelateerde vraag. 
Je kon me zo triggeren dat ik een andere gedachtegang ontwikkelde. Al je hulp heb ik zeer 
gewaardeerd. 
Mijn andere copromoter, beste dr. Ikram, beste Arfan, iets later tijdens mijn promotieperiode 
werd je nauw betrokken bij mijn onderzoek. Ik heb met veel enthousiasme met je samen 
gewerkt. Je snelle reacties en je epidemiologische kennis maakte het een hele fijne 
samenwerking. Succes in de toekomst!
Speciale dank voor Prof.dr. J. Voorberg, Prof.dr. D.W.J. Dippel en Prof.dr. O.H. Franco voor het 
plaatsnemen in de kleine commissie. 
Daarnaast wil ik alle patiënten en vrijwilligers die mee hebben gedaan aan de verschillende 
onderzoeken bedanken. Alle coauteurs tevens bedankt voor hun bijdrage aan de 
manuscripten. 
De oorsprong van dit boekje ligt bij de neurologie. Het begon allemaal tijdens mijn 
keuzeonderzoek bij Prof.dr. Koudstaal, ofwel Peter. Al gauw werd mijn nette opvoeding 
afgeleerd en mocht er geen u meer worden gezegd. Ik vond het heel erg leuk om met je 
samen te werken aangezien je een zeer betrokken en enthousiaste collega bent. Ik heb veel 
van je geleerd. Bedankt voor deze tijd. De neurologie zal altijd een speciaal plekje in mijn 
hart hebben. Evita, heel erg bedankt voor jouw hulp in het begin van mijn keuzeonderzoek. 
Jij hebt er mede voor gezorgd dat ik enthousiast werd voor het onderzoek. Succes in je 
verdere carrière. Anouk, vanaf het begin moesten we al samenwerken. Ik heb dit altijd met 
plezier gedaan. We konden veel van elkaar leren en het liep altijd soepel. Hopelijk kun jij het 
ook snel afronden. Veel succes met de laatste loodjes. Maryam Kavousi, thank you for all 
your help with the data and statistical analyses. 
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Het onderzoek was lang niet zo leuk geweest zonder mijn collega’s. Janine, als beginneling 
kwam ik een beetje onder jouw hoede. Bedankt voor al je hulp en de leuke tijd samen. Veel 
succes met je carrière. Simone, tijdens mijn eerste periode en jouw laatste weken, zaten 
we bij elkaar op de kamer. Nu ik bijna klaar ben, ben jij weer terug. Je bent een spontane 
en gezellige collega. Succes met het aangaan van een nieuwe uitdaging. Carina, een groot 
deel van de promotietijd zaten wij samen. Ik bewonder je discipline enorm. We hebben veel 
gelachen, gediscussieerd en serieuze gesprekken gevoerd samen. Ik wens je veel succes bij 
het afronden van de opleiding. Carolien, wat een enthousiaste en toegewijde collega was jij. 
Je betrokkenheid is een mooie eigenschap. Succes met jouw laatste loodjes. Johan, tijdens 
mijn laatste maanden kwam jij op de vrouwenkamer terecht. Uiteindelijk ga je nu zelfs nog 
verder op mijn project en met jouw enthousiasme gaat dat vast goed komen. Janske, met 
veel plezier heb ik samen met je gewerkt en veel goede gesprekken gehad. Helaas geen 
gouden randje om het boekje. Erg leuk dat we zo dicht op elkaar gaan promoveren. Veel 
succes alvast! Jossi, de eerste man binnen de groep. Jouw kijk op onderwerpen en je droge 
humor zal me altijd bijblijven. Iris, onze eerste ontmoeting met een lekker wijntje in Bari was 
een goed begin. Je bent een enthousiaste en gezellige meid en een goede aanvulling voor 
de groep. Veel succes met de opticlot. Joyce, zoals elke stollingsfactor, ben jij een onmisbare 
factor in het stollingslab. Je bent altijd in voor een praatje of voor hulp, bedankt. Shirley, 
de moeder van alle PhD studenten. Je bent een enorme aanvulling voor de groep en vormt 
een schakel tussen de onderzoekers en begeleiders. Ik ben je zeer dankbaar voor je hulp, je 
altijd kritische en zeer leerzame kijk op het onderzoek en je luisterende oor. Ik wens je heel 
veel succes in je verdere carrière. Shiraaz, succes met het afronden van je project. Lisette, 
net begonnen maar nu al zo gedreven. Veel succes. Marc, ik heb bewondering voor je werk 
naast de kliniek. Het was leuk om met je te discussiëren over medische zaken.
Dick, altijd aanwezig bij besprekingen en presentaties met veel gevatte opmerkingen. 
Zeer doordacht en kritisch. Bedankt voor al deze momenten. Marieke, bedankt voor alle 
onderwijsmomenten en de kritische en klinische blik op het onderzoek. Marjon, bevlogen 
en zo enthousiast. Veel succes met de opticlot. Robbie, Wietse, Dennis, Sjef en Hans, heel 
erg bedankt voor jullie hulp bij de ADAMTS13, Factor H en Von Willebrand Factor bepalingen 
in de verschillende studies. Fahid, je was een gedreven en enthousiaste leerling. Het 
laboratoriumwerk was niet altijd gemakkelijk, maar het is je gelukt. Bedankt voor al je hulp. 
Reshma en Richard, bedankt voor jullie gezelligheid tussen het werk door. Resh, we gaan 
snel weer eens borrelen. Daarnaast wil ik alle collega’s van het hemostaselab bedanken voor 
jullie gezelligheid en hulp bij mijn lab werkzaamheden. 
Ans, Leenke en Els, bedankt voor al jullie hulp bij verschillende taken. Het was altijd even 
gezellig om langs te komen bij jullie voor een praatje. Julia, unfortunately my German is not 
that good as we remained at lesson 3. We had a lot of fun during my stay at the 13th floor. 
Good luck with your career. Roberto, I admire your perseverance. Good luck with finishing 
your thesis. Paulette, Renee, Marijke, Onno, Noemi, Kasia, Avinash, Marshall, Davine, Amiet, 
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Adrian, Marije, Claudia, Francois, Remco and Matthijs, thank you all for the good fun. I wish 
you all the best. 
Egied, heel veel dank gaat uit naar jou voor het maken van mijn voorpagina en de lay-out. 
Tevens de resterende collega’s van de afdeling hematologie waaronder het secretariaat, 
hemostaselab, morfologielab, Greta, Floor, researchverpleegkundigen en medische staf; 
bedankt voor alle gezelligheid!
Lieve Erna, ook jij verdiend een plekje in mijn dankwoord als COEUR coördinator. Onze 
gezamenlijke passie voor reizen bracht ons in het laatste jaar meer bij elkaar. Ik kom snel 
weer eens naar je fotoboeken kijken. 
Sinds mei 2015 ben ik werkzaam in het Ikazia ziekenhuis onder leiding van Adrienne 
Zandbergen, opleider Interne geneeskunde. Onze samenwerking begon eigenlijk al jaren 
geleden met een gezamenlijke auteurschap op een abstract, ondanks dat we hier pas 
een aantal weken geleden achter kwamen. Bedankt voor de mogelijkheid om me in het 
Ikazia ziekenhuis te ontwikkelen en voor jouw open en enthousiaste houding. Dat maakt 
het werken in het ziekenhuis nog aangenamer. Daarnaast zorgen mijn collega Ikaziaantjes: 
Alison, Amber, Babs, Bas, Chadia, Cheno, Evelien, Jan, Jill, Koen, Lisha, Martijn, Milan, 
Mitchell, Robert, Samara, Simon, Wesley, Zana en oud collega’s; er ook voor dat ik met 
plezier naar mijn werk ga. Succes allemaal in jullie carrière en hopelijk kunnen we nog een 
tijd samenwerken, nu en in de toekomst. 
Mijn paranimfen, Franny en Yvonne. Lieve Franny, jij hebt er mede voor gezorgd dat mijn 
promotie een succes werd. Tijdens onze wekelijkse koffiemomenten kon ik even mijn hart 
luchten en relativeren. En hoe leuk is het dat we nu weer in hetzelfde ziekenhuis werken. 
Dank je wel voor je vriendschap en het altijd voor me klaar staan. Succes met jouw 
laatste loodjes, Ibiza komt eraan! Lieve Yvonne, mijn bevlogen en zo enthousiaste collega. 
Gedurende een lange periode tijdens mijn onderzoekstijd hebben we samen gewerkt. We 
hebben heel veel gelachen, maar ook veel gepraat in mindere tijden. Nadat we beide weg 
zijn gegaan is onze vriendschap nog hechter geworden. Daar ben ik je erg dankbaar voor. 
Heel veel geluk samen met Bouke. Bedankt dat je mijn paranimf wil zijn. 
Lieve Hanke en Zjwan, jullie zijn zulke leuke en grappige vriendinnen. Bedankt voor jullie 
gezelligheid en de goede gesprekken. Hopelijk kunnen we naast leuke uitjes, ook nog 
samenwerken in de toekomst. 
Mijn oom Harry en tantes Mieke en Willy verdienen ook nog een speciaal plekje. Op reis 
voor een congres en jullie kwamen op bezoek. Wat hebben we enorm veel gelachen met 
elkaar. Het waren heerlijke dagen in Wenen en Bari. Helaas geen congressen meer in het 
verschiet dus dan moeten we maar gewoon een weekend weg gaan plannen. 
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Lieve Marije, al vanaf de basisschool vriendinnetjes. Onze werelden zijn zo anders en 
misschien daarom dat we het nog steeds zo leuk hebben. Bedankt voor alle leuke uitjes en 
de persoonlijke verzorging. We gaan er een mooie vakantie van maken! 
Lieve Marieke en Judith, mijn lange volleybalvriendinnen. Ik kijk alweer uit naar ons volgende 
etentje. Marieke, veel succes straks met de kleine. Daarna gaan we snel weer een wijntje 
drinken. Judith, ik hoop dat mijn boekje Rwanda bereikt. Helaas kan je er niet bij zijn. Heel 
veel succes en ik kom graag nog een keer op bezoek. 
Lieve high school girls, lieve Caroline, Marja, Pauline, Simone Verschoore, Simone Guinée 
en Tessa; het is altijd een feestje met jullie! Jullie hebben er tevens voor gezorgd, door de 
momenten van ontspanning, dat dit boekje hier ligt. Hopelijk kunnen we nog een heleboel 
leuke avondjes, etentjes en weekendjes weg plannen tot aan de bingo in het bejaardentehuis. 
Bedankt voor jullie vriendschap.
Lieve Mark, de laatste maanden van het afronden van mijn proefschrift leerde ik je kennen. 
We hebben het heel erg leuk samen. Mijn promotie zit er bijna op en jij bent een goede 
bestemming voor mijn vrije tijd straks. Ik kijk uit naar mooie momenten samen. 
Lieve Marloes, Martijn, Sandra en Jaco, mijn lieve zussen en zwangers, al ben ik altijd druk, 
jullie staan altijd voor me klaar. Jullie liefde en gezelligheid zijn erg belangrijk voor me. Wat 
ben ik trots op jullie!
Lieve Daan, Thijs en Lieke, mijn neefjes en nichtje, jullie zijn nog erg klein, maar wat heb 
ik een enorme liefde voor jullie. Over heel wat jaren zal tante Mies dit boekje aan jullie 
uitleggen. 
Lieve pap en mam, mijn dankbaarheid voor jullie is niet uit te drukken. Jullie staan altijd voor 
me klaar, zijn geïnteresseerd en helpen en steunen me altijd. Een klusje in huis, eten voor 
me koken, me ophalen vanaf de metro of een arm om me heen. Ik ben heel erg trots dat ik 
zulke fantastische ouders heb. 
Het zit er nu echt bijna op. Ik kijk er naar uit om dit met jullie allemaal te vieren!
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CurriCuluM VitAe
Michelle Sonneveld werd geboren op 31 december 1985 te Rotterdam. Zij volgde 
het voortgezet onderwijs aan het Sint Laurenscollege te Rotterdam, waar zij in 2004 
haar VWO diploma behaalde. In 2005 behaalde zij haar propedeuse voor de studie 
gezondheidswetenschappen, beleid en management gezondheidszorg aan de Erasmus 
Universiteit Rotterdam. In datzelfde jaar startte zij met de studie Geneeskunde aan de 
Erasmus Universiteit Rotterdam. Op de afdeling neurologie deed zij in 2011 keuzeonderzoek 
onder leiding van Prof. dr. P.J. Koudstaal en dr. E.G. van den Herik, in samenwerking met 
Prof. dr. F.W.G. Leebeek en dr. M.P.M. de Maat. Dit onderzoek was de basis voor dit 
proefschrift. In 2011 behaalde zij haar artsexamen, waarna zij in november 2011 startte met 
haar promotieonderzoek op de afdeling hematologie. Per 1 mei 2015 is zij begonnen met 
de opleiding Interne Geneeskunde in het Erasmus MC (opleider dr. S.C.E. Klein Nagelvoort 
– Schuit). Momenteel volgt zij haar vooropleiding in het Ikazia Ziekenhuis te Rotterdam 
(opleider dr. A. Zandbergen). 
A

223PhD Portfolio Summary
PHd Portfolio SuMMAry
Name PhD student: M.A.H. Sonneveld
Erasmus MC Department: Haematology
Research School: COEUR
PhD period: November 2011 – January 2015
Promotor: Prof. Dr. F.W.G. Leebeek
Supervisors: Dr. M.P.M. de Maat; Dr. M.A. Ikram
1. PHd trAininG
year
Workload 
(Hours/eCtS)
General academic skills 
• Biomedical English Writing and Communication
• Research Integrity
2014
2014
4.0
0.3
research skills
• SNP’s and human disease
• Introduction to clinical research
• Biostatistics for clinicians
• Regression analysis for clinicians
2011
2012
2012
2012
2.0
0.9
1.0
1.9
in-depth courses (e.g. Research school, Medical Training)
•  5x COEUR courses on cardiovascular medicine, pathophysiology of ischemic 
heart disease, cardiovascular imaging and diagnostics, clinical cardiovascular 
epidemiology, and atherosclerotic and aneurysmal disease
• Molmed presenting skills
• 3x NVTH AIO course on thrombosis and hemostasis
2011-2014
2012
2012-2014
7.5
1.0
3.0
Presentations
• 2x oral presentation at Nederlandse Vereniging Trombose en Hemostase
•  3x E-poster oral presentations at International Society of Thrombosis and 
Haemostasis
• Oral presentation at COEUR PhD day
• Poster presentation at Bari International Conference
• Oral presentation at American Society of Hematology annual meeting
• Oral presentation Prof. Heimburger award conference
•  2x oral presentation at International Society of Thrombosis and Haemostasis
2013-2014
2013
2014
2014
2014
2015
2015
1.6
0.9
0.8
0.3
0.8
0.8
1.6
international conferences
• Van Creveld symposium
• 3x NVTH symposium
• 2x International Society of Thrombosis and Haemostasis Congress
• Bari International Conference
• American Society of Haematology annual meeting
• Prof. Heimburger award conference
2011
2012-2014
2013-2015
2014
2014
2015
0.3
1.6
3.6
0.9
1.2
0.3
Seminars and workshops
9x COEUR research seminar
2x COEUR PhD day
3x NVTH PhD day
2012-2013
2012-2013
2012-2014
3.6
0.8
1.2
2. teACHinG ACtiVitieS
lecturing
• 10x coagulation lecture for nurses
• 2x lecture arterial thrombosis 2nd year medical students
2012-2014
2013-2014
1.0
0.4
Supervising Master’s thesis
• Supervision of M.F. Chohan (keuzeonderzoek)
• Supervision of W. Klaasen (HLO student)
2014
2014
1.0
0.9
total 45.2
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